Pharmacopedia - User contributions [en]

Category:Heart failure medications

2026-05-23T19:48:12Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''heart failure medicine''' is one used in the management of [[wikipedia:Heart failure|heart failure]], the clinical syndrome that results when the heart cannot pump enough blood to meet the metabolic demands of the body or can only do so at the cost of elevated filling pressures. The category covers, by clinical use, the medicines that have been shown to reduce mortality and hospitalisation in heart failure with reduced ejection fraction (HFrEF), the medicines that improve symptoms and reduce hospitalisation in heart failure with preserved ejection fraction (HFpEF), the diuretics and venodilators used to manage congestion across the spectrum, and the inotropes and mechanical-support adjuncts of acute decompensation.

The first effective heart-failure medicine was a botanical preparation that has remained in use, with refinements, for more than two centuries. In 1785 the English physician [[wikipedia:William Withering|William Withering]] of [[wikipedia:Birmingham|Birmingham]] published ''An Account of the Foxglove, and Some of its Medical Uses'', the result of a decade of careful observation in patients with dropsy (the clinical syndrome of fluid retention now recognised as congestive heart failure).<ref name="withering1785">Withering W. ''An Account of the Foxglove and Some of Its Medical Uses, with Practical Remarks on Dropsy, and Other Diseases''. Birmingham: Robinson; 1785.</ref> Withering had been shown the foxglove (''[[wikipedia:Digitalis purpurea|Digitalis purpurea]]'') tea by a Shropshire countrywoman who had had clinical success with it, identified the leaf as the active part, established a dose-response, and characterised the cardiac glycoside toxicity (visual disturbance, nausea, bradycardia, arrhythmia) that has remained essentially as he described it. [[wikipedia:Digoxin|Digoxin]], isolated from ''Digitalis lanata'' by Sydney Smith in 1930, retains some place in heart-failure management for symptomatic rate control in atrial fibrillation but, after the Digitalis Investigation Group trial of 1997 showed no mortality benefit of routine digoxin in HFrEF, has retreated from first-line maintenance use.<ref name="dig1997">Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. ''New England Journal of Medicine''. 1997 Feb 20;336(8):525-533. PMID 9036306.</ref>

The transformative event of modern heart-failure pharmacology was the demonstration that the [[:Category:ACE_inhibitors|angiotensin-converting enzyme inhibitor]] enalapril reduced mortality in severe heart failure. The 1987 [[wikipedia:CONSENSUS trial|CONSENSUS trial]] of enalapril versus placebo in patients with NYHA class IV symptoms was stopped early after the active arm showed a 40 percent reduction in six-month mortality.<ref name="consensus1987">CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). ''New England Journal of Medicine''. 1987 Jun 4;316(23):1429-1435. PMID 2883575.</ref> The SOLVD trials in 1991 extended the benefit to milder disease. The angiotensin receptor blockers showed similar benefit a decade later in the ELITE-II and Val-HeFT trials. The [[:Category:Beta-blockers|beta-blocker]] story was more counterintuitive: it had been clinical doctrine for forty years that the negative inotropic effect of a beta-blocker would worsen the failing heart, and the demonstration that low-dose carvedilol (US Carvedilol Trials), bisoprolol (CIBIS-II), and metoprolol succinate extended-release (MERIT-HF) all reduced HFrEF mortality by approximately 35 percent in the late 1990s overturned that doctrine. The mineralocorticoid receptor antagonist spironolactone followed in the RALES trial (1999) and the more selective eplerenone in EPHESUS (2003) and EMPHASIS-HF (2011).

The first decade of the twenty-first century established a four-medicine standard for HFrEF: ACE inhibitor or ARB, beta-blocker, mineralocorticoid antagonist, and loop diuretic for congestion. The 2014 [[wikipedia:PARADIGM-HF|PARADIGM-HF]] trial of [[wikipedia:Sacubitril/valsartan|sacubitril/valsartan]] versus enalapril added a fifth class. Sacubitril/valsartan, the first '''angiotensin receptor / neprilysin inhibitor''' (ARNI), combined an ARB with a neprilysin inhibitor that increases circulating natriuretic peptides by blocking their degradation; the trial was stopped early for a 20 percent mortality reduction over enalapril alone.<ref name="paradigm2014">McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. ''New England Journal of Medicine''. 2014 Sep 11;371(11):993-1004. PMID 25176015.</ref> Sacubitril/valsartan has now replaced ACE inhibitor or ARB monotherapy as the standard initial blocker of the renin-angiotensin axis in HFrEF.

The most recent and most surprising addition is the [[:Category:SGLT2_inhibitors|sodium-glucose cotransporter-2 inhibitor]] class. Originally developed as antihyperglycemic medicines for type-2 diabetes, the SGLT2 inhibitors were tested in heart failure on a mechanistic rationale that combined modest natriuresis, glucose-energetics modulation, and an unexplained but reproducible cardiovascular signal in the EMPA-REG OUTCOME diabetes trial. The DAPA-HF (2019), EMPEROR-Reduced (2020), and EMPEROR-Preserved (2021) trials demonstrated that dapagliflozin and empagliflozin reduced heart-failure hospitalisation and cardiovascular mortality across the full ejection-fraction spectrum, in patients with and without diabetes.<ref name="dapahf2019">McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. ''New England Journal of Medicine''. 2019 Nov 21;381(21):1995-2008. PMID 31535829.</ref> The contemporary guidelines therefore prescribe a quadruple therapy for HFrEF: an ARNI (or ACE inhibitor or ARB), a beta-blocker, a mineralocorticoid antagonist, and an SGLT2 inhibitor, with loop diuretics for congestion.

Heart failure with preserved ejection fraction (HFpEF), which accounts for approximately half of contemporary heart-failure presentations, had been a therapeutic disappointment for two decades: no medicine had shown clear mortality or hospitalisation benefit in the I-PRESERVE (irbesartan), TOPCAT (spironolactone), and other early HFpEF trials. The 2021 EMPEROR-Preserved and 2022 DELIVER trials of empagliflozin and dapagliflozin in HFpEF showed modest but clinically meaningful benefit, the first medicine class to do so in this phenotype. Sacubitril/valsartan in PARAGON-HF in 2019 showed a near-miss benefit that may be real in the lower-EF range of preserved-EF heart failure. The treatment of HFpEF therefore now consists of an SGLT2 inhibitor for all eligible patients, with consideration of ARNI in lower-range preserved EF, diuretics for congestion, and aggressive management of comorbid hypertension, atrial fibrillation, sleep apnea, and obesity (where the recent STEP-HFpEF trial of semaglutide showed substantial functional benefit).

The acute decompensation pharmacopoeia is a separate sub-category. Intravenous loop diuretics (furosemide, bumetanide, torsemide) for congestion; intravenous vasodilators (nitroglycerin, nitroprusside, nesiritide) for pulmonary congestion and afterload; and intravenous inotropes (dobutamine, milrinone, levosimendan in Europe) for low cardiac output dominate the inpatient management of cardiogenic shock and severe decompensation. Mechanical circulatory support (intra-aortic balloon pump, percutaneous left ventricular assist devices Impella and TandemHeart, venoarterial extracorporeal membrane oxygenation, durable LVADs as destination therapy or bridge to transplantation) extends the field beyond pharmacology.

== Classes indexed ==

By the contemporary HFrEF "four pillars":

* '''Renin-angiotensin-aldosterone system blockers''':
** Angiotensin receptor / neprilysin inhibitor (ARNI): [[wikipedia:Sacubitril/valsartan|sacubitril/valsartan (Entresto)]]
** [[:Category:ACE_inhibitors|ACE inhibitors]]: [[Enalapril|enalapril]], [[Lisinopril|lisinopril]], [[Ramipril|ramipril]], [[Benazepril|benazepril]], captopril, quinapril, perindopril
** [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blockers]] (for ACE inhibitor intolerance): [[Losartan|losartan]], [[Valsartan|valsartan]], [[Candesartan|candesartan]]
** [[:Category:Aldosterone_antagonists|Aldosterone antagonists]]: [[wikipedia:Spironolactone|spironolactone]], [[wikipedia:Eplerenone|eplerenone]]
* '''Beta-blockers''' (the three demonstrated to reduce HFrEF mortality):
** Carvedilol, [[wikipedia:Bisoprolol|bisoprolol]], metoprolol succinate extended-release
* '''SGLT2 inhibitors''' (the fourth pillar, also indexed under [[:Category:SGLT2_inhibitors|SGLT2 inhibitors]]):
** [[Dapagliflozin|dapagliflozin]], [[Empagliflozin|empagliflozin]] (the two with the HFrEF and HFpEF outcome data)
* '''Loop diuretics''' (symptom management, not mortality benefit):
** [[wikipedia:Furosemide|furosemide]], [[wikipedia:Bumetanide|bumetanide]], [[wikipedia:Torsemide|torsemide]]
* '''Vasodilator combinations''' (for ACE-intolerant or specific populations):
** Hydralazine + isosorbide dinitrate ([[wikipedia:BiDil|BiDil]], approved in 2005 for self-identified Black patients with HFrEF, the first racially defined medicine approval)
* '''Sinus-node rate control''' (in selected patients): [[wikipedia:Ivabradine|ivabradine]] (SHIFT trial 2010)
* '''Soluble guanylate cyclase stimulator''': [[wikipedia:Vericiguat|vericiguat]] (VICTORIA trial 2020, for HFrEF after a worsening event)
* '''Inotropes''' (acute or bridging): dobutamine, milrinone, levosimendan, digoxin
* '''Cardiac myosin activator''' (in trial / select use): [[wikipedia:Omecamtiv mecarbil|omecamtiv mecarbil]] (GALACTIC-HF, 2020, did not meet primary endpoint)

== Notes on scope ==

The boundary of this category is "medicine used in the chronic or acute management of heart failure." The antihypertensive medicines that are also heart-failure medicines (the [[:Category:ACE_inhibitors|ACE inhibitors]], [[:Category:Angiotensin_receptor_blockers|ARBs]], [[:Category:Beta-blockers|beta-blockers]], MRAs, [[:Category:Loop_diuretics|loop diuretics]], SGLT2 inhibitors) are cross-listed; their primary classification is by mechanism but their HF indication is collected here. The [[:Category:Antiarrhythmics|antiarrhythmics]] used to manage atrial fibrillation in heart-failure patients are listed under [[:Category:Antiarrhythmics|antiarrhythmics]] rather than here. Cardiac amyloidosis (tafamidis, patisiran, vutrisiran, transthyretin gene-silencing agents) and amyloid-cardiomyopathy treatments are listed under their specific indication. Procedural treatments (cardiac resynchronisation therapy, implantable cardioverter-defibrillator, transcatheter mitral valve repair MitraClip, left ventricular assist devices, cardiac transplantation) are device-based and are referenced on the medicine pages but are not collected here.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Cardiovascular_agents]]
[[Category:CuratedCategoryPage]]

Category:Osteoporosis medications

2026-05-23T19:48:12Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''osteoporosis medication''' is a medicine used to prevent fragility fracture in patients with low bone density or with a prior fragility fracture. The category is organised around two complementary pharmacological strategies: '''antiresorptive''' therapy that slows bone loss (the [[:Category:Bisphosphonates|bisphosphonates]], the RANKL antibody denosumab, the selective estrogen-receptor modulators, the older calcitonin, hormone replacement), and '''anabolic''' therapy that stimulates bone formation (the parathyroid hormone analogues teriparatide and abaloparatide, and the sclerostin antibody romosozumab whose dual mechanism combines both). The medicines are supported by foundational mineral supplementation (calcium and vitamin D, the substrate of bone matrix and the regulator of calcium absorption).

The clinical history of osteoporosis pharmacology is told under [[:Category:Antiresorptives|antiresorptives]] and [[:Category:Bisphosphonates|bisphosphonates]] for the bone-loss-prevention side, and under [[:Category:Hormones|hormones]] for the parathyroid-hormone analogues that drive bone formation. The contemporary clinical-pharmacology framing of osteoporosis is described here: the disease, the risk-stratification, the treatment thresholds, and the algorithm by which the available medicines are deployed.

The disease was formally described by the American endocrinologist [[wikipedia:Fuller Albright|Fuller Albright]] of the Massachusetts General Hospital in 1941, who established the connection between postmenopausal estrogen loss and the resulting bone loss as the dominant cause of vertebral and hip fractures in elderly women.<ref name="albright1941">Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: its clinical features. ''JAMA''. 1941 May 31;116(22):2465-2474.</ref> Albright's recommendation of estrogen replacement was the standard treatment for forty years. The 1994 World Health Organization operational definition of osteoporosis (a femoral-neck T-score of 2.5 standard deviations or more below the mean of young adult women, measured by dual-energy X-ray absorptiometry) gave the contemporary diagnostic framework; the 2008 introduction of the [[wikipedia:FRAX|FRAX]] (Fracture Risk Assessment) tool by [[wikipedia:John A. Kanis|John Kanis]] and the WHO Collaborating Centre at Sheffield gave a country-specific 10-year fracture-probability calculator that integrates T-score with clinical risk factors (age, sex, prior fracture, parental hip fracture, smoking, alcohol, glucocorticoid use, rheumatoid arthritis, secondary causes of osteoporosis) and now drives treatment-threshold decisions in many guidelines.

The contemporary indications for pharmacological treatment of osteoporosis are well-defined. Treatment is recommended in postmenopausal women and men age 50 and older when: (1) a prior fragility hip or vertebral fracture has occurred, regardless of T-score; (2) the femoral-neck or total-hip T-score is -2.5 or below; or (3) the T-score is in the osteopenic range (-1.0 to -2.5) and the FRAX 10-year probability of major osteoporotic fracture exceeds country-specific thresholds (in the United States, 20 percent for major osteoporotic fracture or 3 percent for hip fracture). Patients on chronic systemic glucocorticoids (7.5 mg/day prednisone equivalent for over 3 months) are treated more aggressively because of the disproportionate fracture risk that medicine produces.

The contemporary treatment algorithm has been progressively refined. For postmenopausal women and men age 50 and older at significant but not very high risk, first-line therapy is oral bisphosphonate (alendronate or risedronate), with intravenous zoledronate or subcutaneous denosumab for patients intolerant of oral bisphosphonate or with renal impairment. For patients at very high risk (multiple vertebral fractures, hip fracture, T-score below -3.0, FRAX above 30 percent for major osteoporotic fracture), anabolic-first therapy with teriparatide (Forteo, twice-daily subcutaneous injection for up to 2 years), abaloparatide (Tymlos, daily subcutaneous injection), or romosozumab (Evenity, monthly subcutaneous injection for 12 months) followed by antiresorptive maintenance produces greater bone-density gain and greater fracture-risk reduction than antiresorptive monotherapy. Sequential therapy with the anabolic agent first and the antiresorptive second is now standard for this high-risk population.

The duration-of-treatment question is one of the central clinical decisions in osteoporosis care. For oral bisphosphonates, a five-year course followed by a "medicine holiday" of 2-5 years (during which antifracture benefit persists because of the long bone half-life of the bisphosphonate) is the standard for most patients; high-risk patients may continue beyond 5 years. For annual intravenous zoledronate, 3 years followed by a holiday is standard, with 6 years for higher-risk patients. For denosumab, no medicine holiday is recommended: abrupt discontinuation produces a rebound of bone resorption with multiple vertebral fractures within months, and patients who discontinue denosumab for any reason must be transitioned to a bisphosphonate to lock in the gains. For teriparatide and abaloparatide, the 24-month lifetime treatment limit (osteosarcoma concern from rat lifetime exposure, not directly seen in humans but the regulatory caution remains) defines the duration; sequential transition to an antiresorptive is required to maintain the gains. For romosozumab, 12 months of treatment is the maximum (the ARCH trial endpoint), again followed by antiresorptive maintenance.

The supportive-care medicines complete the regimen. Calcium supplementation (1000-1200 mg per day, including dietary sources) and vitamin D supplementation (800-2000 IU per day, with a 25-hydroxyvitamin D target above 30 ng/mL) are foundational and are co-prescribed with every active osteoporosis regimen; the supplementation may be insufficient as monotherapy for established osteoporosis but is necessary to optimise the effect of antiresorptive and anabolic medicines. Physical activity (weight-bearing exercise, resistance training, balance training to reduce fall risk), fall-risk modification (review of sedating medicines, home-safety assessment), and avoidance of bone-toxic medicines (chronic glucocorticoids, aromatase inhibitors in selected patients, GnRH agonist therapy in prostate cancer) are part of standard non-pharmacological management.

== Classes indexed ==

By mechanism:

* '''Antiresorptive''' (cross-indexed under [[:Category:Antiresorptives|antiresorptives]]):
** [[:Category:Bisphosphonates|Bisphosphonates]]: oral alendronate, risedronate, ibandronate; intravenous ibandronate (quarterly) and zoledronate (annual)
** RANKL antibody: [[wikipedia:Denosumab|denosumab]] (Prolia, 60 mg subcutaneous every 6 months)
** SERMs: [[wikipedia:Raloxifene|raloxifene]] (vertebral-fracture reduction; breast-cancer chemoprevention bonus indication), bazedoxifene
** Calcitonin: salmon calcitonin nasal spray (limited current use)
** Hormone replacement: estrogen-progestin combinations (cross-indexed under [[:Category:Hormone_replacement_therapy|hormone replacement therapy]])
* '''Anabolic''' (cross-indexed under [[:Category:Hormones|hormones]] for the PTH analogues):
** PTH analogues: [[wikipedia:Teriparatide|teriparatide]] (Forteo, daily SC for up to 2 years), abaloparatide (Tymlos, daily SC)
** Sclerostin antibody (dual anabolic + antiresorptive): [[wikipedia:Romosozumab|romosozumab]] (Evenity, monthly SC for 12 months)
* '''Foundational mineral supplementation''':
** [[:Category:Calcium_supplements|Calcium supplements]]: calcium carbonate (food-dependent absorption; OTC); calcium citrate (food-independent; smaller doses required for the elderly and PPI users)
** [[:Category:Vitamin_D_analogs|Vitamin D]]: cholecalciferol (D3), ergocalciferol (D2), the active calcitriol in selected indications (renal disease)
** Magnesium where deficient

== Notes on scope ==

The boundary of this category is "medicine prescribed primarily to prevent or treat osteoporotic fracture." Medicines used in [[wikipedia:Paget's disease of bone|Paget's disease of bone]] (the bisphosphonates at different dose schedules), [[wikipedia:Osteogenesis imperfecta|osteogenesis imperfecta]] (intravenous pamidronate or zoledronate in childhood), [[wikipedia:Renal osteodystrophy|renal osteodystrophy]] (vitamin D analogues, calcimimetic cinacalcet, phosphate binders), and [[wikipedia:Hypoparathyroidism|hypoparathyroidism]] (PTH replacement) are cross-listed where the medicines overlap, but their primary classification is by indication. The bone-targeting radiopharmaceuticals (radium-223 for prostate cancer bone metastases, samarium-153 EDTMP for bone-pain palliation) are not osteoporosis medicines and are listed under [[:Category:Antineoplastics|antineoplastics]]. The medicines that secondarily cause osteoporosis (chronic glucocorticoids, aromatase inhibitors, GnRH agonists, the older anticonvulsants, proton pump inhibitors, SSRIs) are noted as risk factors but are not osteoporosis medicines.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Endocrine_therapy]]
[[Category:CuratedCategoryPage]]

Category:DOACs

2026-05-23T19:48:11Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''DOAC''' (direct oral anticoagulant; older abbreviation NOAC for "novel oral anticoagulant", now retired because the medicines are no longer novel) is an oral medicine that directly binds and inhibits a specific factor of the coagulation cascade, in contrast to the [[:Category:Vitamin_K_antagonists|vitamin K antagonists]] (which indirectly reduce the synthesis of multiple coagulation factors) and the heparins (which act indirectly through antithrombin). The category contains four approved medicines in two mechanistic subclasses: the direct thrombin inhibitor [[wikipedia:Dabigatran|dabigatran]], and the [[:Category:Direct_factor_Xa_inhibitors|direct factor Xa inhibitors]] [[Rivaroxaban|rivaroxaban]], [[Apixaban|apixaban]], and [[wikipedia:Edoxaban|edoxaban]] (the U.S./European set; betrixaban, the Asian-market darexaban, and the recently approved abelacimab targeting factor XI are mechanistically related additions in selected jurisdictions).

The DOAC pharmacology is described in detail under [[:Category:Anticoagulants|anticoagulants]]; the contents of this sub-category page focus on what is distinctive about the class: the direct-binding mechanism, the predictable pharmacokinetics that allow fixed-dose administration without routine laboratory monitoring, the rapid onset and offset that simplify perioperative management, and the increasingly available reversal-agent armamentarium.

The DOAC era began with the 2010 RE-LY trial of dabigatran versus warfarin in atrial fibrillation, which demonstrated non-inferior stroke prevention with substantially lower intracranial hemorrhage and a small mortality advantage.<ref name="rely2009">Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. ''New England Journal of Medicine''. 2009 Sep 17;361(12):1139-1151. PMID 19717844.</ref> The 2011 ROCKET-AF trial of rivaroxaban, the 2011 ARISTOTLE trial of apixaban, and the 2013 ENGAGE AF-TIMI 48 trial of edoxaban extended the demonstration to the three principal factor Xa inhibitors, each showing non-inferior or superior efficacy versus warfarin with reduced bleeding (intracranial hemorrhage in particular) for atrial fibrillation stroke prophylaxis. Parallel trials in venous thromboembolism (RECOVER, RECOVER II, RE-MEDY, RE-SONATE for dabigatran; EINSTEIN-DVT, EINSTEIN-PE, EINSTEIN-CHOICE for rivaroxaban; AMPLIFY, AMPLIFY-EXT for apixaban; Hokusai-VTE for edoxaban) established the DOACs for treatment of deep vein thrombosis and pulmonary embolism. The DOACs have largely displaced warfarin for the major thromboembolic indications in patients without specific contraindication.

The contraindications of the DOACs remain warfarin's domain. The DOACs are not approved for the antiphospholipid syndrome (the TRAPS trial of rivaroxaban in high-risk APS showed inferior outcomes versus warfarin), for mechanical heart valves (the RE-ALIGN trial of dabigatran was stopped early for excess thromboembolic and bleeding events; warfarin remains the standard), or for moderate-to-severe mitral stenosis with atrial fibrillation. Severe renal impairment (apixaban being the most renal-friendly with caveats; dabigatran requiring substantial dose reduction below CrCl 30; rivaroxaban contraindicated below CrCl 15; edoxaban requiring careful dose-titration and not above CrCl 95) and substantial hepatic dysfunction limit DOAC use. The DOACs are not currently considered safe in pregnancy or lactation; low-molecular-weight heparins remain the standard anticoagulants for those indications.

The reversal-agent development for the DOACs is among the most active areas of contemporary haemostasis pharmacology. The humanised Fab fragment [[wikipedia:Idarucizumab|idarucizumab]] (Praxbind, Boehringer Ingelheim 2015) binds dabigatran with affinity 350-fold higher than dabigatran's affinity for thrombin and reverses anticoagulant effect within minutes; the REVERSE-AD study established its clinical efficacy. The recombinant inactive factor Xa decoy [[wikipedia:Andexanet alfa|andexanet alfa]] (Andexxa/Ondexxya, Portola/Alexion 2018) binds the factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and the indirect anti-Xa medicines (low-molecular-weight heparins, fondaparinux); the ANNEXA-4 trial demonstrated efficacy in major bleeding on these agents. Four-factor prothrombin complex concentrate (4F-PCC) has off-label efficacy for factor Xa inhibitor reversal at substantially lower cost than andexanet alfa, and the comparative ANNEXa-I trial is intended to clarify the relative role.

The newest DOAC subclass is the factor XI inhibitor. Selective factor XI inhibition is hypothesised to provide anticoagulation with substantially reduced bleeding risk because factor XI is more important for pathological thrombus formation than for physiological hemostasis. [[wikipedia:Abelacimab|Abelacimab]] (monoclonal antibody, Anthos), [[wikipedia:Asundexian|asundexian]] (oral small molecule, Bayer), [[wikipedia:Milvexian|milvexian]] (oral small molecule, BMS/Janssen), and several other agents are in Phase 3 trials for stroke prevention in atrial fibrillation, for VTE treatment, and for secondary cardiovascular event prevention. The OCEANIC-AF trial of asundexian in atrial fibrillation was stopped in 2023 for inferior efficacy versus apixaban; the field continues with the remaining factor XI agents.

== Medicines indexed ==

* '''Direct thrombin inhibitor (factor IIa)''':
** [[wikipedia:Dabigatran|Dabigatran etexilate]] (Pradaxa; the orally bioavailable form, hydrolysed by serum esterases to the active dabigatran; the first DOAC)
* '''[[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitors]]''':
** [[Rivaroxaban|Rivaroxaban]] (Xarelto, Bayer/Janssen)
** [[Apixaban|Apixaban]] (Eliquis, BMS/Pfizer)
** [[wikipedia:Edoxaban|Edoxaban]] (Savaysa, Lixiana; Daiichi Sankyo)
** Betrixaban (Bevyxxa; FDA-approved 2017 for VTE prophylaxis in acute medical illness; commercial withdrawal 2019)
* '''Factor XI inhibitors''' (in trial, not yet approved for stroke prophylaxis):
** Abelacimab (monoclonal antibody)
** Asundexian (oral small molecule; OCEANIC-AF stopped 2023)
** Milvexian (oral small molecule)
* '''Reversal agents''' (cross-listed under [[:Category:Anticoagulants|anticoagulants]]; not DOACs but listed here for clinical-decision context):
** [[wikipedia:Idarucizumab|Idarucizumab]] (Praxbind; for dabigatran)
** [[wikipedia:Andexanet alfa|Andexanet alfa]] (Andexxa; for factor Xa inhibitors)
** Four-factor prothrombin complex concentrate (KCentra; off-label for factor Xa inhibitor reversal)

== Notes on scope ==

The boundary of this category is "medicine that directly binds and inhibits a coagulation-cascade factor and is administered orally." The intravenous direct thrombin inhibitors (argatroban, bivalirudin, hirudin, the recombinant lepirudin and desirudin) are mechanistically related but not oral and are listed under [[:Category:Anticoagulants|anticoagulants]] separately. The factor Xa inhibitors that act indirectly through antithrombin (low-molecular-weight heparins, fondaparinux) are not DOACs in this category sense and are listed under [[:Category:Anticoagulants|anticoagulants]]. The [[:Category:Antiplatelet_agents|antiplatelet agents]] act on platelets rather than the coagulation cascade and are categorised separately. The fibrinolytic medicines (tissue plasminogen activator and related) lyse already-formed thrombus rather than preventing its formation and are listed elsewhere.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Anticoagulants]]
[[Category:CuratedCategoryPage]]

Category:Antivirals

2026-05-23T19:48:11Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''antiviral''' is a medicine that interferes with the replication or assembly of a virus in a human host. The category is younger and more pathogen-specific than the antibacterial one: most antivirals act on a single viral family or even a single viral enzyme, because the [[wikipedia:Obligate intracellular parasite|obligate intracellular]] life cycle of the virus leaves few molecular targets that are not also targets in the host cell, and selective toxicity must usually be obtained by exploiting an enzyme unique to a particular virus.

The clinical use of antiviral medicines began in 1962 with [[wikipedia:Idoxuridine|idoxuridine]], a halogenated pyrimidine analogue developed by [[wikipedia:William Prusoff|William Prusoff]] at Yale as a potential anticancer agent that was found instead to inhibit herpes simplex virus DNA polymerase; it became the first topical treatment for herpetic keratitis. The medicine was too toxic for systemic use, but it established the principle: a nucleoside analogue that the viral enzyme preferentially incorporated into nascent viral DNA, but that the corresponding human enzyme rejected, could selectively kill the virus.

The first effective systemic antiviral was the work of [[wikipedia:Gertrude B. Elion|Gertrude Elion]] and her colleagues at Burroughs Wellcome. Elion had spent decades developing purine and pyrimidine analogues for cancer chemotherapy ([[wikipedia:Mercaptopurine|6-mercaptopurine]], [[wikipedia:Azathioprine|azathioprine]], allopurinol); in the 1970s the same screening framework was turned toward viral enzymes. [[wikipedia:Aciclovir|Aciclovir]] (acyclovir), reported in 1977, was an acyclic guanosine analogue that required phosphorylation by the herpes simplex virus thymidine kinase to its monophosphate, then by cellular kinases to the triphosphate, which selectively inhibited the viral DNA polymerase.<ref name="elion1977">Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. ''Proceedings of the National Academy of Sciences of the United States of America''. 1977 Dec;74(12):5716-5720. PMID 202961.</ref> Because the host cell did not phosphorylate the medicine to any meaningful extent, aciclovir was concentrated, by orders of magnitude, in herpes-infected cells. The selectivity was extraordinary, and the medicine remains the standard treatment for herpes simplex and herpes zoster decades later. Elion shared the 1988 Nobel Prize. [[Valacyclovir|Valacyclovir]] (the L-valyl ester, 1995) and famciclovir (the diacetyl ester of penciclovir, 1994) improved oral bioavailability without changing the underlying pharmacology.

The transformative antiviral event of the late twentieth century was the introduction of antiretroviral therapy for human immunodeficiency virus. [[wikipedia:Zidovudine|Zidovudine]] (azidothymidine, AZT) had been synthesised by Jerome Horwitz in 1964 as a failed anticancer agent. In 1985 [[wikipedia:Hiroaki Mitsuya|Hiroaki Mitsuya]] and [[wikipedia:Samuel Broder|Samuel Broder]] at the National Cancer Institute, screening Horwitz's old compound collection, showed that AZT inhibited HIV reverse transcriptase in vitro; the medicine was rushed through trial and approved in 1987, becoming the first antiretroviral.<ref name="mitsuya1985">Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. ''Proceedings of the National Academy of Sciences of the United States of America''. 1985 Oct;82(20):7096-7100. PMID 2413459.</ref> Monotherapy with zidovudine produced rapid resistance and limited survival benefit; the breakthrough was the 1996 introduction of three-medicine "highly active antiretroviral therapy" (HAART), in which two nucleoside reverse transcriptase inhibitors were combined with either a protease inhibitor (saquinavir, ritonavir, indinavir, nelfinavir) or a non-nucleoside reverse transcriptase inhibitor (nevirapine, efavirenz). HAART converted HIV infection from a uniformly fatal disease (median survival approximately 10 years after seroconversion before 1996) to a chronic manageable condition with near-normal life expectancy on continuous treatment. Subsequent classes (the integrase strand transfer inhibitors raltegravir, dolutegravir, bictegravir; the fusion inhibitors and entry inhibitors maraviroc, enfuvirtide; the capsid inhibitor lenacapavir) and once-daily fixed-dose combination tablets have made modern antiretroviral therapy a single pill, taken once a day, with minimal side effect.

The second great antiviral story of the contemporary period is the cure of [[wikipedia:Hepatitis C|hepatitis C]]. The virus, identified in 1989 by Houghton, Choo, Kuo, and Bradley at Chiron, had been treated with interferon-alpha (combined later with the nucleoside analogue ribavirin) at sustained-virologic-response rates of approximately 50 percent, with substantial flu-like and psychiatric side effects. The introduction of the direct-acting antivirals (DAAs) in 2013-2014 changed the field within two years. [[wikipedia:Sofosbuvir|Sofosbuvir]] (Gilead, 2013), an NS5B polymerase nucleotide inhibitor, combined with the NS5A inhibitors ledipasvir, daclatasvir, velpatasvir, and the protease inhibitors simeprevir and grazoprevir, produced sustained-virologic-response rates above 95 percent across all genotypes with 8-to-12-week oral courses and minimal side effects.<ref name="lawitz2013">Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. ''New England Journal of Medicine''. 2013 May 16;368(20):1878-1887. PMID 23607594.</ref> The DAA-era hepatitis C cure is one of the rare modern examples of a chronic viral infection rendered eliminable by short-course medicine alone, and the WHO has targeted hepatitis C for elimination as a public-health problem by 2030.

The other antiviral pathogens have produced more limited but real progress. [[wikipedia:Influenza|Influenza]] is treated with the [[:Category:Neuraminidase_inhibitors|neuraminidase inhibitors]] [[Oseltamivir|oseltamivir]] (Tamiflu, Gilead/Roche, 1999) and zanamivir, which block release of new viral particles from infected cells, and with the cap-dependent endonuclease inhibitor baloxavir (2018); these medicines shorten symptom duration by approximately one day in immunocompetent adults but have a more substantial benefit in the very young, the elderly, and the immunocompromised. The hepatitis B virus is suppressed (though not cured) by the nucleoside and nucleotide reverse-transcriptase inhibitors tenofovir, entecavir, and (the original) lamivudine. The recently developed antivirals for severe acute respiratory syndrome coronavirus 2 ([[wikipedia:Remdesivir|remdesivir]], the RNA-dependent RNA polymerase nucleotide inhibitor, 2020; [[wikipedia:Nirmatrelvir|nirmatrelvir]]/[[wikipedia:Ritonavir|ritonavir]], the 3CL protease inhibitor combination, 2021) provide modest clinical benefit in early COVID-19 in high-risk patients. The cytomegalovirus medicines ganciclovir and valganciclovir, and the recently approved letermovir, treat CMV in transplantation. The smallpox antiviral tecovirimat (2018), originally developed against bioterrorism strains of variola, was repurposed for human mpox in 2022.

What unifies the contemporary antiviral category, in contrast to the antibacterials, is that for many of the historically lethal viral infections there is now either an effective treatment, an effective vaccine, or both. The category remains poor in agents for the respiratory RNA viruses other than influenza (no effective antiviral for respiratory syncytial virus in adults, none for human metapneumovirus, none for the seasonal coronaviruses); for the dengue and other arboviruses; and for the haemorrhagic-fever viruses except Ebola, where the monoclonal antibody cocktail Inmazeb and the single-agent ansuvimab are now first-line. The expansion of the category continues to be driven by the genomic identification of new viral enzymes that have no human counterpart.

== Classes indexed ==

By target:

* '''Herpesvirus medicines''' ([[:Category:Anti-herpesvirus_agents|anti-herpesvirus agents]], herpes simplex and varicella zoster): [[Acyclovir|aciclovir (acyclovir)]] and its valyl ester [[Valacyclovir|valaciclovir]]; famciclovir (the diacetyl ester of penciclovir); for cytomegalovirus the more potent ganciclovir and valganciclovir, with foscarnet for resistant CMV and the recent letermovir
* '''Influenza medicines''' ([[:Category:Anti-influenza_agents|anti-influenza agents]] and [[:Category:Neuraminidase_inhibitors|neuraminidase inhibitors]]): [[Oseltamivir|oseltamivir]], zanamivir, peramivir (intravenous), baloxavir (cap-dependent endonuclease inhibitor)
* '''Antiretrovirals''' (HIV): the nucleoside / nucleotide reverse transcriptase inhibitors (zidovudine, lamivudine, abacavir, tenofovir alafenamide and disoproxil fumarate, emtricitabine), the non-nucleoside reverse transcriptase inhibitors (efavirenz, rilpivirine, doravirine), the protease inhibitors (ritonavir as booster, darunavir, atazanavir), the integrase strand transfer inhibitors (raltegravir, dolutegravir, bictegravir, cabotegravir), the entry and fusion inhibitors (maraviroc, enfuvirtide), the capsid inhibitor lenacapavir, and the long-acting injectable cabotegravir/rilpivirine
* '''Hepatitis C direct-acting antivirals''': NS5B polymerase inhibitors (sofosbuvir), NS5A inhibitors (ledipasvir, velpatasvir, daclatasvir, pibrentasvir), NS3/4A protease inhibitors (glecaprevir, voxilaprevir, grazoprevir); the fixed-combinations sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir
* '''Hepatitis B''' (suppressive): tenofovir, entecavir, lamivudine; pegylated interferon-alfa for selected patients
* '''SARS-CoV-2''' (COVID-19): [[wikipedia:Remdesivir|remdesivir]] (intravenous, hospitalised patients), [[wikipedia:Nirmatrelvir|nirmatrelvir]]/ritonavir (oral, outpatient), molnupiravir (oral, outpatient, modest benefit)
* '''Other viral families''': tecovirimat for mpox/variola; ribavirin (broad-spectrum guanosine analogue, used for hepatitis C in older regimens, for respiratory syncytial virus in selected paediatric cases, and for selected haemorrhagic fevers); the Ebola monoclonal antibodies Inmazeb and ansuvimab; the broad-spectrum unproven amantadine and rimantadine (now largely retired for influenza because of universal M2 channel resistance)

== Notes on scope ==

The boundary of this category is "medicine that inhibits replication of a virus pathogenic to humans." The vaccines that prevent viral infection (the influenza vaccines, the SARS-CoV-2 mRNA and adenovirus-vectored vaccines, the hepatitis A and B vaccines, the human papillomavirus vaccine, the measles-mumps-rubella vaccine, and many others) are an entirely different pharmacological category, although they accomplish similar clinical aims; they are collected under [[:Category:Biologics|biologics]] and under their specific vaccine indications. The monoclonal antibodies used in pre-exposure or post-exposure prophylaxis of viral disease (the RSV agents palivizumab and nirsevimab; the SARS-CoV-2 agents in the changing succession that resistance has produced; the Ebola Inmazeb and ansuvimab) are biologic medicines and are listed here when used as treatment and under [[:Category:Monoclonal_antibodies|monoclonal antibodies]] otherwise. Interferons (interferon-alpha for hepatitis B and historically hepatitis C; interferon-beta for multiple sclerosis) are collected under [[:Category:Immunomodulators|immunomodulators]] when their indication is autoimmune.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Anti-infectives]]
[[Category:CuratedCategoryPage]]

Category:Glaucoma medications

2026-05-23T19:48:10Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''glaucoma medication''' is an [[wikipedia:Intraocular pressure|intraocular-pressure]]-lowering medicine used in the management of [[wikipedia:Glaucoma|glaucoma]], the optic-nerve disease in which a characteristic excavation of the optic disc and a corresponding loss of peripheral vision occur over years in association with a level of intraocular pressure that the optic nerve of a given patient cannot tolerate. The category includes the five established pharmacological classes ([[wikipedia:Prostaglandin analogue|prostaglandin analogues]], [[:Category:Beta-blockers|topical beta-blockers]], topical alpha-2 agonists, topical and oral [[:Category:Carbonic_anhydrase_inhibitors|carbonic anhydrase inhibitors]], and the cholinergic miotics) and the newer Rho-associated kinase (ROCK) inhibitors and selective adenosine-A1 agonists.

The disease was named in classical antiquity. [[wikipedia:Hippocrates|Hippocrates]] used the word ''glaukos'' (γλαυκός, bluish-grey) for the discoloured iris of advanced cases. The connection between optic-disc cupping, visual-field loss, and elevated intraocular pressure was made by the German ophthalmologist [[wikipedia:Albrecht von Gräfe|Albrecht von Graefe]] in Berlin in 1857, who also performed the first iridectomy as a treatment.<ref name="vongraefe1857">von Graefe A. Ueber die Iridectomie bei Glaucom und über den glaucomatösen Process. ''Archiv für Ophthalmologie''. 1857;3(2):456-555.</ref> Surgical management dominated the field until the late nineteenth century, when the discovery of pharmacological alternatives began.

The first effective medical treatment was a plant alkaloid. The English physician [[wikipedia:Sir Thomas Fraser, 1st Baronet|Thomas Fraser]] of Edinburgh reported in 1862 that an extract of the Calabar bean ''[[wikipedia:Physostigma venenosum|Physostigma venenosum]]'', used as an ordeal poison in West Africa, produced miosis when dropped into the eye; the alkaloid responsible, [[wikipedia:Physostigmine|physostigmine]] (eserine), was isolated by Jobst and Hesse in 1864. Physostigmine and the related cholinergic alkaloid [[wikipedia:Pilocarpine|pilocarpine]] (from the South American plant ''Pilocarpus jaborandi'', isolated by Hardy in 1875) were applied as miotic drops in glaucoma; both lower intraocular pressure by contracting the ciliary muscle and pulling open the trabecular meshwork, improving aqueous outflow. The miotics were the mainstay of medical glaucoma therapy for ninety years, although their pupillary constriction, dim-vision side effect, and induction of cataract progressively narrowed their use.

The first systemic glaucoma medicine was a sulfonamide. [[wikipedia:Acetazolamide|Acetazolamide]] was developed by [[wikipedia:Richard L. M. Synge|Roblin]] and Clapp at Lederle in 1953 as a [[:Category:Carbonic_anhydrase_inhibitors|carbonic anhydrase inhibitor]]; its diuretic effect was noted first, but [[wikipedia:Bernard Becker|Bernard Becker]] in 1954 showed that it also reduced aqueous-humour production by the ciliary epithelium and lowered intraocular pressure substantially.<ref name="becker1954">Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. A preliminary report. ''American Journal of Ophthalmology''. 1954 Jan;37(1):13-15. PMID 13114212.</ref> Systemic carbonic anhydrase inhibitors continue to be used acutely for the management of acute angle-closure glaucoma and chronically in advanced cases not controlled by topical agents; the topical analogues [[Dorzolamide|dorzolamide]] (Merck, 1995) and brinzolamide (Alcon, 1998) provide the local effect without the systemic side effects of paraesthesia, metallic taste, and renal-stone formation.

The 1970s brought the first selective topical adrenergic medicine. [[wikipedia:Timolol|Timolol]], a non-selective beta-blocker originally developed by Merck as a systemic antihypertensive, was reformulated as 0.25% and 0.5% ophthalmic drops and approved for glaucoma in 1978; topical timolol reduces aqueous-humour production by acting on beta-2 receptors of the ciliary epithelium and lowers intraocular pressure by 25 to 30 percent.<ref name="zimmerman1977">Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. ''Archives of Ophthalmology''. 1977 Apr;95(4):601-604. PMID 322647.</ref> Timolol remained the standard first-line medical therapy for the next twenty years, until the prostaglandin era; its systemic absorption from the conjunctival sac, however, is sufficient to produce bradycardia, bronchospasm, and depressed mood in susceptible patients, and the medicine has retreated to second-line use. The selective alpha-2 agonist [[wikipedia:Apraclonidine|apraclonidine]] (1987) and the more selective and better-tolerated [[Brimonidine|brimonidine]] (Allergan, 1996) lower intraocular pressure both by reducing aqueous secretion and by enhancing uveoscleral outflow.

The transformative class of contemporary glaucoma medicine was the prostaglandin analogue. The Hungarian-American pharmacologist [[wikipedia:László Z. Bitó|László Bitó]] at Columbia, working in the 1970s on the effects of prostaglandins on intraocular pressure, observed paradoxically that low concentrations of certain prostaglandin F2α analogues lowered, rather than raised, the pressure by markedly enhancing the uveoscleral pathway of aqueous outflow.<ref name="bito1989">Bito LZ, Stjernschantz J, Resul B, Miranda OC, Basu S. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management. ''Journal of Lipid Mediators''. 1993 Jul;6(1-3):535-543. PMID 8358017.</ref> Bito's collaboration with [[wikipedia:Pharmacia|Pharmacia]] produced [[Latanoprost|latanoprost]] (Xalatan, 1996), the first prostaglandin analogue glaucoma medicine; [[Bimatoprost|bimatoprost]] (Lumigan, Allergan, 2001), travoprost (Alcon, 2001), and tafluprost followed. The class lowers intraocular pressure by 28 to 32 percent on once-daily evening dosing, has minimal systemic effect, and has displaced beta-blockers as the standard first-line medical therapy. The principal cosmetic side effects, progressive darkening of the iris (in genetically heterochromic eyes), darkening and lengthening of the eyelashes (an effect that bimatoprost is separately marketed under the trade name Latisse for cosmetic use), and periorbital fat atrophy with deepening of the upper lid sulcus, are recognised and are accepted in exchange for the IOP benefit.

The most recent pharmacological additions act on the trabecular meshwork directly. The Rho-associated kinase inhibitor [[wikipedia:Netarsudil|netarsudil]] (Aerie, 2017) lowers IOP by relaxing actomyosin contractility in the trabecular meshwork and Schlemm's canal, increasing trabecular outflow. The selective adenosine-A1 receptor agonist [[wikipedia:Trabodenoson|trabodenoson]] and the fixed-combination drops (netarsudil-latanoprost, brimonidine-timolol, dorzolamide-timolol, latanoprost-netarsudil) round out the contemporary pharmacopoeia. Selective laser trabeculoplasty has emerged in parallel as a first-line procedural alternative to chronic eye drops, and the LiGHT trial in 2019 found that primary SLT produced equivalent IOP control with a higher quality-of-life score than primary medical therapy. The medicine-versus-laser-versus-incisional-surgery decision is now a genuine three-way choice rather than a sequential escalation.

== Classes indexed ==

By mechanism:

* Prostaglandin analogues (enhanced uveoscleral outflow): [[Latanoprost|latanoprost]], [[Bimatoprost|bimatoprost]], travoprost, tafluprost
* Topical beta-blockers (reduced aqueous production): timolol, betaxolol (β1-selective, less bronchospasm risk), levobunolol, carteolol
* Topical alpha-2 agonists (reduced aqueous production, enhanced uveoscleral outflow): [[Brimonidine|brimonidine]], apraclonidine
* Topical [[:Category:Carbonic_anhydrase_inhibitors|carbonic anhydrase inhibitors]] (reduced aqueous production): [[Dorzolamide|dorzolamide]], brinzolamide
* Oral carbonic anhydrase inhibitors (advanced or acute cases): [[wikipedia:Acetazolamide|acetazolamide]], methazolamide
* Cholinergic miotics (improved trabecular outflow, ciliary-muscle contraction): pilocarpine, carbachol; the indirect-acting echothiophate (largely obsolete)
* Rho-associated kinase inhibitors: [[wikipedia:Netarsudil|netarsudil]]
* Hyperosmotic agents (emergency IOP reduction in acute angle closure): intravenous [[wikipedia:Mannitol|mannitol]], oral glycerol
* Fixed combinations: dorzolamide-timolol, brimonidine-timolol, brinzolamide-brimonidine, netarsudil-latanoprost, bimatoprost-timolol

== Notes on scope ==

The boundary of this category is "medicine prescribed in the management of glaucoma." The category overlaps almost completely with the [[:Category:Ocular_hypotensive_agents|ocular hypotensive agents]] category, which is organised by the same medicines but emphasises mechanism (IOP lowering) over indication (glaucoma). The two categories are kept as parallel listings for the convenience of readers approaching from each direction. The medicines used in the surgical management of glaucoma (intraoperative mitomycin-C, antiproliferative 5-fluorouracil) are not glaucoma medications in the conventional sense and are listed under their oncologic or surgical categories. The neuroprotective and neurotrophic agents in trial for non-IOP-mediated optic-nerve preservation in glaucoma (citicoline, brimonidine in some neuroprotection trials, intravitreal nerve-growth factor) are not yet established in standard care and are not collected here. Ophthalmologic medicines used for conditions other than glaucoma (the ophthalmic antibiotics, antifungals, mydriatics, cycloplegics, the [[:Category:Ophthalmic_antihistamines|ophthalmic antihistamines]], the intravitreal anti-VEGF agents for macular degeneration) belong to those respective categories.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:CuratedCategoryPage]]

Category:Antiplatelet agents

2026-05-23T19:48:10Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''antiplatelet agent''' is a medicine that interferes with platelet activation, adhesion, or aggregation, reducing the propensity of platelets to form a thrombus on a damaged or atherosclerotic vascular surface. The category is distinct from the [[:Category:Anticoagulants|anticoagulants]], which act on the coagulation cascade rather than on platelet function, although the two are often co-prescribed (and their bleeding risks are additive). The antiplatelet agents are the foundation of secondary prevention in atherothrombotic disease (coronary, cerebrovascular, peripheral arterial), are central to the management of acute coronary syndromes, and are essential to the safe deployment of intravascular devices (coronary stents, mechanical heart valves with thrombogenic surfaces, ventricular assist devices).

The category begins with aspirin. The antiplatelet effect of acetylsalicylic acid, taken since 1899 as an analgesic, antipyretic, and anti-inflammatory, was identified by [[wikipedia:Harvey J. Weiss|Harvey Weiss]] at Roosevelt Hospital in New York in 1967, who showed that ingestion of aspirin in a normal adult abolished the platelet response to collagen and prolonged the bleeding time;<ref name="weiss1967">Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. ''Journal of Clinical Investigation''. 1968 Sep;47(9):2169-2180. PMID 4232539.</ref> the British pharmacologist [[wikipedia:John Vane|John Vane]] four years later demonstrated the mechanism: aspirin irreversibly acetylates cyclooxygenase (COX-1) in the platelet, which lacks a nucleus and cannot resynthesize the enzyme, eliminating the platelet's ability to produce thromboxane A2 for the lifespan of the platelet (approximately ten days). The 1988 ISIS-2 trial of 17,187 patients with suspected acute myocardial infarction randomised to aspirin, intravenous streptokinase, both, or neither showed a 23 percent reduction in 35-day vascular mortality with aspirin alone, additive to the 25 percent reduction with streptokinase alone, and the combination achieved a 42 percent reduction; the trial established daily 75-to-100 mg aspirin as the foundational secondary-prevention medicine.<ref name="isis2_1988">ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ''Lancet''. 1988 Aug 13;2(8607):349-360. PMID 2899772.</ref>

The second class of antiplatelet was the [[:Category:Thienopyridines|thienopyridine]] family of ADP-receptor antagonists. Ticlopidine, introduced in 1991, irreversibly inhibited the platelet P2Y12 receptor for adenosine diphosphate; its development was complicated by a rare but devastating thrombotic thrombocytopenic purpura (TTP) and an idiosyncratic neutropenia. [[wikipedia:Clopidogrel|Clopidogrel]] (Sanofi/BMS, 1997), a closely related compound requiring CYP2C19 activation, replaced ticlopidine with a substantially better safety profile and became, in combination with aspirin, the standard "dual antiplatelet therapy" (DAPT) following coronary stent implantation. The 2001 CURE trial established the benefit of clopidogrel + aspirin over aspirin alone in non-ST-elevation acute coronary syndromes.<ref name="cure2001">CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. ''New England Journal of Medicine''. 2001 Aug 16;345(7):494-502. PMID 11519503.</ref> [[wikipedia:Prasugrel|Prasugrel]] (Daiichi Sankyo/Lilly, 2009) and [[wikipedia:Ticagrelor|ticagrelor]] (AstraZeneca, 2011) followed with more potent, faster-onset, and (for ticagrelor) reversible P2Y12 blockade; the TRITON-TIMI 38 and PLATO trials established their superiority over clopidogrel in selected acute-coronary-syndrome populations, at the cost of a modest increase in major bleeding.

A second mechanism is intravenous glycoprotein IIb/IIIa inhibition. The platelet GP IIb/IIIa receptor is the final common pathway by which platelets cross-link to each other through fibrinogen bridges; its monoclonal antibody [[wikipedia:Abciximab|abciximab]] (Centocor, 1994), and the small-molecule inhibitors [[wikipedia:Eptifibatide|eptifibatide]] (1998) and [[wikipedia:Tirofiban|tirofiban]] (1998), were used extensively during high-risk percutaneous coronary intervention in the early 2000s; their clinical role has narrowed substantially as the oral P2Y12 inhibitors have improved.

The most recent mechanistic addition is protease-activated-receptor-1 (PAR-1) inhibition. The thrombin receptor on the platelet surface, activated by thrombin's proteolytic cleavage of its N-terminus, drives a third independent pathway of platelet activation. [[wikipedia:Vorapaxar|Vorapaxar]] (Merck, 2014), the first PAR-1 antagonist, demonstrated a modest reduction in atherothrombotic events when added to aspirin and clopidogrel in patients with prior myocardial infarction or peripheral arterial disease (TRA 2°P-TIMI 50 trial); its clinical use has been limited by the bleeding-risk increment of triple antiplatelet therapy and by its contraindication in patients with prior stroke.

The duration of dual or triple antiplatelet therapy is one of the most actively investigated clinical decisions in cardiovascular medicine. Modern second-generation medicine-eluting stents allow DAPT durations as short as one month in selected lower-risk patients, balancing the residual stent-thrombosis risk against the cumulative bleeding cost of prolonged treatment. The CHARISMA, DAPT, PEGASUS, TWILIGHT, and HOST-EXAM trials have together defined a complex set of patient-specific algorithms for DAPT duration after acute coronary syndrome and after elective PCI; the contemporary trend has been toward shorter DAPT followed by either aspirin or P2Y12 monotherapy, with monotherapy with the more potent P2Y12 inhibitor (rather than the historical default of aspirin) increasingly favoured.

== Classes indexed ==

By target:

* '''Cyclooxygenase-1 inhibitors''': [[Aspirin|aspirin]] (low-dose for antiplatelet effect, 75-100 mg daily)
* '''[[:Category:P2Y12_inhibitors|P2Y12 inhibitors]]''' (ADP-receptor antagonists):
** [[:Category:Thienopyridines|Thienopyridine]] precursors (irreversible, require hepatic activation): [[wikipedia:Clopidogrel|clopidogrel]] (Plavix), [[wikipedia:Prasugrel|prasugrel]] (Effient), [[wikipedia:Ticlopidine|ticlopidine]] (largely retired)
** Non-thienopyridine direct-acting reversible: [[wikipedia:Ticagrelor|ticagrelor]] (Brilinta), [[wikipedia:Cangrelor|cangrelor]] (intravenous)
* '''Glycoprotein IIb/IIIa receptor antagonists''' (intravenous, in-hospital use):
** [[wikipedia:Abciximab|Abciximab]] (monoclonal antibody Fab), [[wikipedia:Eptifibatide|eptifibatide]] (synthetic peptide), [[wikipedia:Tirofiban|tirofiban]] (small molecule)
* '''Protease-activated-receptor-1 (PAR-1) antagonist''':
** [[wikipedia:Vorapaxar|Vorapaxar]] (Zontivity)
* '''Phosphodiesterase inhibitors''' (with secondary antiplatelet effect):
** [[wikipedia:Dipyridamole|Dipyridamole]] (in fixed combination with aspirin as Aggrenox for secondary stroke prevention)
** [[wikipedia:Cilostazol|Cilostazol]] (for symptomatic peripheral arterial disease intermittent claudication)
* '''Adenosine reuptake inhibitor''' (largely retired): dipyridamole alone

== Notes on scope ==

The boundary of this category is "medicine that inhibits platelet activation, adhesion, or aggregation to prevent or treat arterial thrombosis." The [[:Category:Anticoagulants|anticoagulants]] (heparins, warfarin, DOACs) act on the coagulation cascade rather than on platelets and are collected separately; the two categories are often combined clinically (the "triple therapy" of aspirin + clopidogrel + warfarin or DOAC for atrial fibrillation with concurrent coronary stenting), but the medicines are pharmacologically distinct. The fibrinolytic medicines (alteplase, tenecteplase, streptokinase, reteplase) lyse already-formed thrombi rather than preventing their formation and are listed under a separate category. The thrombopoietin receptor agonists (romiplostim, eltrombopag, avatrombopag) increase platelet production rather than inhibiting platelet function and are not in this category. Selected NSAIDs other than aspirin have some antiplatelet effect at higher doses but are not used clinically for this purpose and are not collected here.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Cardiovascular_agents]]
[[Category:CuratedCategoryPage]]

Category:Antihypertensives

2026-05-23T19:48:09Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''antihypertensive''' is a medicine that lowers the arterial blood pressure. The category, as a category of useful medicines, did not exist until the middle of the twentieth century, for the simple reason that high blood pressure was not, until then, understood to be a treatable disease. In 1931 the British physician [[wikipedia:John Hay (cardiologist)|John Hay]] set down the prevailing view in two sentences that became infamous: "There is some truth in the saying that the greatest danger to a man with a high blood pressure lies in its discovery, because then some fool is certain to try and reduce it."<ref name="hay1931">Hay J. The significance of a raised blood pressure. ''British Medical Journal''. 1931 Jul 11;2(3679):43-47.</ref> The reasoning behind the view was not unreasonable on its face: the elevated pressure was thought to be a compensatory response to a narrowed and hardened circulation, and the fear was that lowering it would reduce perfusion of the brain, the heart, and the kidneys to dangerous levels.

The view was dramatized publicly by the death of [[wikipedia:Franklin D. Roosevelt|President Franklin D. Roosevelt]] on the afternoon of 12 April 1945, of a massive cerebral hemorrhage at the age of sixty-three. His personal physician [[wikipedia:Howard Bruenn|Howard Bruenn]] later published the clinical record: pressures in the months before death of 240/130 millimetres of mercury, treated, in the absence of any effective option, with phenobarbital, digitalis, and bed rest, and rising to 300/190 at the time of the fatal stroke.<ref name="bruenn1970">Bruenn HG. Clinical notes on the illness and death of President Franklin D. Roosevelt. ''Annals of Internal Medicine''. 1970 Apr;72(4):579-591. PMID 4938425.</ref> The case has been reviewed many times in the decades since, both as a clinical history and as an argument that the medical profession had been wrong.

The argument was settled, formally, by [[wikipedia:Edward D. Freis|Edward Freis]] and the Veterans Administration Cooperative Study Group on Antihypertensive Agents, working at the Washington VA Hospital. Their first trial, published in 1967, randomized 143 men with diastolic pressures between 115 and 129 millimetres of mercury to either a combination of hydrochlorothiazide, reserpine, and hydralazine, or to placebo; the placebo arm accumulated strokes, heart failure, and aortic dissections at such a rate that the trial was stopped early and the protocol unblinded.<ref name="va1967">Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. ''JAMA''. 1967 Dec 11;202(11):1028-1034. PMID 4862632.</ref> A second VA Cooperative trial, in milder hypertension, confirmed the benefit in 1970.<ref name="va1970">Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. ''JAMA''. 1970 Aug 17;213(7):1143-1152. PMID 5468336.</ref> Observational data accumulating in parallel from the [[wikipedia:Framingham Heart Study|Framingham Heart Study]] showed that the relationship between blood pressure and cardiovascular events was continuous and monotonic, with no apparent threshold of harm.<ref name="kannel1996">Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. ''JAMA''. 1996 May 22-29;275(20):1571-1576. PMID 8622248.</ref> The 1931 doctrine was abandoned and clinical attention shifted to which medicines to use, and at what blood-pressure target.

Several medicines were already in hand by 1967. The [[:Category:Thiazide_diuretics|thiazide diuretics]] had been introduced in 1957 with chlorothiazide, developed at the [[wikipedia:Merck Sharp & Dohme|Sharp and Dohme]] research laboratories by [[wikipedia:Karl H. Beyer|Karl Beyer]]'s group from an effort to improve on the existing carbonic anhydrase inhibitors; the new compound preferentially blocked sodium and chloride reabsorption in the distal tubule of the nephron and lowered the blood pressure as efficiently as it cleared the edema of heart failure.<ref name="beyer1993">Beyer KH Jr. Chlorothiazide. How the thiazides evolved as antihypertensive therapy. ''Hypertension''. 1993 Sep;22(3):388-391. PMID 8349333.</ref> [[Hydrochlorothiazide]], a closer derivative, followed two years later and became the standard of the class. The [[:Category:Direct_vasodilators|direct vasodilators]] had been developed earlier: [[Hydralazine|hydralazine]] at [[wikipedia:Ciba (company)|Ciba]] in 1949 as an offshoot of antimalarial chemistry, [[wikipedia:Minoxidil|minoxidil]] at [[wikipedia:Upjohn|Upjohn]] in the 1960s. The centrally acting sympatholytic [[wikipedia:Methyldopa|methyldopa]] was introduced by [[wikipedia:Merck & Co.|Merck]] in 1960. The [[:Category:Beta-blockers|beta-adrenergic blockers]], beginning with propranolol synthesized by [[wikipedia:James Black (pharmacologist)|James Black]] at [[wikipedia:Imperial Chemical Industries|Imperial Chemical Industries]] in 1964, lowered blood pressure as a side benefit of their antianginal effect, and were quickly recognized as antihypertensive in their own right.<ref name="black1964">Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic beta-receptor antagonist. ''Lancet''. 1964 May 16;1(7342):1080-1081. PMID 14132613.</ref>

The transformative class of the antihypertensive era was the angiotensin-converting enzyme inhibitor. In 1965 the Brazilian physiologist [[wikipedia:Sérgio Henrique Ferreira|Sérgio Ferreira]], working in [[wikipedia:John Vane|John Vane]]'s laboratory in London, had isolated from the venom of the Brazilian pit viper Bothrops jararaca a series of small peptides that potentiated the action of bradykinin and inhibited the enzyme that converts angiotensin I to angiotensin II; the profound hypotension of a jararaca envenomation is in part the work of these peptides.<ref name="ferreira1965">Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of ''Bothrops jararaca''. ''British Journal of Pharmacology and Chemotherapy''. 1965 Feb;24:163-169. PMID 14302350.</ref> A decade later [[wikipedia:Miguel Ondetti|Miguel Ondetti]] and [[wikipedia:David Cushman (scientist)|David Cushman]] at the [[wikipedia:Squibb|Squibb Institute for Medical Research]], working from a model of the active site informed by what was then known of carboxypeptidase A, designed [[Captopril|captopril]], a small orally bioavailable inhibitor of the converting enzyme.<ref name="ondetti1977">Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. ''Science''. 1977 Apr 22;196(4288):441-444. PMID 191908.</ref> Captopril was approved by the U.S. Food and Drug Administration in 1981 and the class expanded quickly: [[Enalapril|enalapril]], [[Lisinopril|lisinopril]], [[Ramipril|ramipril]], [[Benazepril|benazepril]]. The [[:Category:Angiotensin_receptor_blockers|angiotensin receptor blockers]] followed, beginning with [[Losartan|losartan]] in 1995, developed at the DuPont Merck laboratories from a series of imidazole leads first reported by Takeda chemistry.<ref name="carini1991">Carini DJ, Duncia JV, Aldrich PE, Chiu AT, Johnson AL, Pierce ME, Price WA, Santella JB 3rd, Wells GJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. ''Journal of Medicinal Chemistry''. 1991 Aug;34(8):2525-2547. PMID 1875347.</ref>

The [[:Category:Calcium_channel_blockers|calcium channel blockers]] entered cardiovascular medicine through a separate door. [[Verapamil|Verapamil]], synthesized in Germany in 1962, was the first agent shown by [[wikipedia:Albrecht Fleckenstein|Albrecht Fleckenstein]] to block the slow inward calcium current of cardiac and vascular smooth muscle.<ref name="fleckenstein1983">Fleckenstein A. History of calcium antagonists. ''Circulation Research''. 1983 Feb;52(2 Pt 2):I3-16. PMID 6297830.</ref> [[Nifedipine|Nifedipine]] and the rest of the dihydropyridine family followed; [[Amlodipine|amlodipine]], with its long plasma half-life and gradual onset, provided in 1992 the once-daily dosing and freedom from reflex tachycardia that the immediate-release dihydropyridines had lacked. By the end of the twentieth century five medicine classes, the diuretics, the ACE inhibitors, the angiotensin receptor blockers, the calcium channel blockers, and the beta-blockers, were established as the building blocks of essential-hypertension therapy.

The remaining clinical question, and it remains alive, is the treatment target. The early VA trials set a working aim of "below 140/90" by convention. The Hypertension Optimal Treatment trial in 1998 examined diastolic targets between 80 and 90 millimetres of mercury and could not show clear benefit of the lower one.<ref name="hot1998">Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients at high risk of cardiovascular disease: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. ''Lancet''. 1998 Jun 13;351(9118):1755-1762. PMID 9635947.</ref> The Systolic Blood Pressure Intervention Trial in 2015, by contrast, randomized patients at high cardiovascular risk to a systolic target of 120 versus 140 and was stopped early for benefit in the intensive arm, at the cost of a higher rate of hypotension, syncope, and acute kidney injury.<ref name="sprint2015">SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, et al. A randomized trial of intensive versus standard blood-pressure control. ''New England Journal of Medicine''. 2015 Nov 26;373(22):2103-2116. PMID 26551272.</ref> Current American guidelines have settled, for most adults, on a treatment goal of less than 130/80 millimetres of mercury, while acknowledging that the evidence base for any single threshold remains contested and that the absolute benefit of treatment scales with the patient's baseline cardiovascular risk rather than with the blood pressure alone.<ref name="whelton2018">Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. ''Hypertension''. 2018 Jun;71(6):e13-e115. PMID 29133356.</ref>

== Classes indexed ==

The principal medicine classes by which the arterial blood pressure is lowered in modern practice:

* [[:Category:ACE_inhibitors|Angiotensin-converting enzyme (ACE) inhibitors]]: [[Benazepril|benazepril]], [[Enalapril|enalapril]], [[Lisinopril|lisinopril]], [[Ramipril|ramipril]]
* [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blockers (ARBs)]]: [[Irbesartan|irbesartan]], [[Losartan|losartan]], [[Olmesartan|olmesartan]], [[Telmisartan|telmisartan]], [[Valsartan|valsartan]]
* [[:Category:Calcium_channel_blockers|Calcium channel blockers]] (dihydropyridine and non-dihydropyridine): [[Amlodipine|amlodipine]], [[Diltiazem|diltiazem]], [[Nifedipine|nifedipine]], [[Verapamil|verapamil]]
* [[:Category:Thiazide_diuretics|Thiazide diuretics]] and [[:Category:Thiazide-like_diuretics|thiazide-like diuretics]]: [[Hydrochlorothiazide|hydrochlorothiazide]], [[Chlorthalidone|chlorthalidone]]
* [[:Category:Alpha-1_blockers|Alpha-1 adrenergic blockers]] (where also used in prostatic hyperplasia): [[Doxazosin|doxazosin]], [[Terazosin|terazosin]]
* [[:Category:Direct_vasodilators|Direct arteriolar vasodilators]]: [[Hydralazine|hydralazine]]

Closely related classes whose principal indication is not hypertension but which lower blood pressure as part of their action are collected separately: the [[:Category:Beta-blockers|beta-adrenergic blockers]], the [[:Category:Aldosterone_antagonists|aldosterone antagonists]], the [[:Category:Loop_diuretics|loop diuretics]] when used in resistant hypertension or hypertension complicated by heart failure, and the centrally-acting sympatholytic agents ([[wikipedia:Methyldopa|methyldopa]], [[wikipedia:Clonidine|clonidine]], [[wikipedia:Reserpine|reserpine]]), the last three of which are now of largely historical interest.

== Notes on scope ==

The boundary of this category is "medicine whose principal or clinically important antihypertensive effect contributes to its place in prescribing." A medicine is listed here when blood-pressure lowering is one of its established indications, regardless of how it lowers the pressure. Some medicines listed here are also listed elsewhere because their principal indication is a different cardiovascular problem: the calcium channel blockers are antianginal as well as antihypertensive, the beta-blockers are antianginal and antiarrhythmic, the alpha-1 blockers are also used in benign prostatic hyperplasia. The multi-membership convention of this wiki permits a medicine to sit in every category that describes it. Hypertensive crises, managed with intravenous medicines in the acute setting ([[wikipedia:Sodium nitroprusside|sodium nitroprusside]], intravenous nicardipine, labetalol, esmolol, clevidipine), are within scope when those medicines have a dedicated page.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Cardiovascular_agents]]
[[Category:CuratedCategoryPage]]

Category:Opioid analgesics

2026-05-23T19:48:09Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''opioid analgesic''' is a medicine that relieves pain by binding to one or more of the opioid receptors of the nervous system. The category is named for the [[wikipedia:Opium poppy|opium poppy]] ''[[wikipedia:Papaver somniferum|Papaver somniferum]]'', the natural source of the prototype alkaloid morphine, and includes the natural opium alkaloids ([[Morphine|morphine]], [[Codeine|codeine]]), the semi-synthetic morphine derivatives ([[Hydromorphone|hydromorphone]], [[Oxycodone|oxycodone]], [[Oxymorphone|oxymorphone]], [[Hydrocodone|hydrocodone]], [[wikipedia:Heroin|diacetylmorphine]]), the wholly synthetic agonists (the phenylpiperidines including [[Meperidine|meperidine]] and the [[Fentanyl|fentanyl]] series; the diphenylheptane [[Methadone|methadone]]), the atypical centrally acting agents ([[Tramadol|tramadol]], [[Tapentadol|tapentadol]]), and the partial agonist [[Buprenorphine|buprenorphine]].

The medicinal use of opium is among the oldest documented in medicine. Sumerian tablets from the third millennium BCE name the poppy ''hul gil'', the joy plant. Greek and Roman physicians ([[wikipedia:Hippocrates|Hippocrates]], [[wikipedia:Galen|Galen]]) prescribed opium extracts for pain, cough, and diarrhoea; the Persian polymath [[wikipedia:Avicenna|Avicenna]] cautioned in the eleventh century that the medicine was dangerous in overdose. The Swiss physician [[wikipedia:Paracelsus|Paracelsus]] in the early sixteenth century introduced the tincture of opium in alcohol he called '''laudanum''', which remained, until the nineteenth century, the standard preparation. The transformative event of the pharmacological era was the work of a twenty-one-year-old apothecary's apprentice. In 1804 [[wikipedia:Friedrich Sertürner|Friedrich Sertürner]] of [[wikipedia:Paderborn|Paderborn]] in Westphalia isolated from opium a single crystalline alkaloid that produced the full range of opium's effect in a small fraction of the dose; he named it [[Morphine|morphium]] for Morpheus, the Greek god of dreams.<ref name="serturner1817">Sertürner FW. Über das Morphium, eine neue salzfähige Grundlage, und die Mekonsäure, als Hauptbestandtheile des Opiums. ''Annalen der Physik''. 1817;55(1):56-89.</ref> Morphine was the first alkaloid isolated from any plant, and Sertürner's report marks the conventional beginning of the science of alkaloid pharmacology.

The medicine reached the patient by way of a separate Scottish invention. In 1853 [[wikipedia:Alexander Wood (physician)|Alexander Wood]] of Edinburgh devised a hollow needle and a graduated syringe with which morphine could be injected under the skin, an order of magnitude more powerful and more reliably absorbed than any oral preparation. Hypodermic morphine was widely used in the American Civil War of 1861-1865 and produced an epidemic of dependence among the wounded that contemporaries called '''soldier's disease''', the first opioid-use disorder of the industrial-medical era. The semi-synthetic opioids followed. [[wikipedia:Charles Romley Alder Wright|C.R. Alder Wright]] at [[wikipedia:St Mary's Hospital, London|St Mary's Hospital]] in London synthesized diacetylmorphine in 1874 by acetylating morphine and tested it on a dog with disquieting results before abandoning the work. Twenty-four years later the German pharmaceutical company Bayer, whose chief chemist [[wikipedia:Heinrich Dreser|Heinrich Dreser]] had directed the parallel development of acetylsalicylic acid, marketed Wright's compound under the trade name [[wikipedia:Heroin|Heroin]] (from ''heroisch'', heroic) as a non-addictive cough suppressant and morphine substitute. The medicine was sold in pharmacies across Europe and North America until it became, within a decade, the most heavily diverted opioid in the world.

The wholly synthetic opioid was a wartime product of German industrial chemistry. In 1939 [[wikipedia:Otto Eisleb|Otto Eisleb]] at [[wikipedia:IG Farben|IG Farbenindustrie]] in Frankfurt, screening compounds with anticholinergic structure, identified [[Meperidine|meperidine]] (pethidine, Dolantin), the first agent with morphine-like analgesic action that bore no chemical resemblance to morphine. The same firm's [[wikipedia:Max Bockmühl|Max Bockmühl]] and [[wikipedia:Gustav Ehrhart|Gustav Ehrhart]] in 1937 synthesized the diphenylheptane analogue that became, after wartime nomenclature change, [[Methadone|methadone]]. Two decades later the Belgian physician-chemist [[wikipedia:Paul Janssen|Paul Janssen]], working at his family pharmaceutical company in [[wikipedia:Beerse|Beerse]], modified the phenylpiperidine nucleus of meperidine to produce a series of agents of progressively greater potency: [[Fentanyl|fentanyl]] (1960, approximately one hundred times the potency of morphine on a milligram basis), [[Carfentanil|carfentanil]] (1974), [[Sufentanil|sufentanil]] (1974), and [[Alfentanil|alfentanil]] (1976).<ref name="janssen1965">Janssen PAJ. The development of new synthetic narcotics. In: Foldes FF, ed. ''Narcotics and Narcotic Antagonists''. Springfield, IL: Charles C Thomas; 1965:25-60.</ref> Fentanyl became the standard intraoperative analgesic and, in transdermal and transmucosal formulations, an important option in chronic pain; carfentanil, used in veterinary medicine to immobilise large animals, has appeared in the illicit market in milligram doses sufficient to kill a thousand people.

The molecular pharmacology of the opioid analgesics was established three decades after the synthetic agents had become routine. In 1973 three independent laboratories (those of [[wikipedia:Solomon H. Snyder|Solomon Snyder]] and [[wikipedia:Candace Pert|Candace Pert]] at Johns Hopkins, [[wikipedia:Eric Simon|Eric Simon]] at NYU, and [[wikipedia:Lars Terenius|Lars Terenius]] at Uppsala) demonstrated that opioids bind to specific high-affinity receptors in brain tissue.<ref name="pert1973">Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. ''Science''. 1973 Mar 9;179(4077):1011-1014. PMID 4687585.</ref> The Scottish-trained pharmacologist [[wikipedia:Hans Kosterlitz|Hans Kosterlitz]] and his Aberdeen graduate student [[wikipedia:John Hughes (neuroscientist)|John Hughes]] reported in 1975 the isolation of two endogenous pentapeptides, [[wikipedia:Enkephalin|methionine- and leucine-enkephalin]], that bound these receptors and were the body's own analgesic system; the longer endorphins followed within a year. The classical pharmacology recognises three opioid-receptor types named for the agents at which each was first studied: '''mu''' (μ, for morphine), '''delta''' (δ, for deferens), and '''kappa''' (κ, for ketocyclazocine), each cloned in the early 1990s, with a fourth nociceptin/orphanin receptor added later. Mu-receptor activation is responsible for most of the clinically useful and clinically problematic effects of the agonists in this category: analgesia, respiratory depression, miosis, constipation, euphoria, and the development of physical dependence on chronic use.

The pharmacology of the contemporary opioid is, in clinical use, dominated by the relation between analgesia and respiratory depression. The two effects are produced by activation of the same receptor and have not been successfully separated in any medicine of full agonist class, although the partial agonist [[Buprenorphine|buprenorphine]] approaches that separation at the expense of a ceiling on its analgesic effect. The atypical opioid [[Tramadol|tramadol]], introduced by Grünenthal in 1977, is a weak mu agonist combined with a serotonin- and noradrenaline-reuptake inhibitor, and its descendant [[Tapentadol|tapentadol]] (2008) retains the dual mechanism without the serotonergic component; both have a lower respiratory-depression profile than the corresponding-potency mu agonists and a different but real adverse-effect profile that includes serotonin syndrome (tramadol) and seizure (both). The mixed agonist-antagonists ([[Pentazocine|pentazocine]], nalbuphine, butorphanol) are now of limited use because their kappa-receptor activity produces dysphoria.

The opioid analgesics are, in the present clinical context, among the most consequential medicines to prescribe. The United States overdose mortality from opioid medicines, beginning with the 1996 introduction and aggressive marketing of controlled-release [[Oxycodone|oxycodone]] under the trade name OxyContin and amplified after 2013 by illicit fentanyl analogues, has been documented as one of the few sustained declines in U.S. life expectancy of the post-war period.<ref name="cdc2024">Centers for Disease Control and Prevention. Drug overdose deaths in the United States, 1999-2023. ''NCHS Data Brief''. 2024;(522):1-8.</ref> The contemporary prescriber works in a framework that has changed in the last decade: a presumption against chronic opioid use for non-cancer pain except where carefully considered, careful documentation of indication and duration, naloxone co-prescription, and an explicit clinical pathway to medicine-assisted treatment for opioid use disorder (buprenorphine, [[Methadone|methadone]], or extended-release naltrexone) when use becomes problematic.

== Classes indexed ==

By receptor activity:

* Full mu-receptor agonists, natural and semi-synthetic: [[Morphine|morphine]], [[Codeine|codeine]], [[Hydromorphone|hydromorphone]], [[Hydrocodone|hydrocodone]], [[Oxycodone|oxycodone]], [[Oxymorphone|oxymorphone]], [[wikipedia:Diamorphine|diacetylmorphine (heroin)]]
* Full mu-receptor agonists, synthetic phenylpiperidines (the fentanyl series and parent): [[Meperidine|meperidine]], [[Fentanyl|fentanyl]], [[Sufentanil|sufentanil]], [[Alfentanil|alfentanil]], [[Carfentanil|carfentanil]], [[Remifentanil|remifentanil]]
* Full mu-receptor agonists, diphenylheptane class: [[Methadone|methadone]]
* Atypical centrally acting agents (mu agonist plus monoamine-reuptake inhibition): [[Tramadol|tramadol]], [[Tapentadol|tapentadol]]
* Partial agonist: [[Buprenorphine|buprenorphine]]
* Mixed agonist-antagonists (kappa agonist, mu antagonist or partial agonist): [[Pentazocine|pentazocine]], nalbuphine, butorphanol
* Peripheral mu agonists (acting on gut opioid receptors, not penetrating the central nervous system): [[wikipedia:Loperamide|loperamide]] (also listed under [[:Category:Antidiarrheals|antidiarrheals]]), [[wikipedia:Diphenoxylate|diphenoxylate]]
* Opium itself: [[Opium|opium]] (the tincture, as paregoric and as deodorised tincture of opium, remains in limited use)

== Notes on scope ==

The boundary of this category is "medicine whose principal indication is analgesia through opioid-receptor agonism." The [[:Category:Opioid_antagonists|opioid antagonists]] (naloxone, naltrexone, nalmefene), although they bind the same receptors, are not analgesics and are collected separately. Medications for the treatment of opioid use disorder are collected under [[:Category:MAT_for_opioid_use_disorder|medication-assisted treatment for opioid use disorder]]; methadone and buprenorphine appear in both that category and this one because their clinical roles are distinct in the two settings. The fixed-dose combination products in which an opioid is paired with paracetamol or with a non-steroidal anti-inflammatory (Vicodin, Percocet, Tylenol with Codeine, and the others) are collected here and also under [[:Category:Fixed-dose_combinations|fixed-dose combinations]]. Non-opioid analgesics (paracetamol, the [[:Category:NSAIDs|NSAIDs]], the [[wikipedia:Anticonvulsant#Neuropathic pain|gabapentinoids]] when used for pain) are collected under [[:Category:Non-opioid_analgesics|non-opioid analgesics]] and at their individual class pages.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Analgesics]]
[[Category:CuratedCategoryPage]]

Category:Anti-influenza agents

2026-05-23T19:48:08Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''anti-influenza agent''' is a medicine used to treat or prevent infection by influenza A or influenza B virus. The category sits within [[:Category:Antivirals|antivirals]] and contains three mechanistic classes that have entered clinical use in succession: the [[wikipedia:M2 proton channel|M2 ion-channel inhibitors]] (amantadine, rimantadine; now retired by universal resistance), the [[:Category:Neuraminidase_inhibitors|neuraminidase inhibitors]] (oseltamivir, zanamivir, peramivir, laninamivir), and the cap-dependent endonuclease inhibitor baloxavir marboxil.

The first effective anti-influenza medicine was [[wikipedia:Amantadine|amantadine]], synthesised in 1963 at DuPont as a candidate antiviral on the basis of its symmetric tricyclic structure and shown shortly afterwards to inhibit influenza A virus replication. The clinical mechanism was elucidated in the 1980s: amantadine blocks the M2 proton channel of the influenza A virion envelope, preventing the acidification of the viral interior that is required for uncoating after endocytosis. The medicine was active against influenza A only (influenza B has a structurally distinct M2-equivalent that amantadine does not bind), and its clinical use was limited by central-nervous-system adverse effects (insomnia, dizziness, in older adults occasional psychosis) and by the development of resistance through a single S31N substitution in the M2 channel. By the 2005-2006 season, essentially 100 percent of circulating H3N2 influenza A isolates carried the S31N mutation; the medicine has been retired from anti-influenza use since approximately 2008 and is now used principally for Parkinson's disease.

The transformative event of contemporary anti-influenza pharmacology was the development of the neuraminidase inhibitors. The viral neuraminidase, an enzyme on the influenza envelope that cleaves sialic acid residues from cell-surface glycoproteins and so allows release of newly synthesised virions from infected cells, was identified in the 1950s and crystallised in 1983 by [[wikipedia:Peter Colman|Peter Colman]] at the CSIRO in Melbourne, Australia. Colman's group, working with the GlaxoWellcome team led by Mark von Itzstein, used the crystal-structure-derived knowledge of the active site to design [[wikipedia:Zanamivir|zanamivir]] (Relenza, GlaxoWellcome 1999), the first structure-based-design success in antiviral pharmacology.<ref name="vonitzstein1993">von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Phan TV, Smythe ML, White HF, Oliver SW, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. ''Nature''. 1993 Jun 3;363(6428):418-423. PMID 8502295.</ref> Zanamivir's poor oral bioavailability restricted it to inhalation; [[Oseltamivir|oseltamivir]] (Tamiflu, Gilead/Roche 1999), an orally bioavailable ester whose active metabolite oseltamivir carboxylate binds the same active site, became the standard oral anti-influenza medicine. The intravenous [[wikipedia:Peramivir|peramivir]] (Rapivab, BioCryst 2014) and the inhaled long-acting [[wikipedia:Laninamivir|laninamivir]] (Inavir, Japan 2010) extended the class. The neuraminidase inhibitors are active against both influenza A and B, with substantially lower clinically meaningful resistance than the M2 inhibitors (resistance is reported but has not become epidemic to the extent of M2 resistance).

The clinical effect of neuraminidase inhibitors in influenza is meaningful but modest. In immunocompetent adults treated within 48 hours of symptom onset, oseltamivir reduces symptom duration by approximately one day and reduces the rate of secondary lower-respiratory complications and antibacterial prescription; the absolute benefit is larger in high-risk populations (the elderly, the immunocompromised, pregnant women, those with chronic cardiopulmonary disease) and in severe disease requiring hospitalisation, where intravenous oseltamivir or peramivir may reduce mortality. The 2014 publication of the Cochrane review of the oseltamivir trial data (after a multi-year effort to obtain the full clinical-study reports from Roche) re-evaluated the medicine's benefit downward; the response from the influenza-clinical community has been that the Cochrane analysis underweighted the high-risk-population benefit and that the medicine retains an important role in selected patients.

The most recent addition is the cap-dependent endonuclease inhibitor [[wikipedia:Baloxavir marboxil|baloxavir marboxil]] (Xofluza, Shionogi/Roche 2018). Baloxavir blocks the cap-snatching step of viral mRNA synthesis: the influenza polymerase complex normally cleaves host mRNA cap structures and uses them as primers for viral mRNA, and baloxavir inhibits the endonuclease (PA subunit) responsible for this cleavage. The medicine is administered as a single oral dose and rapidly reduces viral shedding (substantially more rapidly than oseltamivir in head-to-head trials), with comparable effect on symptom duration. The treatment-emergent baloxavir resistance (PA I38T substitution) is a substantial concern: 5-to-10 percent of treated patients develop the mutation, and the clinical implications for the next influenza season are uncertain. Baloxavir is currently used in selected patients rather than as universal first-line.

The contemporary anti-influenza strategy in seasonal practice is therefore: vaccination as the foundation of prevention (described under [[:Category:Biologics|biologics]] rather than here); oseltamivir 75 mg twice daily for 5 days as first-line treatment in symptomatic patients within 48 hours of onset, particularly in high-risk populations; intravenous peramivir or oseltamivir in patients unable to tolerate oral medicine; baloxavir as alternative in selected uncomplicated outpatient cases with full discussion of the resistance risk; and monoclonal antibodies (none currently approved but several in trial) as future options. Avian-influenza (H5N1, H7N9) outbreaks raise the question of pandemic preparedness, in which the neuraminidase inhibitors remain the foundational antiviral.

== Classes indexed ==

By mechanism:

* '''[[:Category:Neuraminidase_inhibitors|Neuraminidase inhibitors]]''' (active against influenza A and B):
** [[Oseltamivir|Oseltamivir]] (Tamiflu; oral; the standard treatment)
** [[wikipedia:Zanamivir|Zanamivir]] (Relenza; inhaled; for patients tolerant of inhaler use)
** [[wikipedia:Peramivir|Peramivir]] (Rapivab; intravenous single dose)
** [[wikipedia:Laninamivir|Laninamivir]] (Inavir; inhaled long-acting; Japan only)
* '''Cap-dependent endonuclease inhibitor''':
** [[wikipedia:Baloxavir marboxil|Baloxavir]] (Xofluza; oral single dose; concern for treatment-emergent PA I38T resistance)
* '''M2 ion-channel inhibitors (largely retired)''':
** [[wikipedia:Amantadine|Amantadine]] (Symmetrel; influenza A only; not used since 2008 because of universal resistance; current use is Parkinson's disease)
** [[wikipedia:Rimantadine|Rimantadine]] (Flumadine; same status)

== Notes on scope ==

The boundary of this category is "medicine used to treat or prevent influenza A or B infection." The influenza vaccines (the inactivated trivalent and quadrivalent vaccines, the live attenuated FluMist, the cell-based and recombinant formulations including Flublok, the high-dose Fluzone for adults over 65, the adjuvanted Fluad) are the foundation of prevention; they are biologics rather than antivirals and are listed under [[:Category:Biologics|biologics]]. The monoclonal antibody candidates in development for influenza prophylaxis or treatment are biologics in the same sense and are not collected here. The supportive-care medicines used in severe influenza (oxygen, mechanical ventilation, extracorporeal membrane oxygenation, the supportive antibiotics for secondary bacterial pneumonia particularly with ''Staphylococcus aureus'' or ''Streptococcus pneumoniae'') are listed under their primary mechanism categories.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Antivirals]]
[[Category:Anti-infectives]]
[[Category:CuratedCategoryPage]]

Category:MAT for opioid use disorder

2026-05-23T19:48:07Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''medicine for opioid use disorder''' (MOUD; the older term "medication-assisted treatment" or MAT is the historical-clinical phrase, retained for recognition) is one used to treat [[wikipedia:Opioid use disorder|opioid use disorder]], with the goal of stabilising the patient, reducing illicit-opioid use, reducing overdose mortality, and supporting recovery and social reintegration. The category is small but exceptionally consequential: three medicines (methadone, buprenorphine, extended-release naltrexone) are approved in the United States for the indication, and they are among the most-studied medicines in clinical pharmacology for any indication, with substantial mortality-reduction data that has driven a generational shift in addiction-medicine practice and a major regulatory loosening of access.

The conceptual founding event of MOUD was the 1965 study by [[wikipedia:Vincent Dole|Vincent Dole]] and [[wikipedia:Marie Nyswander|Marie Nyswander]] at the Rockefeller Hospital in New York, who established the metabolic-disease model of opioid addiction and showed that daily oral [[Methadone|methadone]] stabilised heroin-using patients into productive lives without ongoing illicit use.<ref name="dole1965">Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. ''JAMA''. 1965 Aug 23;193(8):646-650. PMID 14321530.</ref> The Dole-Nyswander framework reframed opioid use disorder as a chronic medical condition treatable with daily long-term medicine, in deliberate contrast to the contemporary abstinence-based and morally framed treatment of addiction. Methadone maintenance was operationalised through the federally licensed Opioid Treatment Programmes (OTPs, originally Narcotic Treatment Programmes) that became the standard delivery model in the U.S. from 1972 onward; the daily clinic visit for observed dosing, with progressively earned take-home doses for patients in stable recovery, has remained the basic structure of methadone-based MOUD.

The transformative development of the past twenty years has been the office-based provision of [[Buprenorphine|buprenorphine]]. Buprenorphine is a partial mu-opioid receptor agonist with high receptor affinity but a ceiling on its analgesic and respiratory-depressant effects; its sublingual formulation, alone (Subutex) or combined with the abuse-deterrent naloxone (Suboxone), was approved by the U.S. FDA for office-based treatment of opioid use disorder in 2002 under the [[wikipedia:Drug Addiction Treatment Act|Drug Addiction Treatment Act]] of 2000.<ref name="data2000mat">U.S. Congress. Drug Addiction Treatment Act of 2000. ''Public Law 106-310'', Title XXXV. October 17, 2000.</ref> The DATA Act represented a substantial regulatory innovation: it permitted physicians who completed an 8-hour training course and obtained a DEA "X-waiver" to prescribe buprenorphine for opioid use disorder from a routine outpatient practice, in contrast to the OTP-restricted dispensing model of methadone. The X-waiver requirement was progressively expanded (mid-level providers including nurse practitioners and physician assistants gained the waiver in 2016; patient caps were raised; the training requirement was suspended in 2021) and was eliminated entirely in the Consolidated Appropriations Act of 2023: any practitioner with a standard DEA registration may now prescribe buprenorphine for opioid use disorder without additional waiver or training. The long-acting injectable buprenorphine formulations Sublocade (monthly subcutaneous, Indivior 2017) and Brixadi (weekly or monthly, Braeburn 2023) provide steady-state plasma concentrations for patients in whom daily sublingual dosing is difficult.

The third MOUD is extended-release naltrexone. [[wikipedia:Naltrexone|Naltrexone]] is a full mu-opioid receptor antagonist; an opioid taken by a patient on naltrexone has no effect. The oral formulation (1984 for opioid use disorder; 1994 for alcohol use disorder) had limited utility because adherence was poor (the patient could simply stop taking the medicine before resuming opioid use), but the depot intramuscular naltrexone (Vivitrol, Alkermes 2010 for opioid use disorder) provides 28-day steady-state opioid receptor blockade and substantially better outcomes than oral naltrexone. Vivitrol requires complete opioid washout (7 to 14 days) before initiation, which limits its use to patients who can tolerate the washout (often inpatient or residential setting) and excludes the substantial fraction of patients who would otherwise initiate MOUD at the point of clinical contact.

The three MOUDs have different mechanism profiles and different patient-population fits. Methadone, as a full mu agonist, produces opioid effect and can be used by patients still in active opioid withdrawal; it is dispensed daily under observation in the OTP setting and requires the patient to come to the clinic every morning, which is structurally demanding but provides daily clinical contact and observed adherence. Buprenorphine, as a partial agonist with a ceiling effect, is safer in overdose (the ceiling on respiratory depression makes fatal overdose substantially harder than with methadone) and is dispensed from any DEA-registered outpatient prescriber, which has enabled rapid scale-up of access. Buprenorphine requires that the patient be in mild-to-moderate opioid withdrawal at initiation, because precipitated withdrawal occurs if buprenorphine is given to a fully opioid-saturated patient (the partial agonist displaces the full agonist from the receptor and reduces total opioid activity). Naltrexone, as a pure antagonist, prevents opioid effect but provides no agonist effect; it is best for highly motivated patients with substantial outside support and is the option that does not require interaction with the controlled-substance prescribing system.

The mortality-reduction data for MOUD are among the most robust in addiction-medicine pharmacology. Cohort studies and randomised trials show approximately 50-percent reduction in all-cause mortality in patients on methadone or buprenorphine compared to no medication, with similar effect on overdose-specific mortality. The cohort data also show that MOUD initiation in the immediate post-overdose period (in the emergency department, on hospital admission for opioid-related cause, at jail release) substantially reduces re-overdose mortality. The 2023 elimination of the X-waiver, the parallel introduction of buprenorphine vending machines and telemedicine prescribing, and the substantial expansion of harm-reduction services (naloxone distribution; supervised consumption sites in selected jurisdictions; fentanyl test strips) represent the contemporary public-health response to the opioid epidemic described under [[:Category:Opioid_analgesics|opioid analgesics]] and [[:Category:Schedule_II_controlled_substances|Schedule II controlled substances]].

== Medicines indexed ==

* '''Full mu-opioid receptor agonists''':
** [[Methadone|Methadone]] (Dolophine, Methadose; daily oral; dispensed through DEA-licensed Opioid Treatment Programmes for the OUD indication)
* '''Partial mu-opioid receptor agonist''':
** [[Buprenorphine|Buprenorphine]] (Subutex; Suboxone with naloxone; Zubsolv; Sublocade monthly SC injection; Brixadi weekly or monthly SC injection); office-based prescribing under any DEA registration since 2023
* '''Mu-opioid receptor antagonists''':
** Oral [[wikipedia:Naltrexone|naltrexone]] (ReVia; limited utility because of adherence)
** Extended-release intramuscular naltrexone (Vivitrol; monthly IM; for adherent patients with complete opioid washout)
* '''Adjuncts and historical agents''':
** Naloxone (Narcan, Zimhi; intranasal and intramuscular formulations for opioid overdose reversal; foundational to MOUD-era community harm reduction; widely distributed since 2014 in the U.S.)
** Lofexidine (Lucemyra), the alpha-2 agonist FDA-approved in 2018 for symptomatic management of opioid withdrawal; the related clonidine has off-label use for the same indication
** Heroin-assisted treatment (diacetylmorphine maintenance, available in Switzerland, the Netherlands, Germany, Canada; not U.S.) is mentioned for completeness but is outside U.S. legal practice

== Notes on scope ==

The boundary of this category is "medicine prescribed for the chronic treatment of opioid use disorder." The medicines used for opioid overdose reversal (naloxone in its various formulations) are cross-listed under [[:Category:Opioid_antagonists|opioid antagonists]] separately, although naloxone is foundational to the contemporary harm-reduction infrastructure of MOUD. The medicines used for treatment of substance use disorders other than opioid ([[wikipedia:Naltrexone|naltrexone]] and [[wikipedia:Acamprosate|acamprosate]] and [[wikipedia:Disulfiram|disulfiram]] for alcohol use disorder; bupropion and varenicline for tobacco use disorder; the absence of FDA-approved medicines for psychostimulant use disorder remains a current research focus) are listed under the respective substance-specific MAT pages. The medicines used in opioid withdrawal symptomatic management (clonidine, lofexidine, the antiemetics, the antidiarrhoeals, the symptomatic comfort medicines) are listed under their primary mechanism categories.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Opioid_analgesics]]
[[Category:CuratedCategoryPage]]

Category:Antiemetics

2026-05-23T19:48:07Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''antiemetic''' is a medicine used to prevent or treat nausea and vomiting. The category is mechanistically heterogeneous because the emetic reflex is coordinated by the brainstem chemoreceptor trigger zone, which integrates signals from the gut (vagal afferents responding to serotonin released by enterochromaffin cells), from the vestibular system (cholinergic and histaminergic input), from higher centres (limbic inputs in anticipatory and psychogenic nausea), and from circulating substances (acting at the area postrema, where the blood-brain barrier is permeable). Each of these inputs is mediated by characteristic neurotransmitter receptors, and the major antiemetic classes correspond to receptor-antagonist medicines for each: the [[:Category:5-HT3_antagonists|5-HT3 antagonists]] for the gut-vagal pathway, the [[:Category:Antihistamines|antihistamines]] and [[:Category:Antimuscarinics|antimuscarinics]] for the vestibular pathway, the [[:Category:Dopamine_D2_antagonists|dopamine D2 antagonists]] for the area postrema, the neurokinin-1 (NK1) receptor antagonists for the late and delayed component of chemotherapy-induced nausea, the corticosteroids by less well-defined mechanism, the cannabinoid receptor agonists for refractory cases, and the [[:Category:Neuroleptics|neuroleptics]] for malignant gastrointestinal emergencies.

The clinical pharmacology of nausea was, until the 1950s, dominated by the antimuscarinic alkaloids of the nightshade family (scopolamine, hyoscyamine, atropine) and by sedating antihistamines (diphenhydramine and its less-sedating successor meclizine; promethazine; dimenhydrinate, a chemical complex of diphenhydramine with 8-chlorotheophylline marketed as Dramamine). These agents, with their substantial central sedation and antimuscarinic toxidrome, remained the standard for motion sickness, for benign vestibular vertigo, and for pregnancy-related nausea until the introduction of more specific receptor antagonists. They have not been replaced for the vestibular indications, where the central anticholinergic action is mechanistically appropriate.

The introduction of the [[:Category:Dopamine_D2_antagonists|dopamine D2 antagonist]] metoclopramide (Reglan) in 1964 brought the first non-sedating oral antiemetic with broader applicability. Metoclopramide combines D2 antagonism at the chemoreceptor trigger zone with peripheral prokinetic action on the upper gastrointestinal tract (5-HT4 agonism, weak peripheral D2 antagonism), making it useful in gastroparesis and in refractory nausea of various causes. Its adverse-effect profile is dominated by extrapyramidal phenomena (acute dystonia, akathisia, parkinsonism, and the most-feared tardive dyskinesia after chronic use), and its FDA boxed warning since 2009 has restricted long-term use. The related domperidone (Janssen, 1974), a peripheral D2 antagonist that does not cross the blood-brain barrier and so does not produce extrapyramidal effects, is widely used outside the United States; it was not approved in the U.S. because of a small but real QT-prolongation signal but is available through a compassionate-use programme.

The transformative event of contemporary antiemetic pharmacology was the discovery of the 5-HT3 receptor antagonists. Working in the Glaxo laboratories in the early 1980s, [[wikipedia:Paul Andrews (pharmacologist)|Paul Andrews]] had shown that cisplatin chemotherapy released serotonin from enterochromaffin cells of the small intestine, and that the released serotonin activated vagal 5-HT3 receptors to produce the severe nausea characteristic of platinum chemotherapy.<ref name="andrews1988">Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. ''Trends in Pharmacological Sciences''. 1988 Sep;9(9):334-341. PMID 3074552.</ref> Selective 5-HT3 antagonists were developed in response: [[wikipedia:Ondansetron|ondansetron]] (Glaxo, 1991), [[wikipedia:Granisetron|granisetron]] (SmithKline Beecham, 1993), dolasetron (1997), [[wikipedia:Palonosetron|palonosetron]] (the second-generation, longer-half-life agent, 2003), and the transdermal granisetron patch (Sancuso, 2008). The 5-HT3 antagonists transformed the tolerability of cancer chemotherapy and now define the foundation of the antiemetic regimen for highly emetogenic chemotherapy. Their use has been extended to postoperative nausea (where ondansetron 4 mg intravenous is now routine), to severe gastroenteritis in children, and to refractory nausea in palliative care.

The neurokinin-1 receptor antagonists were the next mechanistic addition. Aprepitant (Merck, 2003), and the longer-acting fosaprepitant (2008, hydrolysed in vivo to aprepitant), and the second-generation rolapitant and netupitant, block the substance P / NK1 receptor in the brainstem and reduce both acute and (more importantly) delayed chemotherapy-induced nausea. The triplet combination of an NK1 antagonist, a 5-HT3 antagonist, and dexamethasone is the standard premedication for highly emetogenic chemotherapy regimens; the addition of olanzapine (a neuroleptic with broad receptor coverage including D2, 5-HT2, H1, and muscarinic) further improves control in the most emetogenic regimens. The exact mechanism by which corticosteroids are antiemetic remains incompletely understood; the effect is empirically established and is the reason dexamethasone is included in essentially every contemporary chemotherapy-antiemetic regimen.

The cannabinoid receptor agonists ([[wikipedia:Dronabinol|dronabinol]], a synthetic delta-9-THC oral capsule; nabilone, a synthetic cannabinoid analogue) are used for chemotherapy-induced nausea refractory to first-line agents and for HIV-related anorexia. The selected cases of refractory nausea, particularly in palliative care and in cyclic vomiting syndrome, are treated with low-dose olanzapine or with the neuroleptic haloperidol. The pregnancy-specific antiemetic doxylamine-pyridoxine (Bendectin in the 1970s, withdrawn after litigation in 1983 despite the absence of teratogenicity, reintroduced as Diclegis / Bonjesta in 2013) is the standard first-line for nausea of pregnancy in the United States.

== Classes indexed ==

By receptor target:

* '''[[:Category:5-HT3_antagonists|5-HT3 receptor antagonists]]''': [[wikipedia:Ondansetron|ondansetron]], [[wikipedia:Granisetron|granisetron]], dolasetron, [[wikipedia:Palonosetron|palonosetron]] (second-generation, longer half-life)
* '''Dopamine D2 antagonists''' (cross-indexed under [[:Category:Dopamine_D2_antagonists|dopamine D2 antagonists]]): [[wikipedia:Metoclopramide|metoclopramide]] (also indexed under [[:Category:Prokinetics|prokinetics]]); [[wikipedia:Domperidone|domperidone]] (peripheral-only D2); prochlorperazine and chlorpromazine and the older phenothiazine antiemetics; haloperidol (for refractory or palliative-care nausea)
* '''Neurokinin-1 (NK1) receptor antagonists''': aprepitant, fosaprepitant, rolapitant, netupitant (often as fixed combination netupitant-palonosetron, Akynzeo)
* '''Antihistamines''' (H1 antagonists for vestibular and motion-sickness indications; cross-indexed under [[:Category:Antihistamines|antihistamines]]): [[wikipedia:Diphenhydramine|diphenhydramine]], dimenhydrinate, meclizine, promethazine, cyclizine, hydroxyzine
* '''Antimuscarinics''' (for vestibular and motion-sickness indications; cross-indexed under [[:Category:Antimuscarinics|antimuscarinics]]): transdermal [[wikipedia:Scopolamine|scopolamine]]
* '''Corticosteroids''' (cross-indexed): [[Dexamethasone|dexamethasone]], the foundation of CINV regimens at 8 to 12 mg per cycle
* '''Atypical neuroleptics''' (broad receptor coverage; cross-indexed under [[:Category:Neuroleptics|neuroleptics]]): [[wikipedia:Olanzapine|olanzapine]], particularly for highly emetogenic chemotherapy
* '''Cannabinoid agonists''' (synthetic): [[wikipedia:Dronabinol|dronabinol]], [[wikipedia:Nabilone|nabilone]]
* '''Pregnancy-specific''': doxylamine-pyridoxine ([[wikipedia:Bendectin|Bendectin]] history, current Diclegis/Bonjesta), with vitamin B6 (pyridoxine) monotherapy as an alternative; metoclopramide and ondansetron in selected pregnancy cases (with ondansetron use in the first trimester remaining controversial)

== Notes on scope ==

The boundary of this category is "medicine prescribed primarily to prevent or treat nausea and vomiting." The medicines used to treat the underlying cause of nausea (the [[:Category:Antimigraine_agents|antimigraine agents]] in migraine-associated nausea; the [[:Category:Migraine_prophylaxis|migraine prophylaxis]] medicines; the [[:Category:Antibacterials|antibacterials]] in gastroenteritis-associated nausea where antibacterial treatment is indicated; the [[:Category:Prokinetics|prokinetics]] in gastroparesis-associated nausea) are listed under their primary indications. The medicines that may reduce nausea as a side effect of their primary action (selected antidepressants in the management of functional dyspepsia; gabapentin for refractory nausea; benzodiazepines in anticipatory nausea) are listed under their primary class. The intravenous fluid replacement for the dehydration that accompanies severe vomiting is supportive care rather than antiemetic and is listed under [[:Category:Electrolyte_replacements|electrolyte replacements]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:CuratedCategoryPage]]

Category:Adaptogens

2026-05-23T19:48:06Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''adaptogen''' is a plant medicine that increases the body's nonspecific resistance to physical, biological, and emotional stress, restoring physiological homeostasis without producing a primary psychostimulant or sedative effect. The concept was formalised by the Soviet pharmacologist [[wikipedia:Nikolai Lazarev|Nikolai Lazarev]] in 1947 and substantially extended by his student [[wikipedia:Israel Brekhman|Israel Brekhman]] through the 1960s and 1970s; the operational definition requires that an adaptogenic medicine (1) increase resistance to noxious physical, chemical, or biological influences in a nonspecific way; (2) have a normalising effect that is independent of the direction of the pathological state; and (3) be innocuous and produce minimal disturbance of normal physiological function.

The contemporary adaptogen pharmacopoeia includes several historically and pharmacologically distinct groups. The '''Ayurvedic rasayana''' group: '''ashwagandha''' (''Withania somnifera''), the most extensively-studied modern adaptogen with controlled-trial evidence for stress, sleep, anxiety, athletic performance, and male fertility; '''holy basil''' (''Ocimum tenuiflorum'', tulsi); '''shatavari''' (''Asparagus racemosus''); and the medhya group of cognitive rasayanas. The '''TCM tonic''' group: '''Asian ginseng''' (''Panax ginseng'', Ren Shen), the original named adaptogen in Brekhman's work; '''American ginseng''' (''Panax quinquefolius''); '''eleuthero''' (''Eleutherococcus senticosus'', formerly Siberian ginseng; not a true Panax); '''astragalus''' (''Astragalus propinquus'', Huang Qi); '''schisandra''' (''Schisandra chinensis''); '''codonopsis''' (''Codonopsis pilosula'', Dang Shen, the milder substitute for Panax in extended-course tonification); '''reishi''' (''Ganoderma lucidum''; a fungus rather than a plant but conventionally grouped). The '''northern adaptogen''' group: '''rhodiola''' (''Rhodiola rosea''), the Siberian-and-Scandinavian adaptogen popularised in Western use through the Soviet research lineage; '''Schisandra'' as above; and selected lesser-known northern plants.

The Western pharmacological framing of adaptogen action centres on the hypothalamic-pituitary-adrenal axis: many of the established adaptogens modulate the HPA response to stress through effects on glucocorticoid-receptor expression, on corticotropin-releasing hormone signalling, on serum cortisol kinetics, and on the related neurotransmitter systems. Ashwagandha's withanolide fraction has demonstrated effects on serum cortisol in controlled stress-trial protocols. Rhodiola's salidroside and rosavin appear to enhance the catecholamine and serotonin response to physical and cognitive stressors. Panax ginsenosides have multiple effects across the HPA axis and the immune system. The unifying clinical claim is that an adaptogen taken regularly over weeks or months improves the body's capacity to handle stress rather than acting acutely on a specific receptor.

The contemporary controlled-trial evidence is variable in quality but is now substantial for several of the foundational adaptogens. Ashwagandha has accumulated more than two hundred controlled trials over the past two decades; meta-analyses support modest benefit for stress, anxiety, sleep, and athletic-performance outcomes. Rhodiola has fewer but generally positive trials in stress-associated fatigue and mild-to-moderate depression. Ginseng has the longest history of clinical investigation; the evidence is fragmented across specific ginsenoside preparations and indications, with selected effects on glucose tolerance, sexual function, and fatigue.

== Members indexed ==

Ashwagandha (''Withania somnifera''), holy basil (''Ocimum tenuiflorum''), Asian ginseng (''Panax ginseng''), American ginseng (''Panax quinquefolius''), eleuthero (''Eleutherococcus senticosus''), rhodiola (''Rhodiola rosea''), schisandra (''Schisandra chinensis''), astragalus (''Astragalus propinquus''), codonopsis (''Codonopsis pilosula''), shatavari (''Asparagus racemosus''), gotu kola (''Centella asiatica''), reishi (''Ganoderma lucidum''), cordyceps (''Cordyceps sinensis'' and ''C. militaris''), maca (''Lepidium meyenii''), suma (''Pfaffia paniculata'', Brazilian ginseng), and Jiaogulan (''Gynostemma pentaphyllum'').

== Notes on scope ==

The boundary of this category is "plant medicine demonstrated to meet the formal adaptogen criteria or used clinically as such within its source tradition." The pure psychostimulants (the caffeine plants, ephedra in its sympathomimetic action) are not adaptogens despite their wakefulness-promoting effects, because they produce primary psychostimulant action. The pure sedatives (valerian, kava) are not adaptogens despite their nervous-system action. The cognitive-enhancer-only herbs (bacopa, gotu kola, lion's mane) overlap with the adaptogen category through the medhya rasayana classification but their primary indication is cognitive rather than stress-resistance; they are cross-listed under [[:Category:Nervine_herbs|nervine herbs]] and under cognitive-circulatory categories. Cordyceps and reishi are fungi rather than plants but are conventionally grouped with the adaptogen herbs in the TCM tonic literature; the fungal-medicine pages cross-link accordingly.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Sympathomimetics

2026-05-23T19:48:06Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''sympathomimetic''' is a medicine that produces effects similar to those of activation of the sympathetic nervous system, by direct agonism at adrenergic receptors, by indirect release of endogenous catecholamines from nerve terminals, by inhibition of catecholamine reuptake, or by combinations of these. The category is mechanistically broad and clinically spans an unusual range of indications: anaphylaxis and severe asthma exacerbation, the [[:Category:Vasopressors|vasopressor]] support of shock, [[:Category:Bronchodilators|bronchodilation]] in asthma and COPD, the [[wikipedia:Attention deficit hyperactivity disorder|attention deficit hyperactivity disorder]] medicines, [[wikipedia:Decongestant|nasal decongestion]], the relief of urinary stress incontinence (limited use), heart-failure inotropic support, and the older psychostimulant uses.

The history of the category begins with adrenaline. The Japanese-American chemist [[wikipedia:Jokichi Takamine|Jokichi Takamine]], working at Parke-Davis in New York City in 1900, was the first to isolate a pure crystalline preparation of [[wikipedia:Adrenaline|epinephrine]] from the adrenal medulla of cattle.<ref name="takamine1901">Takamine J. Adrenalin: the active principle of the suprarenal glands and its mode of preparation. ''American Journal of Pharmacy''. 1901 Nov;73(11):523-531.</ref> The compound was the first hormone to be isolated in pure form, predating insulin by twenty-one years. Adrenaline's clinical use began immediately, as a topical haemostatic for ophthalmic and surgical bleeding and as an injectable medicine for acute asthmatic attack; the original 1900 preparation, mixed with cocaine, formed the basis of the local-anaesthetic-with-vasoconstrictor combination still used today in dental and minor-surgical anaesthesia. The 1948 demonstration by the American pharmacologist [[wikipedia:Raymond Ahlquist|Raymond Ahlquist]] that the multiple effects of catecholamines were mediated by two receptor types, which he termed alpha and beta, provided the framework that organises the entire category.<ref name="ahlquist1948">Ahlquist RP. A study of the adrenotropic receptors. ''American Journal of Physiology''. 1948 Jun;153(3):586-600. PMID 18882199.</ref> Subsequent work distinguished beta-1 (cardiac), beta-2 (smooth muscle and metabolic), and beta-3 (adipose, bladder) subtypes, and alpha-1 (post-junctional vasoconstrictor) from alpha-2 (presynaptic feedback inhibition and central sedation) subtypes.

The therapeutic pharmacopoeia of the sympathomimetics follows the receptor-subtype map. The non-selective catecholamines [[wikipedia:Adrenaline|epinephrine]] (adrenaline) and [[wikipedia:Norepinephrine|norepinephrine]] activate alpha and beta receptors in different relative balance: epinephrine is alpha-1 = beta-1 ≈ beta-2; norepinephrine is alpha-1 > beta-1, with negligible beta-2. Their clinical uses follow: epinephrine for anaphylaxis (1:1000 intramuscular for the alpha-1 vasoconstriction, the beta-2 bronchodilation, and the cardiac beta-1 inotropy), for cardiac arrest (1:10,000 intravenous), and as a local-anaesthetic adjunct; norepinephrine as the first-line vasopressor in septic shock, where alpha-1-mediated vasoconstriction is the desired effect. [[wikipedia:Dopamine|Dopamine]], the immediate precursor of norepinephrine, is dose-dependent: low-dose ("renal-dose") activates dopaminergic D1 receptors but the resulting natriuresis has no demonstrated clinical benefit; mid-dose activates beta-1 inotropy; high-dose activates alpha-1 vasoconstriction.

The selective sympathomimetics achieve specific receptor subtype effects. The beta-1 selective agonist [[wikipedia:Dobutamine|dobutamine]] (Eli Lilly, 1975) provides inotropic support in acute decompensated heart failure and cardiogenic shock without the marked tachycardia and arrhythmia of isoproterenol. The beta-2 selective agonists ([[Albuterol|albuterol]], salmeterol, formoterol, indacaterol; described under [[:Category:Bronchodilators|bronchodilators]]) provide bronchodilation with reduced cardiac effect. The beta-3 selective agonists [[wikipedia:Mirabegron|mirabegron]] and [[wikipedia:Vibegron|vibegron]] relax detrusor smooth muscle for overactive bladder. The alpha-1 selective agonist [[wikipedia:Phenylephrine|phenylephrine]] is used intravenously as a vasopressor (particularly in anaesthesia-induced hypotension) and as a topical or oral decongestant (the latter with limited evidence of efficacy at the oral 10 mg dose). The alpha-2 selective agonists [[wikipedia:Clonidine|clonidine]], guanfacine, and dexmedetomidine activate presynaptic and central alpha-2 receptors, reducing sympathetic outflow; they are used in hypertension, in ADHD (clonidine and guanfacine extended-release), in opioid and alcohol withdrawal, and (dexmedetomidine) as a sedative in intensive-care settings.

The indirect-acting sympathomimetics displace endogenous catecholamines from storage vesicles or inhibit their reuptake. [[wikipedia:Ephedrine|Ephedrine]], extracted from ''Ephedra sinica'' in 1885 and isolated as a pure compound by Nagai in 1887, releases stored noradrenaline and was the first orally bioavailable sympathomimetic. [[wikipedia:Pseudoephedrine|Pseudoephedrine]], the related stereoisomer, has been used as a nasal decongestant since the 1950s; its over-the-counter availability has been progressively restricted because of methamphetamine-precursor diversion. The [[:Category:Psychostimulants|psychostimulants]] [[wikipedia:Amphetamine|amphetamine]] (synthesised by Lazăr Edeleanu in 1887, brought to clinical use by Smith Kline French as Benzedrine in 1933 for narcolepsy) and [[wikipedia:Methylphenidate|methylphenidate]] (Ciba, 1944, refined to its current dextro-only Focalin formulation) are mixed-mechanism sympathomimetics combining noradrenaline-release with dopamine-reuptake inhibition; their pharmacology is described in detail under their individual medicine pages and under the controlled-substance categories.

The clinical use of a sympathomimetic carries a corresponding profile of adverse effects. Tachycardia and palpitations are characteristic of beta-1 activation; tremor and hypokalemia of beta-2 activation; sympathetic vasoconstriction-induced hypertension, headache, and rare extremity ischaemia of alpha-1 activation; sedation, dry mouth, and rebound hypertension on withdrawal of alpha-2 agonists. The use of any sympathomimetic in a patient on a monoamine oxidase inhibitor produces a hypertensive crisis that is among the most predictable medicine interactions in pharmacology and is the basis of the food-restriction requirements on the older MAOIs. The use of vasopressor sympathomimetics extravasated into peripheral tissue produces ischemic necrosis; central-venous administration is required for prolonged or high-dose infusion of norepinephrine, dopamine, or epinephrine.

== Classes indexed ==

By receptor selectivity:

* '''Non-selective catecholamines''':
** [[wikipedia:Adrenaline|Epinephrine (adrenaline)]]: anaphylaxis, cardiac arrest, local-anaesthetic adjunct, severe asthma, refractory hypotension
** [[wikipedia:Norepinephrine|Norepinephrine]]: first-line vasopressor in septic shock and other distributive shock
** [[wikipedia:Dopamine|Dopamine]]: dose-dependent (D1, beta-1, alpha-1), now less commonly used than norepinephrine
* '''Beta-1 selective''' (inotropic): [[wikipedia:Dobutamine|dobutamine]]
* '''Beta-2 selective''' (bronchodilator, also indexed under [[:Category:Bronchodilators|bronchodilators]] and [[:Category:Beta-2_adrenergic_agonists|beta-2 agonists]]): [[Albuterol|albuterol]], levalbuterol, terbutaline, salmeterol, formoterol, indacaterol, olodaterol, vilanterol, ritodrine (uterine relaxant)
* '''Beta-3 selective''' (overactive bladder; cross-indexed under [[:Category:Overactive_bladder_medications|OAB medicines]]): [[Mirabegron|mirabegron]], [[wikipedia:Vibegron|vibegron]]
* '''Alpha-1 selective''':
** [[wikipedia:Phenylephrine|Phenylephrine]] (intravenous vasopressor, oral and topical decongestant)
** Midodrine (oral, orthostatic hypotension)
** Topical decongestants oxymetazoline, xylometazoline, naphazoline
* '''Alpha-2 selective''' (sympathoinhibitory, central):
** [[wikipedia:Clonidine|Clonidine]] (hypertension, ADHD, opioid withdrawal, restless legs)
** Guanfacine (ADHD extended-release, hypertension)
** [[wikipedia:Dexmedetomidine|Dexmedetomidine]] (ICU sedation, procedural sedation)
** Alpha-methyldopa (hypertension; selected use in pregnancy hypertension)
* '''Indirect-acting''':
** [[wikipedia:Ephedrine|Ephedrine]] (releases stored noradrenaline; intravenous for anaesthesia-induced hypotension, oral as nasal decongestant)
** [[wikipedia:Pseudoephedrine|Pseudoephedrine]] (oral decongestant)
** [[wikipedia:Phenylpropanolamine|Phenylpropanolamine]] (withdrawn for stroke risk in 2000)
* '''Mixed-mechanism (release + reuptake inhibition)''' (cross-indexed under [[:Category:Psychostimulants|psychostimulants]]):
** [[wikipedia:Amphetamine|Amphetamine]] and its derivatives (mixed amphetamine salts as Adderall, dextroamphetamine, lisdexamfetamine, methamphetamine)
** [[wikipedia:Methylphenidate|Methylphenidate]] and dexmethylphenidate

== Notes on scope ==

The boundary of this category is "medicine whose principal action is agonism of adrenergic receptors, directly or indirectly." The non-catecholamine medicines that block these receptors (the [[:Category:Beta-blockers|beta-blockers]], the [[:Category:Alpha-1_blockers|alpha-1 blockers]]) are the opposite of sympathomimetics and are collected under their own categories. The serotonin- and noradrenaline-reuptake inhibitors used as antidepressants (venlafaxine, duloxetine) and the noradrenaline-reuptake-inhibitor ADHD medicine atomoxetine have indirect sympathomimetic properties but are classified by their psychiatric indication. The opioid agonist meperidine has weak amphetamine-like central psychostimulant properties on its normeperidine metabolite but is not a sympathomimetic in any clinically meaningful sense. The [[:Category:Antimigraine_agents|triptans]] act on 5-HT1B/1D receptors of cranial vasculature and are sometimes mistakenly described as sympathomimetic; they are not, and are collected under [[:Category:Triptans|triptans]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:CuratedCategoryPage]]

Category:Schedule III controlled substances

2026-05-23T19:48:05Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''Schedule III controlled substance''' is a medicine that the United States [[wikipedia:Drug Enforcement Administration|Drug Enforcement Administration]] has placed in the third schedule of its [[wikipedia:Controlled Substances Act|Controlled Substances Act]] of 1970. Schedule III substances have an accepted medical use, a potential for abuse less than the [[:Category:Schedule_II_controlled_substances|Schedule II]] medicines but greater than the [[:Category:Schedule_IV_controlled_substances|Schedule IV]] ones, and an abuse pattern that may lead to moderate or low physical dependence or to high psychological dependence. The prescribing restrictions are correspondingly intermediate.

The clinical operating difference between a Schedule III and a Schedule II prescription is substantial in everyday practice. A Schedule III prescription may be telephoned in to the pharmacy or transmitted electronically, may be refilled up to five times within six months of the date of the original prescription, and may be faxed under conditions broader than the narrow Schedule II exceptions. State [[wikipedia:Prescription drug monitoring program|prescription drug monitoring program]] reporting is required for Schedule III in most states. Pharmacy security requirements and dispensing documentation are intermediate between the Schedule II and Schedule IV tiers.

The medicines presently classified as Schedule III are dominated by three groups: certain opioid-containing combination products, the [[wikipedia:Buprenorphine|buprenorphine]] products used for opioid use disorder and for chronic pain, and the [[wikipedia:Anabolic steroid|anabolic-androgenic steroids]]. The combination opioid products in Schedule III include the older codeine-acetaminophen combinations ([[wikipedia:Tylenol with codeine|Tylenol with Codeine]] in the standard doses of codeine, classified Schedule III rather than Schedule II by virtue of the small codeine quantity per dosage unit), the codeine-containing antitussive preparations, the dihydrocodeine-acetaminophen combinations, and the now-rare paregoric (camphorated tincture of opium). [[wikipedia:Fiorinal|Fiorinal]] (butalbital with aspirin and caffeine) and the closely related Fiorinal with Codeine are Schedule III when they contain codeine and Schedule III (without codeine) on the basis of butalbital, a barbiturate. The dronabinol oral capsule (synthetic delta-9-tetrahydrocannabinol) is Schedule III; the standard cannabis-derived medicines remain Schedule I federally, despite extensive state-level rescheduling for medical use.

The decisive Schedule III addition of the 2000s was buprenorphine. Buprenorphine, a partial agonist at the mu opioid receptor with high receptor affinity but a ceiling on its analgesic and respiratory-depressant effect, had been used in Europe as an analgesic for thirty years. The U.S. Drug Addiction Treatment Act (DATA) of 2000 permitted physicians to prescribe buprenorphine for opioid use disorder from an office-based outpatient setting (in contrast to the federally licensed opioid treatment programmes through which methadone for opioid use disorder must be dispensed); the buprenorphine-naloxone combination [[wikipedia:Suboxone|Suboxone]] (Reckitt Benckiser, 2002) and the buprenorphine-only Subutex established a clinical infrastructure of medicine-assisted treatment for opioid use disorder, dispensed in primary care, with a Schedule III prescribing convenience that would not have been possible in Schedule II.<ref name="data2000">U.S. Congress. Drug Addiction Treatment Act of 2000. ''Public Law 106-310'', Title XXXV. October 17, 2000.</ref> The X-waiver requirement, which had restricted buprenorphine prescribing to clinicians who completed an eight-hour training course and registered with the DEA, was eliminated in the Consolidated Appropriations Act of 2023; any practitioner with a current DEA registration may now prescribe buprenorphine for opioid use disorder.

The anabolic-androgenic steroids were added to Schedule III by the Anabolic Steroid Control Act of 1990, which extended the CSA to include all synthetic testosterone derivatives and several non-steroidal selective androgen-receptor modulators. The clinical use of testosterone replacement in hypogonadism and the supraphysiologic-dose use in athletic performance enhancement are both subject to the Schedule III restrictions, although the regulatory environment for clinical replacement therapy is well-defined and routine. [[wikipedia:Ketamine|Ketamine]] was rescheduled from unscheduled to Schedule III in 1999 in response to its growing recreational use; the medicine retains substantial clinical utility in anaesthesia, in subanaesthetic intravenous infusions for treatment-resistant depression and chronic pain, and in the (S)-enantiomer formulation [[Esketamine|esketamine]] nasal spray for treatment-resistant depression and for major depressive disorder with active suicidal ideation. Esketamine is Schedule III in the United States, accessed only through a REMS programme.

== Selected medicines indexed ==

Not exhaustive; the DEA publishes a comprehensive list at [[USLegal:DEA_Schedule_III|DEA Schedule III]] in the USLegal: namespace.

* '''Opioid combination products at restricted codeine doses''': [[wikipedia:Tylenol with codeine|Tylenol with Codeine]] (acetaminophen + codeine, usually 30 mg or less per tablet); dihydrocodeine combinations; the historical paregoric (camphorated tincture of opium)
* '''Buprenorphine and buprenorphine-naloxone combinations''' (for opioid use disorder and chronic pain): [[wikipedia:Suboxone|Suboxone]] (sublingual film and tablet), [[wikipedia:Subutex|Subutex]] (sublingual buprenorphine alone), Zubsolv, Sublocade (monthly extended-release buprenorphine subcutaneous injection)
* '''Barbiturates at the Schedule III tier''' (those whose abuse potential is less than the Schedule II barbiturates, often by virtue of formulation or co-formulation): butalbital combinations including [[wikipedia:Fiorinal|Fiorinal]] (butalbital + aspirin + caffeine), Fioricet (butalbital + acetaminophen + caffeine, Schedule III only when combined with a Schedule III-tier substance)
* '''Anabolic-androgenic steroids''': testosterone esters (cypionate, enanthate, undecanoate); nandrolone; oxandrolone; stanozolol (the medical use that brought oxandrolone to widespread attention was the treatment of Turner syndrome and HIV-associated wasting); methyltestosterone; the synthetic non-steroidal selective androgen-receptor modulators in the same Schedule III tier
* '''Ketamine and esketamine''': [[Ketamine|ketamine]] (anaesthesia, subanaesthetic depression/pain), [[Esketamine|esketamine]] nasal spray
* '''Synthetic cannabinoids in clinical use''': [[wikipedia:Dronabinol|dronabinol]] (synthetic THC, oral capsule for chemotherapy-induced nausea and AIDS-related anorexia)

== Notes on scope ==

The boundary of this category is "medicine or substance placed in Schedule III of the U.S. Controlled Substances Act." The U.S. Schedule III designation is, like the other CSA schedules, a federal classification; state-level scheduling may move medicines between tiers, although typically in the more restrictive direction. The international counterparts (the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, the Canadian CDSA, the UK Misuse of Drugs Act and Misuse of Drugs Regulations) classify these medicines by different criteria and the cross-walk is not always one-to-one. The [[USLegal:|USLegal:]] namespace on this wiki carries the comprehensive Schedule-by-Schedule reference pages.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Controlled_substances]]
[[Category:CuratedCategoryPage]]

Category:Immunosuppressants

2026-05-23T19:48:05Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''immunosuppressant''' is a medicine given to suppress the immune response, whether to permit transplantation of organ or tissue, to treat an autoimmune disease, or to control an exuberant inflammatory reaction. The category includes the [[:Category:Corticosteroids|systemic glucocorticoids]], the antiproliferative antimetabolites, the calcineurin inhibitors, the mTOR inhibitors, the alkylating agents adapted from oncology, and the modern biologics that target specific cytokines and lymphocyte populations.

The category came into being with the transplantation of solid organs, and the founding observations belong to the zoologist [[wikipedia:Peter Medawar|Peter Medawar]]. In 1942 Medawar, then at Oxford, was asked by the Glasgow burns surgeon [[wikipedia:Thomas Gibson (surgeon)|Thomas Gibson]] to investigate why a Glaswegian woman's skin grafts from a donor were repeatedly rejected. Medawar's experiments in rabbits over the following decade established that the rejection was immunological, that it accelerated on second exposure (the second-set phenomenon), and that the response was specific to the donor; he then showed in 1953, with [[wikipedia:Rupert Billingham|Rupert Billingham]] and [[wikipedia:Leslie Brent|Leslie Brent]], that injecting donor cells into a fetal mouse produced lifelong tolerance to that donor's tissues, the principle of acquired immunological tolerance.<ref name="medawar1953">Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. ''Nature''. 1953 Oct 3;172(4379):603-606. PMID 13099277.</ref> Medawar shared the 1960 Nobel Prize for the work, and the question of how to produce a comparable tolerance pharmacologically in an adult became the founding question of clinical transplantation.

The first medicine that gave a workable answer came from the cancer pharmacology of [[wikipedia:Gertrude B. Elion|Gertrude Elion]] and [[wikipedia:George H. Hitchings|George Hitchings]] at [[wikipedia:Burroughs Wellcome|Burroughs Wellcome]], who in the early 1950s had developed [[wikipedia:Mercaptopurine|6-mercaptopurine]] as a purine analogue antimetabolite for childhood acute lymphoblastic leukemia. In 1959 [[wikipedia:Robert Schwartz (immunologist)|Robert Schwartz]] and [[wikipedia:William Dameshek|William Dameshek]] at the New England Medical Center showed that 6-mercaptopurine could prevent rabbits from making antibodies against an injected foreign protein; the medicine was an immunosuppressant as well as a chemotherapeutic.<ref name="schwartz1959">Schwartz R, Dameshek W. Drug-induced immunological tolerance. ''Nature''. 1959 Jun 13;183(4676):1682-1683. PMID 13666859.</ref> [[wikipedia:Roy Calne|Roy Calne]] at Cambridge, working from this lead, used a closely related compound, [[wikipedia:Azathioprine|azathioprine]] (metabolically activated to 6-mercaptopurine), in combination with prednisolone, and in 1962 [[wikipedia:Joseph Murray|Joseph Murray]] at the Peter Bent Brigham Hospital in Boston performed the first successful kidney transplant between unrelated donor and recipient. The azathioprine-prednisone combination was the standard regimen for the next twenty years.

The transformative agent was found in soil. In 1969 the Sandoz microbiologist [[wikipedia:Jean Borel|Jean Borel]], on a hiking holiday in the [[wikipedia:Hardangervidda|Hardangervidda]] plateau of Norway, collected a sample of cold-climate soil for the company's broad screening programme; it yielded a fungus, ''[[wikipedia:Tolypocladium inflatum|Tolypocladium inflatum]]'', whose secondary metabolite [[wikipedia:Ciclosporin|cyclosporin A]] was found in 1972 to suppress T-cell-mediated immunity without the bone-marrow toxicity of azathioprine.<ref name="borel1976">Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. ''Agents and Actions''. 1976 Jul;6(4):468-475. PMID 8969.</ref> [[Cyclosporine|Cyclosporine]] was first given to human kidney-transplant recipients by [[wikipedia:David White (surgeon)|David White]] and Calne at Cambridge in 1978 and was approved for clinical use in 1983; its introduction roughly doubled the one-year survival of cadaveric kidney transplants and opened the era of routine liver, heart, and lung transplantation. A second [[:Category:Calcineurin_inhibitors|calcineurin inhibitor]], tacrolimus (FK-506), was isolated by Fujisawa from ''Streptomyces tsukubaensis'' at Mount Tsukuba in 1984 and proved both more potent and somewhat less nephrotoxic than cyclosporine. The two medicines share a final common pathway: they form a complex with intracellular immunophilins that inhibits the calcium-dependent phosphatase calcineurin and so prevents the dephosphorylation of NFAT and the subsequent transcription of the interleukin-2 gene.

A parallel and equally productive product of soil screening was sirolimus, isolated by [[wikipedia:Suren Sehgal|Suren Sehgal]] at Ayerst Laboratories in 1972 from ''Streptomyces hygroscopicus'' in a soil sample collected on [[wikipedia:Easter Island|Easter Island]]; the medicine retained the islanders' name for their island, '''Rapa Nui''', and was originally pursued as an antifungal before its immunosuppressant action was recognised.<ref name="vezina1975">Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. ''Journal of Antibiotics''. 1975 Oct;28(10):721-726. PMID 1102508.</ref> Sirolimus and its derivative everolimus inhibit the mTOR kinase, a downstream node of the IL-2 receptor pathway, and so block the proliferative response of T cells to interleukin-2 rather than its production. The morpholinoethyl ester of mycophenolic acid, [[wikipedia:Mycophenolate mofetil|mycophenolate mofetil]], a selective inhibitor of inosine monophosphate dehydrogenase in lymphocytes, was added to the transplantation pharmacopoeia in 1995.

The autoimmune-disease side of the category was, until the 1990s, dominated by the same agents transposed from transplantation: glucocorticoids, [[Methotrexate|methotrexate]] (the antifolate originally developed by [[wikipedia:Sidney Farber|Sidney Farber]] and Yellapragada Subbarow at Boston Children's Hospital in 1948 for childhood leukemia, then redeployed for psoriasis in the 1950s and for rheumatoid arthritis in the 1980s after the work of [[wikipedia:Michael Weinblatt|Michael Weinblatt]] at the Brigham), azathioprine, hydroxychloroquine, and cyclophosphamide. The mid-1990s brought the first of the targeted biologic medicines. The [[:Category:TNF_inhibitors|tumour necrosis factor inhibitors]], proposed as a rheumatoid-arthritis therapy on the basis of work in Marc Feldmann and Ravinder Maini's London laboratory showing that TNF-alpha was the upstream driver of synovial inflammation, were brought to clinical use as etanercept (a soluble decoy receptor, Immunex/Amgen, 1998), infliximab (a chimeric monoclonal antibody, Centocor, 1998), and the fully human [[Adalimumab|adalimumab]] (Abbott/AbbVie, 2002).<ref name="elliott1994">Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. ''Lancet''. 1994 Oct 22;344(8930):1105-1110. PMID 7934491.</ref> The TNF inhibitors were the prototype for a class that has since extended through inhibitors of interleukin-1 (anakinra), interleukin-6 (tocilizumab), interleukin-17 (secukinumab), interleukin-12/23 (ustekinumab), and the small-molecule Janus kinase inhibitors (tofacitinib, baricitinib, upadacitinib).

The therapeutic role of an immunosuppressant carries a corresponding therapeutic cost. The pharmacology of the calcineurin inhibitors is dominated by nephrotoxicity, hypertension, hyperkalemia, and tremor; the mTOR inhibitors by pneumonitis and impaired wound healing; the antimetabolites by myelosuppression; the biologics by reactivation of latent tuberculosis, hepatitis B, and the deep fungal mycoses, and (for some agents) by demyelinating disease and a small but characteristic excess of lymphoma. The risk-benefit assessment of an immunosuppressive regimen, particularly a long-term one in autoimmune disease where the alternative is not death but disability, is among the more demanding judgments in internal medicine.

== Classes indexed ==

By mechanism:

* [[:Category:Corticosteroids|Systemic glucocorticoids]] (the foundational immunosuppressants): [[Dexamethasone|dexamethasone]], [[Methylprednisolone|methylprednisolone]], [[Prednisolone|prednisolone]], [[Prednisone|prednisone]]
* Antimetabolites: [[Methotrexate|methotrexate]] (also indexed as [[:Category:Antifolates|antifolate]] and [[:Category:DMARDs|DMARD]]), [[wikipedia:Azathioprine|azathioprine]], [[wikipedia:Mycophenolate mofetil|mycophenolate]]
* [[:Category:Calcineurin_inhibitors|Calcineurin inhibitors]]: [[Cyclosporine|cyclosporine]], [[wikipedia:Tacrolimus|tacrolimus]]
* mTOR inhibitors (where built): [[wikipedia:Sirolimus|sirolimus]], [[wikipedia:Everolimus|everolimus]]
* Alkylating agents used outside cancer: cyclophosphamide
* [[:Category:Biologics|Biologic agents]]: [[:Category:TNF_inhibitors|TNF inhibitors]] including [[Adalimumab|adalimumab]], etanercept, and infliximab; the interleukin-pathway and lymphocyte-depleting [[:Category:Monoclonal_antibodies|monoclonal antibodies]]; the Janus kinase inhibitors
* Antimalarial-derived disease-modifying agents: [[wikipedia:Hydroxychloroquine|hydroxychloroquine]]

== Notes on scope ==

The boundary of this category is "medicine prescribed to suppress an undesired immune response, whether in transplantation or in autoimmune disease." Medicines whose principal indication is cancer chemotherapy (the alkylating agents in oncologic doses, the cytotoxic antimetabolites, the antineoplastic monoclonal antibodies) are collected under [[:Category:Antineoplastics|antineoplastics]]; the small number of agents that cross both categories, principally methotrexate and cyclophosphamide, are listed under both. The intravenous immunoglobulin preparations are not in the strict sense immunosuppressants but immunomodulators, and although they are administered for some of the same conditions they are collected under [[:Category:Immunomodulators|immunomodulators]]. Topical preparations whose principal indication is dermatologic (the topical calcineurin inhibitors tacrolimus and pimecrolimus, topical corticosteroids) are listed under the appropriate route-specific category in addition to this one.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Immunomodulators]]
[[Category:CuratedCategoryPage]]

Category:Anti-herpesvirus agents

2026-05-23T19:48:04Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''anti-herpesvirus agent''' is a medicine used to treat infection by one of the eight human [[wikipedia:Herpesviridae|herpesviruses]]: herpes simplex virus 1 (HSV-1, principally oral and central-nervous-system disease), herpes simplex virus 2 (HSV-2, principally genital disease), varicella-zoster virus (VZV, primary varicella and reactivated zoster), Epstein-Barr virus (EBV), [[wikipedia:Cytomegalovirus|cytomegalovirus]] (CMV), and the more recently characterised human herpesviruses 6, 7, and 8. The category falls within [[:Category:Antivirals|antivirals]] and consists predominantly of nucleoside analogues that exploit the viral thymidine kinase and the viral DNA polymerase, with a small set of mechanistically distinct agents for resistant or mechanistically separate indications.

The pharmacological history of the category is the founding chapter of the contemporary antiviral pharmacopoeia (described under [[:Category:Antivirals|antivirals]]). [[wikipedia:Idoxuridine|Idoxuridine]] in 1962 was the first clinically used systemic antiviral and was the first medicine of any kind to selectively inhibit a virus by a defined molecular mechanism: an iodinated thymidine analogue that the viral DNA polymerase incorporated preferentially over the host enzyme. Idoxuridine's systemic toxicity restricted it to topical ophthalmic use, but the medicine established the nucleoside-analogue principle that has dominated anti-herpesvirus pharmacology ever since.

The transformative agent was [[Acyclovir|aciclovir]] (acyclovir), reported by [[wikipedia:Gertrude B. Elion|Gertrude Elion]] and colleagues at [[wikipedia:Burroughs Wellcome|Burroughs Wellcome]] in 1977. Acyclovir is an acyclic guanosine analogue that requires phosphorylation by the herpesvirus-encoded [[wikipedia:Thymidine kinase|thymidine kinase]] to its monophosphate, then by cellular kinases to the active triphosphate; the triphosphate is a chain-terminator at the viral DNA polymerase. Because the host thymidine kinase phosphorylates the medicine at negligible rate, acyclovir is concentrated by orders of magnitude in herpes-infected cells over uninfected cells, giving extraordinary selectivity. The therapeutic index of acyclovir is one of the highest in antimicrobial pharmacology, and the medicine has remained the foundation of anti-herpesvirus therapy for nearly fifty years.<ref name="elion1977ahv">Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. ''Proceedings of the National Academy of Sciences of the United States of America''. 1977 Dec;74(12):5716-5720. PMID 202961.</ref>

The clinical indications of acyclovir map to its activity spectrum. HSV-1 and HSV-2 are highly sensitive; the medicine is used for primary genital herpes (200 mg five times daily or 400 mg three times daily for 7 to 10 days), for recurrent episodes (3 to 5 days at the same dose), and for chronic suppressive therapy (400 mg twice daily) in patients with frequent recurrences. Varicella-zoster virus is approximately ten-fold less sensitive and requires higher doses (800 mg five times daily for 7 days for shingles; 800 mg four times daily for varicella). Epstein-Barr virus is variably sensitive at higher doses and is not a standard acyclovir indication. Cytomegalovirus is essentially insensitive at clinically achievable doses and requires the related but distinct ganciclovir.

The improved-bioavailability acyclovir derivatives followed. [[Valacyclovir|Valaciclovir]] (Valtrex, 1995, the L-valyl ester) is converted to acyclovir on first pass and provides three-to-five-fold higher oral bioavailability, allowing once- or twice-daily dosing for most indications. [[wikipedia:Famciclovir|Famciclovir]] (Famvir, 1994, the diacetyl ester of penciclovir, hydrolysed in vivo to the active compound) provides similar oral bioavailability through a closely related guanosine analogue. The acyclic phosphonate cidofovir (Vistide, 1996), administered intravenously with concurrent probenecid and saline diuresis, retains activity against acyclovir-resistant HSV and against CMV, but at the cost of substantial dose-related nephrotoxicity; brincidofovir, the lipid-conjugated oral derivative of cidofovir, was approved in 2021 for smallpox and may extend cidofovir's anti-herpesvirus use.

The cytomegalovirus medicines complete the contemporary category. [[wikipedia:Ganciclovir|Ganciclovir]] (Cytovene, Roche 1989) is a guanosine analogue similar in structure to acyclovir but phosphorylated by the CMV-encoded UL97 kinase rather than by HSV thymidine kinase; it is the standard treatment of CMV retinitis, CMV pneumonitis, CMV colitis, and prophylaxis in transplantation. Its myelosuppression limits chronic use. The orally bioavailable L-valyl ester [[wikipedia:Valganciclovir|valganciclovir]] (Valcyte, 2001) provides oral bioavailability sufficient for routine outpatient CMV prophylaxis and pre-emptive therapy. The phosphonoformate [[wikipedia:Foscarnet|foscarnet]] (Foscavir, 1991) is used for ganciclovir-resistant CMV and for acyclovir-resistant HSV, particularly in immunocompromised hosts; its nephrotoxicity, electrolyte derangement (hypocalcemia, hypomagnesemia, hypophosphatemia, hyperphosphatemia), and genital ulceration limit its use. The most recent CMV-specific medicine, [[wikipedia:Letermovir|letermovir]] (Prevymis, Merck 2017), inhibits the CMV terminase complex (a target absent from human cells) and is used as primary CMV prophylaxis in adult hematopoietic-cell transplant recipients; its CMV-specific mechanism gives it a favourable safety profile compared to the older agents. The newer [[wikipedia:Maribavir|maribavir]] (Livtencity, Takeda 2021), an inhibitor of the CMV UL97 kinase, is used for refractory CMV after transplantation.

== Classes indexed ==

By target:

* '''Acyclic guanosine analogues''' (HSV, VZV; thymidine-kinase-dependent activation):
** [[Acyclovir|Aciclovir (acyclovir)]] (Zovirax; intravenous, oral, topical)
** [[Valacyclovir|Valaciclovir]] (Valtrex; L-valyl valyl ester of acyclovir)
** [[wikipedia:Famciclovir|Famciclovir]] (Famvir; diacetyl diacetyl ester of penciclovir)
** Penciclovir (Denavir; topical only)
** Trifluridine (Viroptic; topical ophthalmic only, also used in oncology as trifluridine-tipiracil for colorectal cancer)
* '''Acyclic guanosine analogues with broader spectrum''' (HSV, VZV, CMV, EBV):
** [[wikipedia:Ganciclovir|Ganciclovir]] (Cytovene; intravenous and oral; CMV-active)
** [[wikipedia:Valganciclovir|Valganciclovir]] (Valcyte; L-valyl L-valyl ester of ganciclovir)
* '''Acyclic phosphonates''' (no viral kinase needed; broader spectrum, more toxicity):
** [[wikipedia:Cidofovir|Cidofovir]] (Vistide; intravenous)
** Brincidofovir (Tembexa; oral lipid-conjugated derivative of cidofovir; smallpox and selected anti-herpesvirus use)
* '''Pyrophosphate analogues''':
** [[wikipedia:Foscarnet|Foscarnet]] (Foscavir; intravenous; for ganciclovir-resistant CMV and acyclovir-resistant HSV)
* '''CMV-specific small molecules''':
** [[wikipedia:Letermovir|Letermovir]] (Prevymis; terminase inhibitor; CMV prophylaxis post-HSCT)
** [[wikipedia:Maribavir|Maribavir]] (Livtencity; UL97 kinase inhibitor; refractory CMV)
* '''Topical anti-herpesvirus''':
** Penciclovir cream, acyclovir cream and ointment, docosanol cream (Abreva; OTC)
** Trifluridine ophthalmic, idoxuridine ophthalmic (mostly retired)
* '''Other''':
** [[wikipedia:Vidarabine|Vidarabine]] (Vira-A, adenine arabinoside; largely retired, replaced by acyclovir)

== Notes on scope ==

The boundary of this category is "medicine active against one of the human herpesviruses and prescribed primarily for this indication." The vaccines for varicella (Varivax, ProQuad), zoster (Zostavax live, Shingrix recombinant adjuvanted), and the cytomegalovirus vaccines in trial are biologics rather than antiviral medicines and are listed under [[:Category:Biologics|biologics]]. The Epstein-Barr-virus targeted CAR-T cell products and EBV-specific cytotoxic T lymphocyte preparations are cellular immunotherapies and are listed under [[:Category:Immunomodulators|immunomodulators]]. The medicines used for human herpesvirus 8 (HHV-8, Kaposi-sarcoma-associated herpesvirus) are largely the same nucleoside analogues plus the antiretroviral therapy for the underlying HIV when KS is HIV-associated; they are cross-listed under [[:Category:Antineoplastics|antineoplastics]] for the KS indication.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Antivirals]]
[[Category:Anti-infectives]]
[[Category:CuratedCategoryPage]]

Category:Mucolytics

2026-05-23T19:48:03Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''mucolytic''' is a medicine that thins or breaks down respiratory or other body-secretion mucus, making it easier to clear by ciliary action, by coughing, or by suctioning. The category is used principally in [[wikipedia:Cystic fibrosis|cystic fibrosis]] (where airway mucus is the dominant pathophysiologic problem), in [[wikipedia:Chronic obstructive pulmonary disease|chronic obstructive pulmonary disease]] (where mucus hypersecretion contributes to airway obstruction and recurrent infection), in bronchiectasis, in selected severe acute bronchitis and pneumonia (where retained secretions impair gas exchange), and in [[wikipedia:Acetaminophen poisoning|paracetamol poisoning]] (the unrelated antidotal use of N-acetylcysteine).

The mucolytic category divides by mechanism. The '''thiol-disulfide-exchange''' agents (N-acetylcysteine, the related carbocysteine and erdosteine) reduce the disulfide cross-links between mucin molecules in mucus, lowering its viscosity and elasticity. The '''recombinant deoxyribonuclease''' dornase alfa cleaves the extracellular DNA released from neutrophils in the inflammatory mucus of cystic fibrosis, reducing its viscosity by a quite different mechanism. The '''hyperosmotic''' agents (hypertonic saline and mannitol inhaled) hydrate the airway surface and produce a thinner periciliary fluid layer that improves mucociliary clearance. The '''ambroxol-bromhexine''' group enhances surfactant production and modifies mucus viscoelasticity by mechanisms incompletely characterised.

The most clinically significant mucolytic medicine in absolute outcome terms is dornase alfa. [[wikipedia:Dornase alfa|Dornase alfa]] (Pulmozyme, Genentech 1993) is a recombinant human deoxyribonuclease I expressed in CHO cells; it is administered by nebuliser to patients with cystic fibrosis and cleaves the polymerised DNA that is the principal contributor to the unusual viscosity of CF mucus.<ref name="fuchs1994">Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. ''New England Journal of Medicine''. 1994 Sep 8;331(10):637-642. PMID 7503821.</ref> The 1994 Fuchs trial demonstrated reduced exacerbation rate and improved lung function with daily dornase alfa, and the medicine has been a foundation of CF pulmonary care since. The introduction of the CFTR modulators ([[wikipedia:Ivacaftor|ivacaftor]] 2012, ivacaftor-lumacaftor 2015, ivacaftor-tezacaftor 2018, the highly transformative elexacaftor-tezacaftor-ivacaftor [[wikipedia:Trikafta|Trikafta]] 2019) has substantially reduced the role of dornase alfa in CFTR-modulator-eligible patients, although the medicine retains a place in the CF pharmacopoeia.

The other major CF mucolytic, [[wikipedia:Hypertonic saline (medical use)|hypertonic saline]] (7 percent saline, inhaled by nebuliser twice daily), was shown in the 2006 Donaldson and Boucher trials to improve mucociliary clearance and to reduce exacerbations in CF.<ref name="elkins2006">Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. ''New England Journal of Medicine''. 2006 Jan 19;354(3):229-240. PMID 16421364.</ref> Hypertonic saline produces airway-surface hydration; the resulting expansion of the periciliary fluid layer improves cilia function and the gel-layer mucus is mobilised more easily. Inhaled [[wikipedia:Mannitol|mannitol]] (Bronchitol, Pharmaxis 2020 in U.S.) works by the same hyperosmotic mechanism and is an alternative for patients intolerant of hypertonic-saline-induced cough.

[[wikipedia:Acetylcysteine|N-acetylcysteine]] (NAC; Mucomyst as nebuliser; Acetadote intravenous) is the prototype thiol mucolytic. Its acetylated sulfhydryl group reduces the disulfide bonds of mucus glycoproteins, lowering viscosity. The medicine has been used by nebuliser since the 1960s for retained secretions in COPD, post-operative atelectasis, and selected bronchiectasis; the clinical evidence for routine COPD mucolytic use is mixed and current guidelines recommend it only for patients with frequent exacerbations on optimal bronchodilator therapy. The oral preparation, much less effective for respiratory secretions because of substantial first-pass metabolism, has small evidence-base utility in idiopathic pulmonary fibrosis (the PANTHER-IPF and IFIGENIA trials) and remains in selected use as antioxidant therapy in IPF. The dominant clinical use of N-acetylcysteine is, in contrast to its mucolytic indication, the antidotal treatment of [[wikipedia:Paracetamol poisoning|paracetamol overdose]] (replenishment of hepatic glutathione consumed by the reactive paracetamol metabolite NAPQI), described under [[Acetaminophen|acetaminophen]].

The carbocysteine, erdosteine, and bromhexine class are widely used in European and Asian practice but not approved in the United States. [[wikipedia:Carbocysteine|Carbocysteine]] (S-carboxymethyl-L-cysteine, Mucodyne in U.K.) is an oral thiol mucolytic with mixed evidence for COPD; erdosteine has antioxidant and mucolytic properties; ambroxol and its precursor bromhexine enhance surfactant production and have been used widely in Europe and Asia for acute and chronic bronchitis.

The '''expectorants''' (the largest of which is [[wikipedia:Guaifenesin|guaifenesin]], available over-the-counter in many cough-and-cold preparations) are conventionally considered alongside mucolytics, although they act by a slightly different mechanism: guaifenesin increases the volume and reduces the viscosity of respiratory secretions by enhancing vagal-mediated reflex bronchial secretion. The clinical evidence for expectorant efficacy in routine acute bronchitis is limited.

== Classes indexed ==

By mechanism:

* '''Thiol mucolytics''' (disulfide-bond reduction):
** [[wikipedia:Acetylcysteine|N-acetylcysteine]] (NAC; Mucomyst nebulised; Acetadote and Cetylev oral/IV for paracetamol overdose)
** [[wikipedia:Carbocysteine|Carbocysteine]] (Mucodyne; European)
** Erdosteine, fudosteine
* '''Recombinant DNase''':
** [[wikipedia:Dornase alfa|Dornase alfa]] (Pulmozyme; for cystic fibrosis)
* '''Hyperosmotic''' (airway-surface hydration):
** [[wikipedia:Hypertonic saline (medical use)|Hypertonic saline]] (3%, 7%, 10% nebulised)
** [[wikipedia:Mannitol|Inhaled mannitol]] (Bronchitol)
* '''Surfactant modifiers / mucokinetic''':
** Ambroxol, bromhexine (European, Asian use)
* '''[[:Category:Expectorants|Expectorants]]''' (cross-indexed; enhance reflex bronchial secretion):
** [[wikipedia:Guaifenesin|Guaifenesin]] (Mucinex; OTC and prescription)
** Potassium iodide (older expectorant; uncommon current use)
* '''Other''':
** Inhaled isotonic saline (less established; some bronchiectasis use)
** Antibody-targeted MUC5AC modulators in trial

== Notes on scope ==

The boundary of this category is "medicine that reduces the viscosity or volume of respiratory mucus to improve clearance." The [[:Category:Bronchodilators|bronchodilators]] indirectly improve clearance by enlarging the airway lumen but are not mucolytics in mechanism and are listed under [[:Category:Bronchodilators|bronchodilators]] separately. The mucus-blocking medicines used in COPD with predominant cough-and-mucus phenotype (the inhaled corticosteroids in combination with LABA) are listed under [[:Category:Antiasthmatic_agents|antiasthmatic agents]] and [[:Category:Bronchodilators|bronchodilators]]. The medicines for selected non-airway mucus indications (the saline irrigations for chronic rhinosinusitis; the meibum-targeted medicines for dry eye; the cervical-mucus modulators of selected reproductive-medicine indications) are listed under their primary system categories. The non-mucolytic antitussives (the central-acting dextromethorphan, codeine, and benzonatate; the peripheral-acting menthol and camphor) are conventionally listed alongside mucolytics in cough-and-cold OTC categories but act by suppression of cough rather than mucus modification.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:CuratedCategoryPage]]

Category:Antithyroid agents

2026-05-23T19:48:03Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''antithyroid agent''' is a medicine that reduces the production or peripheral action of thyroid hormone, used to treat hyperthyroidism. The category contains the two [[wikipedia:Thionamide|thionamide]] medicines that block the thyroid synthesis pathway ([[wikipedia:Methimazole|methimazole]] and [[wikipedia:Propylthiouracil|propylthiouracil]]), the radioactive iodine isotope I-131 that destroys the thyroid gland by beta-radiation, and the adjunctive medicines that control symptoms or block peripheral conversion of thyroxine to triiodothyronine while the primary treatment takes effect (beta-blockers; iodine; corticosteroids in thyroid storm).

The pharmacological history of antithyroid medicine began at the [[wikipedia:Mayo Clinic|Mayo Clinic]] in the 1940s. The American physiologist [[wikipedia:Edwin B. Astwood|Edwin Astwood]] at [[wikipedia:Harvard Medical School|Harvard]] reported in 1943 that thiourea and the related thiouracil inhibited thyroid hormone synthesis and produced clinical improvement in thyrotoxic patients; the toxicity of thiourea limited its clinical use, but [[wikipedia:Propylthiouracil|propylthiouracil]] (PTU), introduced shortly afterwards, became the standard medical treatment for [[wikipedia:Graves' disease|Graves' disease]] thyrotoxicosis and for toxic multinodular goiter.<ref name="astwood1943">Astwood EB. Treatment of hyperthyroidism with thiourea and thiouracil. ''JAMA''. 1943 Oct 9;122(2):78-81.</ref> [[wikipedia:Methimazole|Methimazole]] (carbimazole's active metabolite; carbimazole used in Europe, methimazole in the U.S.) was developed in 1949 and gradually replaced PTU as first-line for most indications, on the basis of its longer half-life (six hours versus one hour), once-daily dosing convenience, and lower hepatotoxicity profile.

The thionamides act by inhibiting [[wikipedia:Thyroid peroxidase|thyroid peroxidase]], the enzyme responsible for iodination of tyrosine residues on thyroglobulin and for the coupling of iodotyrosines to form thyroxine (T4) and triiodothyronine (T3) within the thyroid follicular lumen. Propylthiouracil has the additional peripheral action of inhibiting type 1 5'-deiodinase, the enzyme that converts T4 to the more active T3 in peripheral tissues, which gives it a small but real clinical advantage in the management of severe thyrotoxicosis and thyroid storm. The disadvantage of PTU is its three-times-daily dosing, its higher hepatotoxicity (rare but devastating fulminant hepatic failure including in children, which led to a 2010 FDA boxed warning restricting first-line use to the first trimester of pregnancy and to thyroid storm), and its higher rate of ANCA-associated vasculitis.

The contemporary clinical positioning is well-established. Methimazole is first-line for nonpregnant adult Graves' disease and for toxic multinodular goiter; propylthiouracil is reserved for the first trimester of pregnancy (where methimazole has been associated with aplasia cutis and a small but real choanal-atresia signal), for thyroid storm (where its peripheral T4-to-T3 inhibition is useful), and for the rare patient intolerant of methimazole. The titration is to clinical and biochemical euthyroidism, with dose reduction over 12 to 18 months and a trial of withdrawal at approximately 18 months; approximately 40 percent of Graves' patients achieve sustained remission after a single course, with the remainder requiring continued thionamide therapy or definitive treatment (radioactive iodine or thyroidectomy).

Radioactive iodine (I-131) is administered as a single oral dose calculated to deliver approximately 100 to 200 microcuries per gram of estimated thyroid weight, the cells of which concentrate iodine via the sodium-iodide symporter (NIS) and are destroyed by the beta-radiation from the captured isotope. The treatment was developed by [[wikipedia:Saul Hertz|Saul Hertz]] and [[wikipedia:Arthur Roberts (physicist)|Arthur Roberts]] at the [[wikipedia:Massachusetts General Hospital|Massachusetts General Hospital]] and the [[wikipedia:MIT|MIT]] cyclotron facility in the early 1940s; their first clinical use of I-131 for hyperthyroidism was on 31 March 1941, making it the first therapeutic use of an artificially produced radionuclide.<ref name="hertz1942">Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves' disease. ''Journal of Clinical Investigation''. 1942 Jan;21(1):624.</ref> Radioactive iodine is the most common definitive treatment for Graves' disease in the United States; the European preference is more often for thionamide therapy first with surgery as backup. The post-treatment hypothyroidism is essentially inevitable and is treated with lifelong [[wikipedia:Levothyroxine|levothyroxine]] replacement (described under [[:Category:Thyroid_hormones|thyroid hormones]]).

The adjunctive antithyroid medicines complete the category. The [[:Category:Beta-blockers|beta-blocker]] propranolol controls the tachycardia, tremor, and anxiety of severe hyperthyroidism within hours and is added to thionamide therapy at presentation. Stable iodine (potassium iodide as saturated solution SSKI or as Lugol's solution) blocks thyroid hormone release acutely by the Wolff-Chaikoff effect; it is given for 7 to 14 days before thyroid surgery to reduce gland vascularity, and intravenously in thyroid storm. Lithium has historical use as a thyroid-hormone-release inhibitor in selected refractory thyroid storm or in radioactive-iodine-rejection cases; its narrow therapeutic window limits routine use. Corticosteroids (intravenous hydrocortisone or oral prednisone) block peripheral T4-to-T3 conversion and are used in thyroid storm and in the rare amiodarone-induced thyrotoxicosis. Cholestyramine binds enterohepatically recirculated thyroid hormones and accelerates their elimination in selected severe cases.

Two specific clinical scenarios deserve mention. [[wikipedia:Thyroid storm|Thyroid storm]] (severe decompensated thyrotoxicosis with hyperpyrexia, tachyarrhythmia, encephalopathy) is treated with high-dose intravenous propranolol or esmolol, intravenous propylthiouracil, intravenous corticosteroid, and stable iodine (after the first thionamide dose to avoid loading the gland with substrate); supportive care for fever, fluid balance, and arrhythmia is foundational. Amiodarone-induced thyrotoxicosis (described under [[:Category:Antiarrhythmics|antiarrhythmics]]) is managed by methimazole, corticosteroids, and (in type II destructive thyroiditis variant) thyroidectomy if medically uncontrolled; the underlying amiodarone may be continued in selected cases because its withdrawal does not rapidly reverse the thyrotoxicosis.

== Classes indexed ==

By mechanism:

* '''Thionamides''' (inhibit thyroid peroxidase):
** [[wikipedia:Methimazole|Methimazole]] (Tapazole; first-line for most adult indications)
** [[wikipedia:Carbimazole|Carbimazole]] (European preference; metabolised to methimazole in vivo)
** [[wikipedia:Propylthiouracil|Propylthiouracil]] (PTU; first-trimester pregnancy, thyroid storm, methimazole intolerance)
* '''Radioactive iodine''':
** I-131 (sodium iodide oral capsule; definitive ablative treatment for Graves' disease, toxic adenoma, toxic multinodular goiter, residual thyroid cancer after thyroidectomy)
* '''Inhibitors of thyroid hormone release''':
** Stable iodine: potassium iodide as SSKI, Lugol's solution; intravenous sodium iodide
** Lithium carbonate (historical, selected refractory use)
* '''Symptomatic adjuncts''':
** [[:Category:Beta-blockers|Beta-blockers]] (cross-indexed): propranolol, atenolol, metoprolol, esmolol (intravenous for thyroid storm)
* '''Peripheral T4-to-T3 conversion inhibitors''' (in thyroid storm):
** [[:Category:Corticosteroids|Corticosteroids]] (hydrocortisone IV, prednisone PO)
** Propylthiouracil (in addition to its primary thyroid-peroxidase action)
** Propranolol (small effect)
** Iopanoic acid and ipodate (radiographic contrast agents with antithyroid effect; largely unavailable in the U.S.)
* '''Bile-acid sequestrants''' (cross-indexed; accelerate thyroid hormone elimination):
** [[wikipedia:Cholestyramine|Cholestyramine]]

== Notes on scope ==

The boundary of this category is "medicine that reduces thyroid hormone production, release, or action, used to treat hyperthyroidism." The [[:Category:Thyroid_hormones|thyroid hormones]] (levothyroxine, liothyronine, desiccated thyroid extract) are the opposite-direction medicines and are collected under [[:Category:Thyroid_hormones|thyroid hormones]] separately, although they are used in this category's patients after definitive treatment with radioactive iodine or thyroidectomy. The medicines used for [[wikipedia:Hashimoto thyroiditis|Hashimoto thyroiditis]] (largely just levothyroxine; selected use of selenium with weak evidence) are not antithyroid agents and are listed under thyroid hormones. The medicines used for [[wikipedia:Graves' ophthalmopathy|Graves' ophthalmopathy]] (intravenous methylprednisolone, teprotumumab, orbital irradiation, surgical decompression) are listed under their primary mechanism classes; teprotumumab (Tepezza, Horizon 2020), an IGF-1 receptor antagonist, is the first medicine specifically approved for thyroid eye disease.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Endocrine_therapy]]
[[Category:CuratedCategoryPage]]

Category:Schedule II controlled substances

2026-05-23T19:48:02Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''Schedule II controlled substance''' is a medicine, a precursor chemical, or a substance of abuse that the United States [[wikipedia:Drug Enforcement Administration|Drug Enforcement Administration]] has placed in the second schedule of its [[wikipedia:Controlled Substances Act|Controlled Substances Act]] (CSA), the 1970 legislation that consolidated and replaced the previous Harrison Narcotics Act of 1914. Schedule II substances are those that have an accepted medical use but also a high potential for abuse, with abuse liability that may lead to severe psychological or physical dependence; they are subject to the most restrictive prescribing requirements of any clinically used medicine class in the United States, and their movement and dispensing are tracked by the DEA at every step from manufacturer to pharmacy.

The federal regulatory framework that this category reflects was assembled in three stages. The [[wikipedia:Pure Food and Drug Act|Pure Food and Drug Act]] of 1906 required accurate labelling of patent medicines but did not restrict their sale; cocaine, morphine, and heroin were sold freely in soda fountains, pharmacies, and mail-order catalogues. The [[wikipedia:Harrison Narcotics Tax Act|Harrison Narcotics Tax Act]] of 1914, framed nominally as a revenue measure (the Act required registration and tax stamps for the importation, manufacture, and distribution of "opium and coca leaves and their salts, derivatives, and preparations"), was used by the Bureau of Internal Revenue and its successor enforcement agencies to prosecute physicians who maintained opioid-dependent patients on opioid medicines and to construct, in effect, a federal prohibition of opioid use outside the strict bounds of acute therapeutic treatment.<ref name="harrison1914">U.S. Congress. An Act to Provide for the Registration of, with Collectors of Internal Revenue, and to Impose a Special Tax on All Persons Who Produce, Import, Manufacture, Compound, Deal in, Dispense, Sell, Distribute, or Give Away Opium or Coca Leaves, Their Salts, Derivatives, or Preparations, and for Other Purposes. ''Public Law 63-223''. December 17, 1914.</ref> The Controlled Substances Act of 1970 superseded the Harrison framework, established the five-schedule classification that remains in use, and created the DEA (then the Bureau of Narcotics and Dangerous Drugs) as the federal enforcement authority.<ref name="csa1970">U.S. Congress. Comprehensive Drug Abuse Prevention and Control Act of 1970. ''Public Law 91-513''. October 27, 1970.</ref>

The Schedule II tier carries restrictions distinct from any other prescription medicine class. A Schedule II medicine cannot be refilled; each prescription requires a new written order or, since the federal regulations were updated in 2010, an electronic prescription transmitted through an EPCS (Electronic Prescriptions for Controlled Substances)-certified system. A faxed Schedule II prescription is accepted only in limited specified circumstances (long-term-care facilities, hospice patients, parenteral home-infusion). State-level requirements often add additional restrictions: a maximum thirty-day supply on a single prescription, mandatory consultation of the state's [[wikipedia:Prescription drug monitoring program|prescription drug monitoring program]] (PDMP) before prescribing, and (in several states) a maximum days-supply limit on the initial opioid prescription for an acute pain indication. The pharmacy that fills the prescription is required to verify identity, log the dispensing transaction in the state PDMP, and maintain physical security of the unfilled and filled Schedule II inventory.

The medicines presently classified as Schedule II are dominated by the opioid analgesics and the medical psychostimulants. Most of the full mu-receptor opioid agonists are Schedule II: [[Morphine|morphine]], [[Oxycodone|oxycodone]] and its combination products ([[wikipedia:Percocet|Percocet]] is oxycodone plus paracetamol; Percodan is oxycodone plus aspirin), [[Hydrocodone|hydrocodone]] (moved from Schedule III to Schedule II in October 2014, including [[wikipedia:Vicodin|Vicodin]] which had been Schedule III since 1970), [[Hydromorphone|hydromorphone]], [[Oxymorphone|oxymorphone]], [[Fentanyl|fentanyl]] and its medical congeners [[Sufentanil|sufentanil]] and [[Alfentanil|alfentanil]] and [[Remifentanil|remifentanil]], [[Methadone|methadone]] (Schedule II for analgesic use; the medication-assisted-treatment use of methadone is regulated separately through DEA-licensed opioid treatment programmes), and [[Meperidine|meperidine]]. Cocaine, used now medically only as a topical anaesthetic in ear-nose-and-throat procedures, remains Schedule II. The medical [[:Category:Psychostimulants|psychostimulants]] used for [[wikipedia:Attention deficit hyperactivity disorder|ADHD]] are Schedule II: [[wikipedia:Methylphenidate|methylphenidate]], the amphetamines (mixed amphetamine salts marketed as [[wikipedia:Adderall|Adderall]], dextroamphetamine, [[wikipedia:Lisdexamfetamine|lisdexamfetamine]]), and the very-short-half-life dextromethamphetamine (rarely prescribed for ADHD but Schedule II when it is). Phencyclidine (now used in research and rarely in veterinary medicine) is also Schedule II.

Several Schedule II medicines exist principally as scheduling artefacts of compounding regulations. [[wikipedia:Pentobarbital|Pentobarbital]] and [[wikipedia:Secobarbital|secobarbital]] (Schedule II [[:Category:Barbiturates|barbiturates]]) and [[wikipedia:Amobarbital|amobarbital]] (Schedule II as the parent; in combination with other ingredients drops to Schedule III) remain in occasional use for refractory status epilepticus, for medically assisted dying in the jurisdictions where the practice is legal, and (in Mexico and the United Kingdom) for veterinary euthanasia. Several precursor chemicals (anhydrous hydrogen iodide and red phosphorus, key precursors of methamphetamine synthesis) are also Schedule II, although these are regulated under separate sections of the CSA that affect manufacturers and chemists rather than prescribers.

The clinical implications of the Schedule II classification go well beyond the additional paperwork. The 1996 introduction and aggressive marketing of [[wikipedia:OxyContin|controlled-release oxycodone (OxyContin)]] was followed by a two-decade rise in opioid prescribing, dependence, and overdose mortality that has been the subject of substantial legal action against the manufacturer ([[wikipedia:Purdue Pharma|Purdue Pharma]]) and its owners. The contemporary regulatory environment of Schedule II prescribing reflects that history: state PDMP consultation is now mandatory in 49 states for opioid prescriptions; CMS audit and the corresponding fear of regulatory consequence have measurably reduced opioid prescribing in primary care; and the "OUD" (opioid use disorder) and "MAT" (the older term for medicine-assisted treatment, now usually styled "MOUD" for medicines for opioid use disorder) infrastructure of [[Buprenorphine|buprenorphine]] (Schedule III), [[Methadone|methadone]] (Schedule II via opioid-treatment programmes), and extended-release naltrexone has developed in parallel. The Schedule II classification is, in clinical practice, a marker that prescribing carries regulatory consequence in addition to clinical responsibility.

== Selected medicines indexed ==

Not exhaustive; the DEA publishes a comprehensive list at the [[USLegal:DEA_Schedule_II|DEA Schedule II]] reference page in the [[wikipedia:USLegal|USLegal:]] namespace of this wiki.

* '''Opioid analgesics''': [[Morphine|morphine]], [[Oxycodone|oxycodone]], [[Hydrocodone|hydrocodone]], [[Hydromorphone|hydromorphone]], [[Oxymorphone|oxymorphone]], [[Fentanyl|fentanyl]], [[Sufentanil|sufentanil]], [[Alfentanil|alfentanil]], [[Remifentanil|remifentanil]], [[Meperidine|meperidine]], [[Methadone|methadone]], tapentadol (note: distinct from non-Schedule II [[Tramadol|tramadol]], which is Schedule IV); the high-potency carfentanil is Schedule II (in veterinary use)
* '''Combination opioid products''': [[wikipedia:Percocet|Percocet]] (oxycodone + paracetamol), [[wikipedia:Percodan|Percodan]] (oxycodone + aspirin), [[wikipedia:Vicodin|Vicodin]] (hydrocodone + paracetamol, all hydrocodone combinations moved to Schedule II in 2014)
* '''Psychostimulants''': [[wikipedia:Methylphenidate|methylphenidate]] (Ritalin, Concerta), [[wikipedia:Dextroamphetamine|dextroamphetamine]], mixed amphetamine salts ([[wikipedia:Adderall|Adderall]]), [[wikipedia:Lisdexamfetamine|lisdexamfetamine]] (Vyvanse), [[wikipedia:Methamphetamine|methamphetamine]] (Desoxyn, rarely prescribed)
* '''Barbiturates (Schedule II tier)''': [[wikipedia:Pentobarbital|pentobarbital]], [[wikipedia:Secobarbital|secobarbital]], [[wikipedia:Amobarbital|amobarbital]] (parent)
* '''Other''': [[wikipedia:Cocaine|cocaine]] (medical topical anaesthetic), [[wikipedia:Phencyclidine|phencyclidine]] (research, veterinary), [[wikipedia:Nabilone|nabilone]] (synthetic cannabinoid, antiemetic for chemotherapy)

== Notes on scope ==

The boundary of this category is "medicine or substance placed in Schedule II of the U.S. Controlled Substances Act." The Schedule designation is United States federal; other jurisdictions have analogous but not identical classifications (the Canadian Controlled Drugs and Substances Act schedules I-VIII; the United Kingdom Misuse of Drugs Act Class A/B/C and the Misuse of Drugs Regulations Schedules 1-5; the international schedules established by the [[wikipedia:Single Convention on Narcotic Drugs|1961 Single Convention]] and the [[wikipedia:Convention on Psychotropic Substances|1971 Convention on Psychotropic Substances]]). Cross-references to these other jurisdictions are made on individual medicine pages where the international scheduling differs notably from the U.S. designation. The [[USLegal:|USLegal:]] namespace on this wiki contains a comprehensive set of pages for each of the U.S. legal status categories (Prescription only, Over-the-counter, [[USLegal:DEA_Schedule_I|DEA Schedule I]] through [[USLegal:DEA_Schedule_V|DEA Schedule V]]) and serves as the authoritative reference for the regulatory framework.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Controlled_substances]]
[[Category:CuratedCategoryPage]]

Category:Vasopressors

2026-05-23T19:48:01Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''vasopressor''' is a medicine that raises the blood pressure by producing arterial vasoconstriction. The category sits at the intersection of [[:Category:Sympathomimetics|sympathomimetics]], [[:Category:Hormones|hormones]], and the small set of pressor agents acting on other mechanisms. The clinical use of vasopressors is concentrated in the acute-care setting: distributive shock (septic, anaphylactic, neurogenic), cardiogenic shock when filling pressures are adequate, anaesthesia-induced hypotension, and the emergency management of cardiac arrest where the inotropic and vasoconstrictor effects are co-equally desired.

The history of the category coincides with the isolation of adrenaline by [[wikipedia:Jokichi Takamine|Jokichi Takamine]] in 1900, the first hormone isolated in pure form and the first systematically used vasopressor. The clinical pharmacology has been progressively refined as the receptor classification (alpha vs beta of [[wikipedia:Raymond Ahlquist|Ahlquist]] 1948, then the alpha-1/alpha-2 and beta-1/beta-2/beta-3 subtypes through the 1960s and 1980s) has clarified which receptor activation produces which physiological effect. The modern vasopressor pharmacopoeia is built on the principle that septic shock is dominated by vasodilatation rather than by depressed inotropy, and that an alpha-1-predominant agent is therefore the first-line approach.

The SOAP-II trial in 2010 compared norepinephrine and dopamine as initial vasopressors in shock and found that norepinephrine was associated with substantially fewer arrhythmic events and a trend toward lower mortality;<ref name="soapii2010">De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. ''New England Journal of Medicine''. 2010 Mar 4;362(9):779-789. PMID 20200382.</ref> norepinephrine has since been the first-line vasopressor in essentially every contemporary septic-shock guideline. The VASST trial in 2008 demonstrated that the addition of low-dose [[wikipedia:Vasopressin|vasopressin]] (0.03 units per minute, replacing the relative vasopressin deficiency of septic shock) to norepinephrine produced a non-inferior outcome with reduced norepinephrine requirement, and vasopressin has become the standard second-line agent in catecholamine-refractory shock.

The most recent vasopressor approval is the recombinant human angiotensin II (Giapreza, La Jolla Pharmaceutical, 2017), studied in the ATHOS-3 trial of catecholamine-resistant vasodilatory shock and used as a third-line agent in selected patients with profound vasoplegia.<ref name="athos2017">Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of vasodilatory shock. ''New England Journal of Medicine''. 2017 Aug 3;377(5):419-430. PMID 28528561.</ref> The clinical use of angiotensin II in shock remains, as of the mid-2020s, niche but mechanistically distinct from the catecholamines, and a small body of evidence suggests it may be particularly useful in shock complicating cardiac surgery and in acute-on-chronic kidney injury with vasoplegia.

The other vasopressor agents fill more specific niches. Intravenous phenylephrine, an alpha-1 selective agonist, is used by anaesthetists for the transient hypotension of spinal or epidural anaesthesia; the lack of beta-1 inotropic effect makes it useful where reflex tachycardia is to be avoided (aortic stenosis, tetralogy of Fallot, hypertrophic cardiomyopathy). Oral midodrine (an alpha-1 agonist metabolically activated to desglymidodrine) is used for chronic orthostatic hypotension in autonomic failure. Methylene blue, originally an antimalarial and a methemoglobinemia antidote, is used off-label in selected catecholamine-refractory vasoplegic shock through inhibition of soluble guanylate cyclase and nitric oxide synthase. The intravenous calcium-channel antagonist reversal protocols use [[Calcium|calcium]] gluconate, glucagon, insulin-glucose, and intravenous lipid emulsion in addition to the standard catecholamine vasopressors.

The clinical management of a vasopressor infusion is, like that of many intensive-care medicines, as much about technique as about dose. Central-venous access is required for sustained infusion to avoid extravasation injury; arterial-line monitoring is required for titration; the choice of agent and the rate of escalation are guided by the clinical context (sepsis: norepinephrine first, vasopressin second, angiotensin II or epinephrine third; cardiogenic shock with inadequate cardiac output: dobutamine first, epinephrine or milrinone second; anaphylaxis: intramuscular epinephrine first, intravenous epinephrine and pressors as needed; neurogenic shock with bradycardia: norepinephrine with chronotropic support).

== Classes indexed ==

By mechanism:

* '''Catecholamines (endogenous and synthetic)''' (cross-indexed under [[:Category:Sympathomimetics|sympathomimetics]] and [[:Category:Catecholamines|catecholamines]] where built):
** [[wikipedia:Norepinephrine|Norepinephrine]] (first-line in septic and distributive shock)
** [[wikipedia:Epinephrine|Epinephrine]] (anaphylaxis, cardiac arrest, refractory shock, severe asthma exacerbation)
** [[wikipedia:Dopamine|Dopamine]] (less commonly used since SOAP-II)
** [[wikipedia:Dobutamine|Dobutamine]] (beta-1 selective inotrope, not strictly a vasopressor)
** [[wikipedia:Phenylephrine|Phenylephrine]] (alpha-1 selective)
* '''Vasopressin and its analogues''' (cross-indexed under [[:Category:Hormones|hormones]]):
** [[wikipedia:Vasopressin|Vasopressin]] (arginine vasopressin, antidiuretic hormone) for catecholamine-refractory shock
** [[wikipedia:Terlipressin|Terlipressin]] (selective V1 receptor agonist; hepatorenal syndrome, oesophageal variceal bleeding, refractory shock in selected jurisdictions)
* '''Renin-angiotensin pathway''':
** Recombinant human [[wikipedia:Angiotensin II|angiotensin II]] (Giapreza, 2017)
* '''Other''':
** Methylene blue (intravenous, off-label, refractory vasoplegic shock)
** Hydroxocobalamin (cyanokit, occasionally used for cyanide-induced vasoplegia)
** Midodrine (oral, chronic orthostatic hypotension; not for acute shock)
** Droxidopa (oral, metabolised to norepinephrine; neurogenic orthostatic hypotension)

== Notes on scope ==

The boundary of this category is "medicine prescribed to raise arterial blood pressure through vasoconstriction in the acute or chronic setting." The [[:Category:Antihypertensives|antihypertensives]] are the pharmacologic opposite of vasopressors and are collected separately. The intravenous fluid resuscitation of hypotensive shock with crystalloid or colloid is a volume intervention rather than a vasopressor and is listed under [[:Category:Electrolyte_replacements|electrolyte replacements]]. The chronic medicines used in autonomic failure for orthostatic hypotension (midodrine, droxidopa, fludrocortisone for volume expansion, pyridostigmine in selected cases) are collected here when their use is specifically for blood-pressure support. The combined alpha-and-beta blocker labetalol, although it lowers rather than raises blood pressure, is sometimes mentioned in hypertensive-emergency context alongside vasopressor pharmacology because of the clinical-pharmacology overlap; labetalol is listed under [[:Category:Beta-blockers|beta-blockers]] and [[:Category:Antihypertensives|antihypertensives]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Cardiovascular_agents]]
[[Category:CuratedCategoryPage]]

Category:Overactive bladder medications

2026-05-23T19:48:00Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

An '''overactive bladder medication''' is a medicine used to treat the symptom complex of urinary urgency, frequency, nocturia, and (in approximately one-third of cases) urge incontinence that characterises [[wikipedia:Overactive bladder|overactive bladder syndrome]]. The condition is now understood as a clinical-symptom diagnosis rather than a urodynamic one, and the category includes medicines that act on the detrusor muscle of the bladder wall and on its neural input: the [[:Category:Antimuscarinics|antimuscarinic agents]] that block the M3-mediated detrusor contraction, the beta-3 adrenergic agonists that promote detrusor relaxation, and, for refractory cases, [[wikipedia:OnabotulinumtoxinA|onabotulinumtoxinA]] injected directly into the detrusor.

The clinical understanding of the syndrome has evolved substantially. The term "overactive bladder" was introduced by the [[wikipedia:International Continence Society|International Continence Society]] in 2002 to displace the older "detrusor instability" or "detrusor hyperreflexia" terminology, recognising that the symptoms could be diagnosed clinically without urodynamic confirmation and that medicines could be initiated on the basis of symptom assessment alone.<ref name="abrams2002">Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. ''Neurourology and Urodynamics''. 2002;21(2):167-178. PMID 11857671.</ref> The pharmacological landscape has been transformed by this redefinition, which made overactive bladder a treatable outpatient diagnosis for the substantial fraction (approximately one in six adults) of the developed-world population with relevant symptoms.

The first effective pharmacological treatment was the non-selective antimuscarinic [[Oxybutynin|oxybutynin]], introduced by Marion Laboratories in 1975 on the rationale that the detrusor contraction was driven by parasympathetic acetylcholine acting on muscarinic receptors. Oxybutynin was effective but produced the full antimuscarinic toxidrome (dry mouth, blurred vision, constipation, somnolence, confusion in the elderly) at clinically useful doses; the immediate-release formulation has been progressively replaced by the extended-release tablet (1998), the transdermal patch (2003), and the topical gel (2009), each of which reduces peak concentrations and the corresponding dose-limiting adverse effects.

The next generation of antimuscarinics aimed for greater selectivity for the M3 receptor predominant on the detrusor, with less M1 affinity (the M1 receptor of the central nervous system and of the salivary acini accounts for much of the dry mouth and cognitive toxicity). [[wikipedia:Tolterodine|Tolterodine]] (Pharmacia, 1998), [[Solifenacin|solifenacin]] (Yamanouchi, 2004), [[wikipedia:Darifenacin|darifenacin]] (Pfizer, 2004, the most M3-selective of the class), fesoterodine (Pfizer, 2008, hydrolysed in vivo to the active metabolite of tolterodine), and [[wikipedia:Trospium chloride|trospium]] (a quaternary amine that does not cross the blood-brain barrier and so produces less central toxicity) extended the class. Comparative meta-analyses show similar efficacy across the antimuscarinic class, with the differences principally in side-effect profile rather than in symptom reduction.

The transformative agent in the 2010s was the first beta-3 adrenergic agonist. Detrusor smooth muscle, although under predominant parasympathetic stimulatory control through M3 receptors, also expresses beta-3 adrenoceptors whose activation produces relaxation; the receptor was poorly accessible to traditional adrenergic medicines because beta-3 selectivity is difficult to achieve. [[Mirabegron|Mirabegron]] (Astellas, 2012) was the first orally bioavailable selective beta-3 agonist; it reduced urge incontinence episodes and micturition frequency comparable to the antimuscarinics, without dry mouth or cognitive effect, although with a small but real signal of hypertension that has required blood-pressure monitoring on treatment.<ref name="khullar2013">Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. ''European Urology''. 2013 Feb;63(2):283-295. PMID 23182126.</ref> [[wikipedia:Vibegron|Vibegron]] (Urovant, 2020) followed with a similar efficacy profile and a smaller blood-pressure signal. The combination of a beta-3 agonist with an M3 antimuscarinic is now standard for symptoms not controlled on monotherapy, with the additive efficacy of two mechanisms and largely non-overlapping side-effect profiles.

For refractory cases, intradetrusor injection of [[wikipedia:OnabotulinumtoxinA|onabotulinumtoxinA]] (Botox), administered cystoscopically at 100 to 200 units divided across 20 to 30 detrusor sites, provides 6 to 9 months of symptomatic relief by chemical denervation of detrusor muscle, at the cost of incomplete bladder emptying (and rarely the need for clean intermittent catheterisation) in approximately 5 percent of patients. Posterior tibial nerve stimulation and sacral neuromodulation are device-based alternatives. The selective M3 antagonists, the beta-3 agonists, and the chemodenervation therapies have together made overactive bladder a substantially treatable condition, and the older recommendation to "live with it" in middle age has retreated.

== Classes indexed ==

By mechanism:

* '''Antimuscarinics''' (cross-indexed under [[:Category:Antimuscarinics|antimuscarinics]]):
** Non-selective (older, less expensive, more side effects): [[Oxybutynin|oxybutynin]] (oral immediate- and extended-release, transdermal patch, topical gel)
** M3-selective (modern, fewer central effects): [[Solifenacin|solifenacin]], [[wikipedia:Tolterodine|tolterodine]], [[wikipedia:Darifenacin|darifenacin]], [[wikipedia:Fesoterodine|fesoterodine]]
** Quaternary amines (do not cross blood-brain barrier): [[wikipedia:Trospium chloride|trospium]]
* '''Beta-3 adrenergic agonists''': [[Mirabegron|mirabegron]], [[wikipedia:Vibegron|vibegron]]
* '''Chemodenervation''': [[wikipedia:OnabotulinumtoxinA|onabotulinumtoxinA]] (intradetrusor injection)
* '''Tricyclic antidepressants''' (off-label, principally for nocturnal enuresis): [[wikipedia:Imipramine|imipramine]] (largely retired for this indication in favour of better-tolerated alternatives but still used in selected cases)
* '''Topical estrogen''' (for the urgency component in postmenopausal women with genitourinary syndrome of menopause): vaginal [[Estradiol|estradiol]], vaginal estriol, conjugated estrogen cream

== Notes on scope ==

The boundary of this category is "medicine used to treat the symptoms of overactive bladder." Medicines used in stress urinary incontinence (the [[wikipedia:Duloxetine|duloxetine]] approved in Europe but not in the United States for this indication; topical estrogen as adjunct) are listed under those categories. Medicines used in benign prostatic hyperplasia ([[:Category:Alpha-1_blockers|alpha-1 blockers]], [[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitors]], the [[:Category:BPH_treatments|BPH treatments]] umbrella) are collected separately, although the urgency component of BPH-associated lower-urinary-tract symptoms is sometimes treated with an OAB medicine in combination with a BPH medicine. The medicines used for nocturnal polyuria (desmopressin, the synthetic vasopressin analogue used at bedtime) are not OAB medicines per se but are mentioned where their indication overlaps the OAB phenotype. The neuromodulation devices (sacral, tibial) and the surgical procedures (augmentation cystoplasty, urinary diversion) are not medicines and are referenced only for clinical-decision context on the medicine pages.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:CuratedCategoryPage]]

Category:Schedule IV controlled substances

2026-05-23T19:47:59Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''Schedule IV controlled substance''' is a medicine that the United States [[wikipedia:Drug Enforcement Administration|Drug Enforcement Administration]] has placed in the fourth schedule of its [[wikipedia:Controlled Substances Act|Controlled Substances Act]] of 1970. Schedule IV substances have an accepted medical use, a lower abuse potential than the [[:Category:Schedule_III_controlled_substances|Schedule III]] medicines, and an abuse pattern that may lead to limited physical or psychological dependence relative to the higher schedules.

The prescribing convenience of a Schedule IV medicine approaches that of a non-controlled prescription. A Schedule IV prescription may be telephoned in to the pharmacy, may be refilled up to five times within six months of the original prescription date, and may be transmitted by fax without restriction. Most states require [[wikipedia:Prescription drug monitoring program|PDMP]] reporting of Schedule IV dispensing, and the controlled-substance registration requirement on the prescribing clinician remains the same as for the higher schedules, but the practical day-to-day differences from a non-controlled prescription are limited to those reporting and the absence of the refill-after-six-months allowance.

The medicines that populate Schedule IV are dominated by the [[:Category:Benzodiazepines|benzodiazepines]] and the related "Z-drug" non-benzodiazepine hypnotics. The benzodiazepines (chlordiazepoxide, [[wikipedia:Diazepam|diazepam]], [[wikipedia:Lorazepam|lorazepam]], [[wikipedia:Alprazolam|alprazolam]], [[wikipedia:Clonazepam|clonazepam]], [[wikipedia:Midazolam|midazolam]], [[wikipedia:Temazepam|temazepam]], and the longer list of clinically used agents) were introduced in 1960 with chlordiazepoxide and followed shortly by diazepam, both developed at Hoffmann-La Roche by [[wikipedia:Leo Sternbach|Leo Sternbach]] on a screening programme that began with a discarded series of "useless" tricyclic compounds from his earlier work. Diazepam (Valium) became the most prescribed medicine in the world between 1969 and 1982. The class produced rapid and reliable anxiolysis and sedation, but with a tolerance and dependence pattern that emerged over the following decade and led, in the 1980s, to the recognition of benzodiazepine withdrawal syndrome and to a substantial tightening of prescribing practice. The Z-drug hypnotics ([[wikipedia:Zolpidem|zolpidem]] (Ambien, Sanofi, 1992), zaleplon, eszopiclone) were developed in the late 1980s and 1990s as selective alpha-1-subunit GABA-A agonists with hypnotic but reduced anxiolytic and muscle-relaxant action; they share Schedule IV with the benzodiazepines.

The Schedule IV tier also includes the wakefulness-promoting medicine [[wikipedia:Modafinil|modafinil]] (Provigil, Cephalon, 1998) and the related armodafinil; the anti-obesity medicines [[wikipedia:Phentermine|phentermine]] (a sympathomimetic psychostimulant with substantially lower abuse potential than the Schedule II amphetamines), diethylpropion, and the older phendimetrazine (Schedule III rather than IV); [[wikipedia:Tramadol|tramadol]], the atypical opioid that was unscheduled at U.S. introduction in 1995 and was moved to Schedule IV by the DEA in 2014 in response to accumulating evidence of dependence and overdose; and the GABA-receptor partial agonist [[wikipedia:Suvorexant|suvorexant]] (an orexin-receptor antagonist for insomnia) along with the related lemborexant and daridorexant. Selected anticonvulsants used principally for benzodiazepine indications (carisoprodol, the muscle relaxant metabolically activated to meprobamate, was moved to Schedule IV in 2012) round out the category.

The benzodiazepine class deserves particular clinical attention given its size and its overdose profile. Concurrent prescription of a benzodiazepine and an opioid is associated with a substantial excess of fatal respiratory depression compared to either alone, a finding that is reflected in the FDA boxed warning that has been on these medicines since 2016 and in the contemporary guidelines that recommend against routine co-prescription except in carefully considered circumstances. The benzodiazepines and Z-drugs are also implicated in falls and fracture in elderly patients, in cognitive impairment that may not fully reverse on discontinuation, in motor-vehicle collision risk, and in disinhibition phenomena. The contemporary practice has moved toward shorter courses, lower doses, taper rather than abrupt discontinuation when long use is to be stopped, and increasing use of non-benzodiazepine alternatives for anxiety (the SSRIs and SNRIs for chronic anxiety, propranolol for performance anxiety, the new gepants and antihistamines for situational use).

== Selected medicines indexed ==

Not exhaustive; see [[USLegal:DEA_Schedule_IV|DEA Schedule IV]] for the comprehensive list.

* '''Benzodiazepines''' (anxiolytic, hypnotic, anticonvulsant, muscle relaxant): [[wikipedia:Alprazolam|alprazolam]] (Xanax), [[wikipedia:Lorazepam|lorazepam]] (Ativan), [[wikipedia:Clonazepam|clonazepam]] (Klonopin), [[wikipedia:Diazepam|diazepam]] (Valium), [[wikipedia:Midazolam|midazolam]] (Versed), [[wikipedia:Temazepam|temazepam]] (Restoril), [[wikipedia:Oxazepam|oxazepam]], chlordiazepoxide (Librium, the original of the class), flurazepam, triazolam, estazolam, quazepam
* '''Z-drug hypnotics''': [[wikipedia:Zolpidem|zolpidem]] (Ambien), [[wikipedia:Eszopiclone|eszopiclone]] (Lunesta), [[wikipedia:Zaleplon|zaleplon]] (Sonata)
* '''Wakefulness-promoting medicines''': [[wikipedia:Modafinil|modafinil]] (Provigil), [[wikipedia:Armodafinil|armodafinil]] (Nuvigil)
* '''Atypical opioid analgesics''' (less abuse potential than the Schedule II opioids): [[Tramadol|tramadol]] (rescheduled to Schedule IV in 2014); [[wikipedia:Butorphanol|butorphanol]]; [[wikipedia:Pentazocine|pentazocine]]
* '''Anti-obesity sympathomimetics''': [[wikipedia:Phentermine|phentermine]], diethylpropion
* '''Other''': [[wikipedia:Carisoprodol|carisoprodol]] (Soma, the muscle relaxant metabolised to meprobamate), [[wikipedia:Suvorexant|suvorexant]] and the related orexin antagonists [[wikipedia:Lemborexant|lemborexant]] and [[wikipedia:Daridorexant|daridorexant]] (insomnia)

== Notes on scope ==

The boundary of this category is "medicine placed in Schedule IV of the U.S. Controlled Substances Act." The U.S. designation is federal; many of these medicines have different international classification. Of historical interest, several medicines have moved between the federal schedules over time: [[Tramadol|tramadol]] from unscheduled to Schedule IV in 2014, [[Hydrocodone|hydrocodone]] combination products from Schedule III to Schedule II in 2014, carisoprodol from unscheduled to Schedule IV in 2012, propoxyphene (Darvon, Darvocet) from Schedule IV to fully withdrawn in 2010. The schedule of an individual medicine is therefore not necessarily a permanent feature of its regulatory status.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Controlled_substances]]
[[Category:CuratedCategoryPage]]

Category:Lymphatic herbs

2026-05-23T19:24:10Z

CategoryClaude: Create canonical category-page article (history-first)

A '''lymphatic herb''' is a plant medicine used to support lymphatic-system function, traditionally indicated in chronic glandular swelling, recurrent tonsillitis and sore throat, skin conditions associated with poor lymphatic drainage (chronic eczema, acne, boils, abscess), and selected oncologic-supportive indications. The category is drawn principally from the British clinical-herbalist tradition and the American Eclectic dispensatories; the contemporary mechanistic understanding involves modulation of lymphocyte function, modest direct effects on lymphatic-vessel contractility, and broader anti-inflammatory and antimicrobial actions.

The foundational lymphatic herbs of Western use are '''cleavers''' (''Galium aparine''; the gentle alterative-lymphatic of British clinical practice, used in chronic glandular swelling and as a "blood cleanser" in the older terminology); '''poke root''' (''Phytolacca americana''; the strong Eclectic lymphatic, used for chronic mastitis, lymphadenopathy, and selected oncologic-supportive indications; the herb is potently toxic at higher doses and requires expert practitioner supervision); '''calendula''' (''Calendula officinalis''; cross-listed for its dermatologic and vulnerary uses); '''burdock''' (''Arctium lappa''; the alterative-lymphatic of European folk and Eclectic use, for chronic skin conditions); and '''red root''' (''Ceanothus americanus''; the American Eclectic specific for lymphatic congestion and post-mononucleosis lymphadenopathy).

The Ayurvedic lymphatic tradition uses '''manjistha''' (''Rubia cordifolia'') for ''rakta'' (blood) cleansing and lymphatic support, and the bitter-cooling herbs ('''neem''', '''guduchi''') for the related ''ama'' (toxin) clearance. The TCM tradition does not use the lymphatic concept in the same form but has parallel uses in its "clear heat and resolve toxin" category (''Pu Gong Ying'' dandelion, ''Zi Hua Di Ding'' violet ''Viola yedoensis'', ''Jin Yin Hua'' honeysuckle).

== Members indexed ==

Cleavers (''Galium aparine''), poke root (''Phytolacca americana''), calendula (''Calendula officinalis''), burdock (''Arctium lappa''), red root (''Ceanothus americanus''), echinacea (cross-listed for immune use), manjistha (''Rubia cordifolia''), the TCM "clear heat resolve toxin" herbs dandelion (''Taraxacum mongolicum'', Pu Gong Ying), violet (''Viola yedoensis''), honeysuckle (''Lonicera japonica'', Jin Yin Hua), and the broader alterative herbs that have lymphatic-clearing application (yellow dock ''Rumex crispus'', sarsaparilla ''Smilax ornata'', stillingia ''Stillingia sylvatica''). The contemporary clinical interest in '''dry-skin-brushing''' and '''manual lymph drainage''' (Vodder method) techniques as adjuncts to herbal therapy is referenced for context.

== Notes on scope ==

The boundary of this category is "herb whose principal or important action is on the lymphatic system or on chronic glandular and skin conditions associated with lymphatic congestion." Several lymphatic herbs are also alteratives (the broader Western category of "blood-cleansing" herbs); the categories overlap in clinical use and the herbs are cross-listed. The contemporary lymphoma and leukemia chemotherapies are pharmaceutical [[:Category:Antineoplastics|antineoplastics]] and are not in this category; the herbal-supportive use of selected medicines (astragalus, reishi, ashwagandha) in cancer care is cross-listed under [[:Category:Adaptogens|adaptogens]] and [[:Category:Immune_herbs|immune herbs]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Anxiolytic herbs

2026-05-23T19:24:09Z

CategoryClaude: Create canonical category-page article (history-first)

An '''anxiolytic herb''' is a plant medicine whose principal indication is the reduction of anxiety symptoms (generalised anxiety, situational anxiety, panic, anxious insomnia). The category overlaps substantially with [[:Category:Nervine_herbs|nervine herbs]]; the distinction is principally one of clinical emphasis. The pharmacological mechanism across the category is dominated by activity at the GABA-A receptor (the same target as the pharmaceutical benzodiazepines but at distinct binding sites and with substantially lower receptor occupancy), with additional mechanisms involving serotonergic modulation, adenosine signalling, and parasympathetic outflow.

The foundational anxiolytic herbs of contemporary use include '''chamomile''' (''Matricaria chamomilla''; the apigenin-GABA-A mechanism, with substantial controlled-trial evidence in generalised anxiety disorder through the Amsterdam and Mao trials of 2009 and 2016 respectively); '''lemon balm''' (''Melissa officinalis''; rosmarinic-acid-and-citral GABA-transaminase inhibition); '''passionflower''' (''Passiflora incarnata''; the apigenin-and-chrysin GABA-A mechanism); '''lavender''' (''Lavandula angustifolia''; the linalool-mediated anxiolysis, with the standardised silexan oral preparation having controlled-trial evidence in mild-to-moderate anxiety); '''valerian''' (''Valeriana officinalis''; the valerenic-acid GABA-A modulation, with primary indication for sleep but secondary anxiolytic use); '''kava''' (''Piper methysticum''; the kavalactone GABA-A modulation, with substantial controlled-trial evidence and the substantial hepatotoxicity restriction that has driven its withdrawal from many Western jurisdictions); '''ashwagandha''' (''Withania somnifera''; cross-listed under [[:Category:Adaptogens|adaptogens]]); and '''skullcap''' (''Scutellaria lateriflora''; the American clinical-herbalist anxiolytic, distinct from the Chinese ''Scutellaria baicalensis'').

The clinical use of anxiolytic herbs is supported by controlled-trial evidence that varies in quality across the class. Chamomile, lavender, and ashwagandha have the most extensive contemporary trial-evidence base; passionflower and lemon balm have substantial preliminary trial data; valerian's primary evidence is for sleep but anxiolytic use is widespread. Kava has the highest acute anxiolytic potency but the hepatotoxicity concern (particularly the case-cluster of severe hepatic injury reported in the early 2000s that led to EMA withdrawal) has restricted its current use. The interaction profile across the class includes additive sedation with the pharmaceutical benzodiazepines and Z-drugs, with alcohol, and with the older antihistamines; combined use requires the same caution as for any sedative combination.

== Members indexed ==

Chamomile (''Matricaria chamomilla''), lemon balm (''Melissa officinalis''), passionflower (''Passiflora incarnata''), lavender (''Lavandula angustifolia''), valerian (''Valeriana officinalis''), kava (''Piper methysticum''; hepatotoxicity restriction), ashwagandha (''Withania somnifera''), skullcap (''Scutellaria lateriflora''), California poppy (''Eschscholzia californica''), hops (''Humulus lupulus''), magnolia bark (''Magnolia officinalis''), wild lettuce (''Lactuca virosa''), Albizia (''Albizia julibrissin'' bark, He Huan Pi), the TCM anxiolytics ''Bai Zi Ren'' (Platycladus seed), ''Suan Zao Ren'' (jujube seed, ''Ziziphus jujuba''), and ''Yuan Zhi'' (polygala root, ''Polygala tenuifolia'').

== Notes on scope ==

The boundary of this category is "herb whose principal or important clinical indication is reduction of anxiety symptoms." Many anxiolytic herbs have parallel sedative-hypnotic action and are cross-listed under [[:Category:Nervine_herbs|nervine herbs]]. The pharmaceutical anxiolytics (the benzodiazepines and Z-drugs of [[:Category:Schedule_IV_controlled_substances|Schedule IV]], the SSRIs and SNRIs of [[:Category:Antidepressants|antidepressants]] used for anxiety, the older antihistamines hydroxyzine and diphenhydramine, the beta-blockers used for performance-anxiety somatic-symptom suppression, the newer pregabalin and gepant indications) are listed under their primary umbrellas.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Expectorants

2026-05-23T19:24:09Z

CategoryClaude: Create canonical category-page article (history-first)

An '''expectorant''' is a herbal medicine that promotes the clearance of respiratory mucus, by thinning the mucus (mucolytic action), by stimulating the cough reflex on the basis of secretion (reflex expectorant action), or by reducing bronchial smooth-muscle spasm (the antitussive-and-expectorant combination). The Western clinical-herbalist tradition has used the expectorant category for several centuries, with substantial subdivision into stimulating expectorants (which produce more cough), relaxing expectorants (which reduce cough while still clearing mucus), and combined expectorant-antitussives.

The foundational expectorants of the British Herbal Pharmacopoeia and ESCOP traditions include '''thyme''' (''Thymus vulgaris''), the principal Western antitussive-expectorant with thymol-mediated antimicrobial action and substantial controlled-trial evidence for acute bronchitis; '''mullein''' (''Verbascum thapsus''), the Native American and Eclectic expectorant for productive cough; '''elecampane''' (''Inula helenium''), the inulin-and-alantolactone expectorant for chronic bronchial conditions; '''hyssop''' (''Hyssopus officinalis''); '''white horehound''' (''Marrubium vulgare''); '''licorice''' (''Glycyrrhiza glabra''; cross-listed under demulcents); '''lobelia''' (''Lobelia inflata''; the Eclectic respiratory antispasmodic-expectorant); '''ipecac''' (''Cephaelis ipecacuanha''; in low dose as expectorant, in high dose as emetic; historical use); '''bloodroot''' (''Sanguinaria canadensis''; the Native American expectorant with significant toxicity restriction); and '''pleurisy root''' (''Asclepias tuberosa''; the Eclectic pulmonary expectorant). The Ayurvedic '''vasaka''' (''Adhatoda vasica'') is the principal Indian expectorant.

The pharmaceutical expectorant '''guaifenesin''' (cross-listed at [[:Category:Expectorants|expectorants]] under the broader pharmaceutical-class umbrella) was originally isolated from guaiac wood (''Guaiacum officinale''), a traditional herbal medicine of the Caribbean; the herbal and pharmaceutical traditions are continuous in this case.

== Members indexed ==

Thyme (''Thymus vulgaris''), mullein (''Verbascum thapsus''), elecampane (''Inula helenium''), hyssop (''Hyssopus officinalis''), white horehound (''Marrubium vulgare''), licorice (''Glycyrrhiza glabra''), lobelia (''Lobelia inflata''), ipecac (''Cephaelis ipecacuanha''), bloodroot (''Sanguinaria canadensis''), pleurisy root (''Asclepias tuberosa''), vasaka (''Adhatoda vasica''), guaiac (''Guaiacum officinale''), grindelia (''Grindelia robusta''), yerba santa (''Eriodictyon californicum''), wild cherry (''Prunus serotina''; for cough), and the TCM expectorants ''Jie Geng'' (platycodon, ''Platycodon grandiflorus''), ''Qian Hu'' (''Peucedanum praeruptorum''), and ''Xing Ren'' (apricot kernel, ''Prunus armeniaca''; restricted, cyanogenic).

== Notes on scope ==

The boundary of this category is "herb whose principal or important action is promotion of respiratory mucus clearance." Several expectorant herbs have additional and overlapping respiratory actions (demulcent, bronchodilator, antitussive) and are cross-listed where appropriate. The pharmaceutical expectorants (guaifenesin, the inhaled mucolytics dornase alfa and hypertonic saline; described under [[:Category:Mucolytics|mucolytics]] and the broader pharmaceutical expectorants umbrella) are listed under their primary umbrellas.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Astringents

2026-05-23T19:22:29Z

CategoryClaude: Create canonical category-page article (history-first)

An '''astringent''' is a herbal medicine whose principal action is the precipitation of tissue proteins through tannin-binding, producing local tissue contraction, reduced membrane permeability, and reduced secretion. The clinical use is in diarrhoea (intestinal tannin-mediated reduction of secretion), in haemorrhage (topical and selected internal use for haemoptysis, haematuria, menorrhagia, and minor wound bleeding), in inflammatory dermatoses (the topical contracting effect), in oral and pharyngeal inflammation (gargles), and in haemorrhoidal indications.

The active fraction across the category is the tannins, a structurally diverse group of polyphenolic compounds that bind and precipitate proteins. The hydrolyzable tannins (gallotannins, ellagitannins) are more common in oak, sumac, witch hazel; the condensed tannins (proanthocyanidins) are more common in cranberry, grape seed, hawthorn, pine bark; the dimeric and trimeric pyran-containing tannins of cinnamon are intermediate. The clinical effect of any astringent herb depends on the tannin concentration (typically 5 to 20 percent in the standard preparations), on the preparation form (decoction extracts more tannin than infusion; alcoholic tincture preserves the tannins well), and on the mucosal surface to which it is applied.

The foundational astringents of European herbal use are '''oak bark''' (''Quercus robur'' or ''Q. petraea''; the strongest standard astringent, used in decoction); '''agrimony''' (''Agrimonia eupatoria''; the gentler intestinal astringent of British use); '''raspberry leaf''' (''Rubus idaeus''; the women's-reproductive astringent, used in late pregnancy and postpartum); '''yarrow''' (''Achillea millefolium''; astringent and vulnerary); '''lady's mantle''' (''Alchemilla vulgaris''; gynaecological astringent); '''cinquefoil''' (''Potentilla erecta''; the British strong astringent); '''tormentil''' (''Potentilla tormentilla''); '''bistort''' (''Persicaria bistorta''); '''witch hazel''' (''Hamamelis virginiana''; the Native American medicine, principally topical); and '''rhatany''' (''Krameria triandra''; the South American oral-mucositis astringent).

== Members indexed ==

Oak bark (''Quercus robur''), agrimony (''Agrimonia eupatoria''), raspberry leaf (''Rubus idaeus''), yarrow (''Achillea millefolium''), lady's mantle (''Alchemilla vulgaris''), cinquefoil (''Potentilla erecta''), tormentil, bistort (''Persicaria bistorta''), witch hazel (''Hamamelis virginiana''), rhatany (''Krameria triandra''), the TCM astringent ''Wu Mei'' (smoked plum, ''Prunus mume''), the green tea (''Camellia sinensis''; for its catechin-mediated astringency), the cranberry (''Vaccinium macrocarpon''; cross-listed for urological use), the bilberry (''Vaccinium myrtillus''), pomegranate rind (''Punica granatum''; the Unani-tradition astringent), and the various Indian tannin-rich Terminalia species (chebula, bellirica) of Triphala fame.

== Notes on scope ==

The boundary of this category is "herb whose principal action is tannin-mediated tissue contraction and reduced secretion." Astringents are often combined with demulcents in clinical practice (the agrimony-marshmallow combination for diarrhoea and gastric inflammation) to balance their drying effect with mucosal protection. Several astringent herbs have other primary indications (raspberry leaf as women's-reproductive, cranberry as urological); they are cross-listed under their primary indication.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Carminatives

2026-05-23T19:22:28Z

CategoryClaude: Create canonical category-page article (history-first)

A '''carminative''' is a herbal medicine that relieves intestinal gas, post-prandial bloating, and dyspeptic discomfort through volatile-oil-mediated relaxation of intestinal smooth muscle and through reflex effects on gastric motility. The category is the smooth-muscle-relaxant complement to the bitter-tonic digestive tradition; bitters stimulate secretion, carminatives relieve spasm and gas.

The mechanism of carminative action is well-characterised. The volatile oils of the carminative herbs (menthol, anethole, carvone, eugenol, gingerols, cineole, fenchone) act directly on intestinal smooth muscle to produce relaxation, principally through L-type calcium channel blockade; they also reduce visceral hypersensitivity (the basis of the peppermint-oil benefit in irritable bowel syndrome), promote gastric emptying (the basis of the ginger benefit in dyspepsia and motion sickness), and reduce coliform bacterial fermentation gas production through direct antimicrobial action.

The foundational carminatives of European and global use are '''peppermint''' (''Mentha × piperita''), the most-studied with substantial controlled-trial evidence in irritable bowel syndrome; '''fennel''' (''Foeniculum vulgare'') and '''anise''' (''Pimpinella anisum''), the classical "gripe-water" components used for infant colic in the European folk tradition; '''caraway''' (''Carum carvi''); '''dill''' (''Anethum graveolens''); '''cardamom''' (''Elettaria cardamomum''); '''ginger''' (''Zingiber officinale''; cross-listed for its broader digestive and antiemetic actions); '''cinnamon''' (''Cinnamomum verum''); '''cloves''' (''Syzygium aromaticum''); '''nutmeg''' (''Myristica fragrans''; small dose). The Ayurvedic ''Trikatu'' (the three-pungent combination of black pepper ''Piper nigrum'', long pepper ''Piper longum'', and ginger) is a foundational carminative formulation; the Chinese five-spice combination preserves a parallel tradition.

== Members indexed ==

Peppermint (''Mentha × piperita''), fennel (''Foeniculum vulgare''), anise (''Pimpinella anisum''), caraway (''Carum carvi''), dill (''Anethum graveolens''), cardamom (''Elettaria cardamomum''), ginger (''Zingiber officinale''), cinnamon (''Cinnamomum verum''), cloves (''Syzygium aromaticum''), nutmeg (''Myristica fragrans''), black pepper (''Piper nigrum''), long pepper (''Piper longum''), coriander (''Coriandrum sativum''), cumin (''Cuminum cyminum''), star anise (''Illicium verum''), the European aromatic-bitter combinations (Swedish bitters, Underberg, the various amaro formulations; cross-listed under [[:Category:Bitters|bitters]]), and the Ayurvedic Trikatu and TCM five-spice combinations.

== Notes on scope ==

The boundary of this category is "herb whose principal action is relief of intestinal gas, bloating, and dyspeptic spasm through volatile-oil-mediated smooth-muscle relaxation." Carminative herbs whose principal indication is something else (peppermint's anti-IBS use, ginger's antiemetic use) are listed under their primary indication category. The non-herbal pharmaceutical equivalents (simethicone, the pharmaceutical antispasmodics) are listed under their primary categories.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Diaphoretics

2026-05-23T19:22:28Z

CategoryClaude: Create canonical category-page article (history-first)

A '''diaphoretic''' is a herbal medicine that induces or supports sweating, traditionally used to break a fever, to clear acute viral and febrile illness, and to support detoxification through cutaneous elimination. The Western clinical herbalist tradition distinguishes the '''stimulating diaphoretics''' (which produce active sweating; ginger, yarrow, peppermint, prickly ash) from the '''relaxing diaphoretics''' (which reduce sympathetic peripheral vasoconstriction and allow the body to release built-up heat; elderflower, boneset, catnip).

The clinical use is documented across essentially every traditional medicine system. The Western febrifuge tradition runs from the Greco-Roman use of warm aromatic infusions through medieval European herbalism (the elderflower-yarrow-peppermint combination is the classical "cold and flu tea") to the contemporary herbal-practitioner repertoire. The TCM tradition has a parallel "release-the-exterior" category of herbs (''Jie Biao'') used in early-stage wind-cold or wind-heat patterns: '''Ma Huang''' (ephedra, the warming diaphoretic; restricted in Western jurisdictions); '''Sheng Jiang''' (fresh ginger); '''Gui Zhi''' (cinnamon twig); '''Bo He''' (peppermint, the cooling diaphoretic); '''Sang Ye''' (mulberry leaf); '''Ju Hua''' (chrysanthemum). The Ayurvedic ''swedana'' tradition uses internal diaphoretic herbs (ginger, fennel, coriander, cumin) and external sweating techniques (warm-oil massage with sweat-induction).

The pharmacology of the diaphoretic effect involves cutaneous vasodilation (allowing heat loss), stimulation of eccrine sweat glands (the active sweating component), and central thermoregulatory effects (the febrifuge-by-cooling mechanism). The aromatic-volatile-oil-containing herbs produce diaphoresis through skin-irritation reflex when taken as hot infusions; the stimulating diaphoretics produce diaphoresis through cardiovascular stimulation as well.

== Members indexed ==

Yarrow (''Achillea millefolium''), elderflower (''Sambucus nigra'' flowers), peppermint (''Mentha × piperita''), ginger (''Zingiber officinale''), boneset (''Eupatorium perfoliatum''), catnip (''Nepeta cataria''), Indian peppermint (''Mentha arvensis''), prickly ash (''Zanthoxylum americanum''), basil (''Ocimum basilicum''), holy basil (''Ocimum tenuiflorum''; cross-listed), the TCM ''Jie Biao'' herbs (cinnamon twig ''Gui Zhi'', ginger ''Sheng Jiang'', mulberry leaf ''Sang Ye'', chrysanthemum ''Ju Hua'', kudzu ''Ge Gen'', ephedra ''Ma Huang''), and the Ayurvedic warming spices used as ''swedana'' inducers.

== Notes on scope ==

The boundary of this category is "herb whose principal or important action is induction of sweating." The pharmaceutical antipyretics (paracetamol, the NSAIDs) act on central thermoregulation rather than peripheral diaphoresis; they are listed under their primary categories. Herbs with secondary diaphoretic action whose principal indication is elsewhere (ginger as digestive carminative, peppermint as digestive antispasmodic) are listed under their primary indication category with cross-reference.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Vulneraries

2026-05-23T19:21:08Z

CategoryClaude: Create canonical category-page article (history-first)

A '''vulnerary''' (Latin ''vulnerarius'', wound-healer) is a herbal medicine applied to wounds, bruises, sprains, ulcers, and other tissue injury to support healing. The Western clinical-herbalist tradition has used the vulnerary category for several centuries and the action overlaps with topical anti-inflammatory and antimicrobial effects; the contemporary mechanistic understanding involves angiogenic stimulation, fibroblast and keratinocyte proliferation, modulation of inflammatory mediators, and direct antimicrobial activity in the wound bed.

The foundational vulneraries of Western use are '''calendula''' (''Calendula officinalis''; the European pot marigold, with substantial controlled-trial evidence for radiation-dermatitis prevention and accelerated wound healing); '''comfrey''' (''Symphytum officinale''; the "knit-bone" of medieval folk-herbalism, with documented topical wound-healing through allantoin-mediated cell proliferation and rosmarinic-acid anti-inflammatory effect; pyrrolizidine-alkaloid hepatotoxicity restricts use to topical-only application); '''plantain''' (''Plantago major'' and ''P. lanceolata''; the universal Eurasian wound-and-bite herb); '''yarrow''' (''Achillea millefolium''; the Native American and European wound-styptic, the source of the historical name "soldier's woundwort"); '''St John's wort''' (''Hypericum perforatum''; oil-infusion for nerve-pain wounds, bruising, and minor burns); '''self-heal''' (''Prunella vulgaris''; widely-distributed Northern Hemisphere wound herb); and the Australian '''tea tree oil''' (''Melaleuca alternifolia'') for antimicrobial wound action.

The TCM and Ayurvedic vulnerary traditions contribute '''San qi''' (''Panax notoginseng''; the Yunnan haemostatic-and-tissue-healing medicine, used in the proprietary "Yunnan Baiyao" wound powder), '''Centella asiatica''' (gotu kola; particularly for scar prevention and selected wound indications), '''aloe vera''' (cross-listed; for burns), and '''neem''' (''Azadirachta indica''; for tropical wound infection).

== Members indexed ==

Calendula (''Calendula officinalis''), comfrey (''Symphytum officinale''; topical only), plantain (''Plantago major''), yarrow (''Achillea millefolium''), St John's wort (''Hypericum perforatum''), self-heal (''Prunella vulgaris''), tea tree oil (''Melaleuca alternifolia''), centella (''Centella asiatica''), aloe vera (cross-listed), San qi (''Panax notoginseng''), goldenseal (''Hydrastis canadensis''), echinacea (cross-listed), arnica (''Arnica montana''; topical only for bruises and sprains, contraindicated on broken skin), and the historical herbal-wound preparations of the European folk tradition (woundwort ''Stachys officinalis'', knapweed, the "all-heal" plants of various species).

== Notes on scope ==

The boundary of this category is "herb applied topically to wounds or to similar tissue injury to support healing." The systemic vulnerary action of selected herbs (the wound-healing-supportive effect of zinc-containing preparations, of vitamin C, of arginine and glutamine) is mineral and biochemical rather than herbal and is listed elsewhere. The pharmaceutical wound-healing medicines (topical antibiotics, the recombinant PDGF gel becaplermin, the modern wound-care dressings) are listed under their primary classes. Several vulneraries are cross-listed under [[:Category:Dermatologic_herbs|dermatologic herbs]] for the broader skin-and-mucous-membrane application.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Demulcents

2026-05-23T19:21:07Z

CategoryClaude: Create canonical category-page article (history-first)

A '''demulcent''' is a herbal medicine that soothes and protects inflamed or irritated mucous membranes by forming a viscous coating, typically through high mucilage content. The clinical use is principally in the gastrointestinal tract (gastritis, peptic ulcer, oesophagitis, reflux), in the upper respiratory tract (sore throat, dry cough, laryngitis), and in the urinary tract (cystitis, irritated urethral mucosa); topical demulcent application is used for inflammatory skin conditions and minor wounds.

The principal demulcent herbs share the chemistry of high-molecular-weight polysaccharides (mucilage), which dissolve or disperse in water to form a viscous gel. The mucilage coats the inflamed mucous surface and provides physical barrier and osmotic effect, with secondary reflex effects on inflammation through vagal afferents and through reduced contact between inflamed tissue and luminal contents. The action is mechanical and topical rather than systemic; the herbal preparation must reach the affected mucosa to act.

The foundational demulcents of Western use are '''slippery elm''' (''Ulmus rubra'', the Native American medicine adopted by the Eclectic tradition); '''marshmallow''' (''Althaea officinalis''; the root and leaf both used, the root higher in mucilage; the original "marsh-mallow" was a confection made from the boiled root); '''licorice''' (''Glycyrrhiza glabra''; cross-listed for sweetness and for the steroid-glycyrrhizin caveats); '''oats''' (''Avena sativa''; oat-straw decoction for demulcent baths in eczema, oatmeal porridge in gastric inflammation); '''plantain''' (''Plantago major'' and ''P. lanceolata''; cross-listed for vulnerary use); '''Iceland moss''' (''Cetraria islandica''; the cool-temperate respiratory demulcent); and '''Irish moss''' (''Chondrus crispus''; the seaweed-source carrageenan). The Ayurvedic '''licorice''' (''yashtimadhu'') and '''psyllium''' (''Plantago ovata''; both demulcent and bulk-forming) round out the principal set.

== Members indexed ==

Slippery elm (''Ulmus rubra''), marshmallow (''Althaea officinalis''), licorice (''Glycyrrhiza glabra''), oats (''Avena sativa''), plantain (''Plantago major''), Iceland moss (''Cetraria islandica''), Irish moss (''Chondrus crispus''), psyllium (''Plantago ovata''), flaxseed (''Linum usitatissimum''; cross-listed for omega-3 and for bulk-fibre action), comfrey (''Symphytum officinale''; topical only because of pyrrolizidine alkaloids), corn silk (''Zea mays''; urinary demulcent), couch grass (''Elymus repens''), the Ayurvedic shatavari (''Asparagus racemosus'') for its mucilaginous root, and the rice and barley waters used as paediatric demulcents.

== Notes on scope ==

The boundary of this category is "herb whose principal action is mucilage-mediated protection of inflamed mucous membrane." The astringent-and-demulcent combinations (yarrow, agrimony, meadowsweet, raspberry leaf) where both actions co-exist are listed under [[:Category:Astringents|astringents]] for their primary action with cross-reference here. The mineral demulcents (sucralfate, the bismuth compounds) are listed under [[:Category:Mucosal_protectants|mucosal protectants]] under [[:Category:Anti-ulcer_agents|anti-ulcer agents]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Bitters

2026-05-23T19:21:07Z

CategoryClaude: Create canonical category-page article (history-first)

A '''bitter''' is a herbal medicine whose principal pharmacological action is the stimulation of digestive secretion through activation of the bitter-taste receptors (the TAS2R family) on the tongue, on the gastric mucosa, and on the pancreatic islet. The bitter-tonic tradition is among the oldest in continuous use in European herbal medicine: the small dose of an intensely bitter plant taken fifteen to thirty minutes before a meal stimulates salivary, gastric, and pancreatic secretion through the cranial-nerve-mediated bitter-taste reflex, with corresponding improvement in appetite, dyspepsia, and post-prandial digestive function. The clinical use is documented in Egyptian, Greek, and Roman medicine and was codified into the modern Western herbal tradition through the British clinical herbalists and the American Eclectic dispensatories.

The molecular pharmacology of the bitter-taste reflex is well-established. The TAS2R bitter-taste receptors, originally identified on the taste buds of the tongue, are expressed in enterochromaffin cells of the gastric and intestinal mucosa, in pancreatic islet cells, and in respiratory smooth muscle. Activation by bitter-tasting compounds produces vagal-mediated release of gastric acid, pepsinogen, and pancreatic enzymes (the appetite-and-digestion mechanism), of cholecystokinin (the satiety mechanism that has been proposed as an obesity-medicine target), and of insulin (the secretagogue mechanism that has been proposed for type-2 diabetes). The traditional pre-meal-bitter clinical practice is therefore mechanistically grounded.

The foundational bitters of Western practice are '''gentian''' (''Gentiana lutea''), the most-prescribed and the principal component of the British Herbal Pharmacopoeia bitter formulations; '''wormwood''' (''Artemisia absinthium''), the most intensely bitter and the historical absinthe component; '''dandelion''' (''Taraxacum officinale'' root, the gentle and broadly applicable); '''artichoke''' leaf (''Cynara scolymus''; cross-listed under [[:Category:Hepatoprotective_herbs|hepatoprotective herbs]]); '''quassia''' (''Quassia amara''); '''goldenseal''' (''Hydrastis canadensis''; the Eclectic bitter-antimicrobial; cross-listed under [[:Category:Antimicrobial_herbs|antimicrobial herbs]]); '''bitter orange''' (''Citrus aurantium''); '''centaury''' (''Centaurium erythraea''); '''angelica''' (''Angelica archangelica'' root). The classical European compound bitter is '''Swedish bitters''' (the Maria Treben formulation), and the proprietary digestive bitters (Underberg, Fernet-Branca, the various amaro formulations) preserve the same essential tradition in non-clinical use.

== Members indexed ==

Gentian (''Gentiana lutea''), wormwood (''Artemisia absinthium''), dandelion root (''Taraxacum officinale''), artichoke leaf (''Cynara scolymus''), quassia (''Quassia amara''), goldenseal (''Hydrastis canadensis''), bitter orange (''Citrus aurantium''), centaury (''Centaurium erythraea''), angelica (''Angelica archangelica''), barberry (''Berberis vulgaris''), Oregon grape (''Mahonia aquifolium''), hops (''Humulus lupulus''; cross-listed for sleep), yarrow (''Achillea millefolium''), bogbean (''Menyanthes trifoliata''), and the bitter Asian medicines including ''Andrographis paniculata'' (the "king of bitters" of Ayurvedic and TCM use) and ''Coptis chinensis''.

== Notes on scope ==

The boundary of this category is "herb taken in low pre-meal dose for digestive stimulation through the bitter-taste reflex." The bitter mineral medicines (the bitter salts) and the synthetic bitter compounds are not in this category. Bitters used for indications other than digestion (gentian as a febrifuge, hops as a sedative) are cross-listed where appropriate.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Antimicrobial herbs

2026-05-23T19:19:42Z

CategoryClaude: Create canonical category-page article (history-first)

An '''antimicrobial herb''' is a plant medicine with documented activity against bacteria, fungi, viruses, or parasites. The category covers the broad-spectrum traditional antimicrobials (garlic, oregano, thyme, goldenseal), the antifungal-prominent herbs (tea tree, oregano, neem, pau d'arco), the antiviral-active herbs (elderberry, olive leaf, lemon balm for herpes simplex), and the antiparasitic-active herbs (wormwood, black walnut hull, pumpkin seed, the Artemisia annua of artemisinin fame).

The foundational antimicrobial herb in Western practice is '''garlic''' (''Allium sativum''), whose allicin and the related thiosulfinates produce broad-spectrum antibacterial, antifungal, and modest antiviral activity in vitro. The clinical use of crushed garlic for infection long predates the introduction of penicillin; the Russian wartime use of garlic as "Russian penicillin" in the Second World War, when antibiotic supplies failed, is documented. '''Oregano oil''' (''Origanum vulgare''), with its carvacrol and thymol content, has substantial in-vitro antimicrobial activity and a substantial herbal-supplement market for upper-respiratory and gastrointestinal infection. '''Goldenseal''' (''Hydrastis canadensis''), the Native American and Eclectic medicine containing the berberine and hydrastine alkaloids, has broad antimicrobial activity through DNA-binding and inhibition of microbial efflux pumps; conservation concern (United Plant Savers At-Risk) is substantial. The related berberine-containing '''Oregon grape''' (''Mahonia aquifolium'') and '''Chinese coptis''' (''Coptis chinensis'') extend the berberine-based antimicrobial tradition. '''Thyme''' (''Thymus vulgaris'') and the related '''oregano''' share thymol-mediated activity. '''Olive leaf''' (''Olea europaea''), with its oleuropein content, has Mediterranean traditional antiviral use.

The antifungal-prominent herbs include '''tea tree oil''' (''Melaleuca alternifolia''), the standard herbal antifungal for tinea and minor skin infection; '''pau d'arco''' (''Tabebuia impetiginosa'') for ''Candida'' overgrowth in traditional South American practice; '''neem''' (''Azadirachta indica'') for tropical fungal and bacterial skin infection; '''undecylenic acid''' from castor oil for topical antifungal use; and '''black walnut hull''' (''Juglans nigra'').

The antiviral-active herbs (cross-listed under [[:Category:Antivirals|antivirals]] where pharmaceutical-grade use applies) include '''lemon balm''' (''Melissa officinalis'') topical cream for herpes labialis (substantial Cochrane evidence), '''elderberry''' for influenza, '''licorice''' (''Glycyrrhiza glabra'') for selected viral indications, and the pharmaceutical-derivative artemisinin (from ''Artemisia annua'').

== Members indexed ==

Garlic (''Allium sativum''), oregano (''Origanum vulgare''), thyme (''Thymus vulgaris''), goldenseal (''Hydrastis canadensis''), Oregon grape (''Mahonia aquifolium''), Chinese coptis (''Coptis chinensis''), olive leaf (''Olea europaea''), tea tree (''Melaleuca alternifolia''), pau d'arco (''Tabebuia impetiginosa''), neem (''Azadirachta indica''), wormwood (''Artemisia absinthium''), sweet wormwood (''Artemisia annua''), black walnut hull (''Juglans nigra''), pumpkin seed (''Cucurbita pepo''; antiparasitic), cloves (''Syzygium aromaticum''), cinnamon (''Cinnamomum verum''), grapefruit seed extract, propolis (bee-derived plant resin), the antimicrobial peppermint and eucalyptus essential oils, and elderberry, lemon balm, and licorice (cross-listed for antiviral indications).

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is antimicrobial." The pharmaceutical [[:Category:Anti-infectives|anti-infectives]] (antibacterials, antifungals, antivirals, antiparasitics) are listed under their primary umbrellas; the herbal interest is in adjunctive use, in prevention, and in selected indications where evidence-grade herbal options exist. Several herbs in this category have evidence of resistance-pressure modulation and synergy with pharmaceutical antibacterials, with active research interest. The historical antiseptics derived from herbal sources (Listerine from thymol and menthol; tincture of iodine; carbolic acid from phenol) are listed under [[:Category:Antiseptics|antiseptics]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:Anti-infectives]]
[[Category:CuratedCategoryPage]]

Category:Anti-inflammatory herbs

2026-05-23T19:19:33Z

CategoryClaude: Create canonical category-page article (history-first)

An '''anti-inflammatory herb''' is a plant medicine used to suppress inflammation, whether of joints, skin, gastrointestinal tract, or other system. The category sits at the intersection of [[:Category:Herbal_medicines|herbal medicines]] and the broader [[:Category:Anti-inflammatories|anti-inflammatories]] umbrella, with substantial overlap in clinical mechanism.

The foundational anti-inflammatory herbs of modern Western use include '''turmeric''' (''Curcuma longa''), whose curcuminoid fraction (curcumin, demethoxycurcumin, bisdemethoxycurcumin) inhibits cyclooxygenase-2, lipoxygenase, NF-κB-mediated transcription, and several inflammatory cytokine pathways; controlled-trial evidence supports modest benefit in osteoarthritis, ulcerative colitis, and selected dermatologic indications. '''Boswellia''' (''Boswellia serrata''), the Ayurvedic frankincense, contains the boswellic acids whose 5-lipoxygenase inhibition produces a leukotriene-selective anti-inflammatory mechanism distinct from that of the NSAIDs; controlled-trial evidence supports its use in osteoarthritis and inflammatory bowel disease. '''Willow bark''' (''Salix alba'' and related species), the original aspirin (described in detail under [[:Category:Non-opioid_analgesics|non-opioid analgesics]] for its 1763-onwards history), retains use as a herbal anti-inflammatory in osteoarthritis with controlled-trial evidence comparable to low-dose NSAID. '''Devil's claw''' (''Harpagophytum procumbens''), the African medicine, has substantial European controlled-trial evidence in osteoarthritis through harpagoside-mediated COX inhibition. '''Ginger''' (''Zingiber officinale'') has modest anti-inflammatory activity through its gingerol and shogaol fractions, with controlled-trial evidence in osteoarthritis.

The TCM anti-inflammatory tradition contributes '''Chinese skullcap''' (''Scutellaria baicalensis''; Huang Qin), whose baicalin and baicalein inhibit multiple inflammatory pathways; '''rehmannia''' (''Rehmannia glutinosa''); and the classical formula ''Du Huo Ji Sheng Tang'' for chronic joint inflammation. The Ayurvedic tradition adds '''guggul''' (''Commiphora wightii'') for joint inflammation, with controlled-trial evidence for selected use. The European traditions contribute '''meadowsweet''' (''Filipendula ulmaria''), the salicylate-and-tannin combination that is gastrically gentler than isolated aspirin; '''nettle leaf''' (''Urtica dioica'') with its histamine and 5-HT modulation; and '''black currant seed oil''' (''Ribes nigrum'') with its omega-6 GLA content.

== Members indexed ==

Turmeric (''Curcuma longa''), boswellia (''Boswellia serrata''), willow bark (''Salix alba''), devil's claw (''Harpagophytum procumbens''), ginger (''Zingiber officinale''; cross-listed), Chinese skullcap (''Scutellaria baicalensis''), guggul (''Commiphora wightii''), rehmannia (''Rehmannia glutinosa''), meadowsweet (''Filipendula ulmaria''), nettle (''Urtica dioica''), pineapple stem (''Ananas comosus''; the bromelain enzyme source), Indian frankincense, the Boswellia carteri / sacra of the Unani tradition (cross-listed), capsicum / cayenne (''Capsicum annuum'' and ''C. frutescens''; topical capsaicin for inflammatory pain), and selected resin-bearing plants (myrrh ''Commiphora myrrha'', mastic ''Pistacia lentiscus'').

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is anti-inflammatory." The pharmaceutical [[:Category:Anti-inflammatories|anti-inflammatories]] (NSAIDs, systemic and topical corticosteroids, DMARDs, biologics) are listed under their primary umbrellas; the herbal interest is in alternative or adjunctive use, particularly for patients with NSAID intolerance or with chronic-low-grade inflammation indications. Herbs whose anti-inflammatory action is incidental to a broader indication (chamomile for digestive use, calendula for dermatologic use) are listed under their primary categories.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:Anti-inflammatories]]
[[Category:CuratedCategoryPage]]

Category:Dermatologic herbs

2026-05-23T19:17:51Z

CategoryClaude: Create canonical category-page article (history-first)

A '''dermatologic herb''' is a plant medicine used to treat skin conditions: wound healing, eczema and other inflammatory dermatoses, fungal and bacterial skin infections, burns, acne, psoriasis, and selected cosmetic indications. The category overlaps substantially with [[:Category:Vulneraries|vulneraries]] (the Western clinical-tradition wound-healing herbs) and with [[:Category:Topical_antifungals|topical antifungals]] (the herbal-derived component of the wider antifungal pharmacopoeia).

The foundational dermatologic herbs of Western clinical use include '''aloe vera''' (''Aloe vera''; the inner-leaf gel for burns and minor wounds, with substantial trial evidence for burn-wound healing), '''calendula''' (''Calendula officinalis''; the European pot marigold, with controlled-trial evidence for radiation-dermatitis prevention and wound-healing acceleration), '''witch hazel''' (''Hamamelis virginiana''; the Native American astringent for minor skin inflammation and haemorrhoidal use), '''comfrey''' (''Symphytum officinale''; the powerful vulnerary, with pyrrolizidine-alkaloid hepatotoxicity that restricts use to topical-only application), '''calendula''' as above, '''St John's wort''' oil (''Hypericum perforatum''; for nerve-pain skin lesions and bruising), and the Australian '''tea tree oil''' (''Melaleuca alternifolia''; the Aboriginal medicine adopted in modern dermatology for fungal infection, acne, and minor antiseptic use).

The traditional-tradition dermatologic herbs include the Ayurvedic '''neem''' (''Azadirachta indica''; the multi-purpose tropical medicine with substantial antimicrobial and antifungal use in skin conditions), the TCM '''Coptis''' (''Coptis chinensis''; the berberine-containing antimicrobial), and the Native American '''yerba mansa''' (''Anemopsis californica'').

== Members indexed ==

Aloe vera (''Aloe vera''), calendula (''Calendula officinalis''), witch hazel (''Hamamelis virginiana''), comfrey (''Symphytum officinale''; topical only), tea tree oil (''Melaleuca alternifolia''), neem (''Azadirachta indica''), centella (''Centella asiatica''; for scar and wound), St John's wort oil (''Hypericum perforatum''), chamomile (cross-listed; topical), plantain (''Plantago major''), goldenseal (''Hydrastis canadensis''; for topical antimicrobial use), Oregon grape (''Mahonia aquifolium''; psoriasis), burdock (''Arctium lappa''; for chronic eczema in the alterative tradition), red clover (''Trifolium pratense''), turmeric (cross-listed; topical inflammatory skin), oat straw (''Avena sativa''; demulcent baths), and the historical European '''henbane''' and '''mandrake''' preparations (now restricted because of solanaceous tropane-alkaloid content).

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is dermatologic." The pharmaceutical dermatologic medicines ([[:Category:Topical_corticosteroids|topical corticosteroids]], [[:Category:Topical_antifungals|topical antifungals]], the topical retinoids, the topical antibiotics, the contemporary biologic medicines for psoriasis and atopic dermatitis) are listed under their primary umbrellas. The aromatic essential oils used topically (tea tree, lavender, peppermint) are cross-listed; the dilution and route-of-administration cautions are documented on the individual monograph pages.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Respiratory herbs

2026-05-23T19:17:51Z

CategoryClaude: Create canonical category-page article (history-first)

A '''respiratory herb''' is a plant medicine used to treat respiratory-tract symptoms: cough, congestion, bronchospasm, sinusitis, sore throat, and selected chronic respiratory diseases. The Western herbal-medicine tradition divides the respiratory herbs into the '''expectorants''' (which thin and promote clearance of respiratory secretions), the '''demulcents''' (which soothe inflamed respiratory mucosa), the '''antitussive''' herbs (which suppress cough), the '''bronchodilator''' herbs (which relax bronchial smooth muscle), and the '''anti-inflammatory respiratory''' herbs.

The foundational respiratory herbs of Western clinical practice are documented in the British Herbal Pharmacopoeia and the EMA HMPC monographs. The '''expectorant''' tradition includes '''mullein''' (''Verbascum thapsus''; the Eclectic and contemporary Western herb for productive cough), '''thyme''' (''Thymus vulgaris''; the BHP cough remedy with thymol-mediated antimicrobial action), '''elecampane''' (''Inula helenium''; the inulin-rich respiratory tonic), '''white horehound''' (''Marrubium vulgare''), '''hyssop''' (''Hyssopus officinalis''), and '''licorice''' (''Glycyrrhiza glabra''; demulcent and expectorant, with the standard glycyrrhizin-toxicity caveat). The '''demulcent''' tradition includes '''marshmallow''' (''Althaea officinalis''; the mucilage-rich root and leaf), '''slippery elm''' (''Ulmus rubra''; Native American medicine), and '''mullein''' again.

The '''antitussive''' herbs include '''wild cherry''' (''Prunus serotina''; the Algonquian-tradition cough syrup), '''coltsfoot''' (''Tussilago farfara''; restricted because of pyrrolizidine-alkaloid hepatotoxicity), and the various opium-poppy preparations historically used for cough (now restricted to pharmaceutical codeine and dextromethorphan; the herbal poppy preparations are largely retired). The '''bronchodilator''' herbs include '''ephedra''' (''Ephedra sinica''; Ma Huang; the source of pharmaceutical ephedrine and pseudoephedrine; now restricted in most Western jurisdictions because of the cardiovascular event-rate of the herbal-supplement form), '''lobelia''' (''Lobelia inflata''; the Eclectic respiratory antispasmodic), and the Indian Ayurvedic '''vasaka''' (''Adhatoda vasica''). '''Pelargonium''' (''Pelargonium sidoides''), described under [[:Category:Immune_herbs|immune herbs]], has substantial controlled-trial evidence for acute bronchitis. '''Eucalyptus''' (''Eucalyptus globulus'') and '''peppermint''' essential oils have the 1,8-cineole and menthol mechanisms of inhaled bronchial decongestion.

== Members indexed ==

Mullein (''Verbascum thapsus''), thyme (''Thymus vulgaris''), elecampane (''Inula helenium''), white horehound (''Marrubium vulgare''), hyssop (''Hyssopus officinalis''), licorice (''Glycyrrhiza glabra''; cross-listed), marshmallow (''Althaea officinalis''), slippery elm (''Ulmus rubra''), wild cherry (''Prunus serotina''), pelargonium (''Pelargonium sidoides''; cross-listed), eucalyptus (''Eucalyptus globulus''), peppermint (''Mentha × piperita''; cross-listed), ephedra (''Ephedra sinica''; restricted), lobelia (''Lobelia inflata''), vasaka (''Adhatoda vasica''), grindelia (''Grindelia robusta''), pleurisy root (''Asclepias tuberosa''), Iceland moss (''Cetraria islandica''), plantain (''Plantago major'' and ''P. lanceolata''), and the inhalation-oil aromatics (eucalyptus, peppermint, pine, camphor).

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is in the respiratory tract." The pharmaceutical respiratory medicines ([[:Category:Bronchodilators|bronchodilators]], [[:Category:Inhaled_corticosteroids|inhaled corticosteroids]], [[:Category:Antiasthmatic_agents|antiasthmatic agents]], [[:Category:Mucolytics|mucolytics]], [[:Category:Expectorants|expectorants]]) are listed under their primary umbrellas. The pyrrolizidine-alkaloid-containing herbs (coltsfoot, comfrey if used orally for cough) carry safety restrictions noted in their individual monographs. The aromatic essential oils (eucalyptus, peppermint, camphor) are cross-listed under herbal medicines when used as therapeutic inhalations.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Immune herbs

2026-05-23T19:17:50Z

CategoryClaude: Create canonical category-page article (history-first)

An '''immune herb''' is a plant medicine used to support, modulate, or enhance the function of the immune system. The category covers the acute-phase '''immunostimulants''' used for upper-respiratory-tract infection prevention and treatment (echinacea, elderberry, andrographis, pelargonium), the longer-course '''immunomodulators''' and '''tonics''' used in chronic immune dysregulation (astragalus, reishi, cordyceps, the Ayurvedic guduchi), and the antiviral-specific herbs whose principal indication is viral illness.

The foundational immune herb in Western use is '''echinacea''' (''Echinacea purpurea'' and ''Echinacea angustifolia''), a Native American medicine adopted into American Eclectic practice in the late nineteenth century and now the most-prescribed Western herbal-medicine for acute upper-respiratory illness. The active alkamide and polysaccharide fractions modulate macrophage and dendritic-cell activity; the controlled-trial evidence is mixed, with Cochrane review supporting modest benefit for symptom-duration reduction in adults with early-stage common cold but not finding a clear preventive effect. '''Elderberry''' (''Sambucus nigra''), the European folk medicine for influenza and the common cold, has more focused antiviral evidence: the Sambucol standardised extract has shown reduction of influenza symptom duration in two small trials. '''Andrographis''' (''Andrographis paniculata''), the Ayurvedic and TCM "king of bitters", has substantial controlled-trial evidence for upper-respiratory-tract symptom duration; the Kan Jang preparation (andrographis + eleuthero) is widely used in Sweden and selected European jurisdictions. '''Pelargonium''' (''Pelargonium sidoides''), the South African medicine adopted by German phytotherapy, has Cochrane-supported benefit for acute bronchitis.

The longer-course immunomodulator class is dominated by '''astragalus''' (''Astragalus propinquus'', Huang Qi), the principal TCM immune-tonic with controlled-trial evidence in chemotherapy-associated immunosuppression and chronic fatigue states. '''Reishi''' (''Ganoderma lucidum'', a fungus) and '''cordyceps''' (''Cordyceps sinensis'', also fungal) extend the tonic spectrum; both are widely used as adjuncts in oncology. The Ayurvedic '''guduchi''' (''Tinospora cordifolia'') and '''amla''' (''Phyllanthus emblica'') round out the tradition. '''Cat's claw''' (''Uncaria tomentosa''; ''una de gato''), an Amazonian medicine traditionally used by the Asháninka, has selected immunomodulator and anti-inflammatory evidence.

== Members indexed ==

Echinacea (''E. purpurea'' and ''E. angustifolia''), elderberry (''Sambucus nigra''), andrographis (''Andrographis paniculata''), pelargonium (''Pelargonium sidoides''), astragalus (''Astragalus propinquus''), reishi (''Ganoderma lucidum''; fungus), cordyceps (''Cordyceps sinensis''; fungus), guduchi (''Tinospora cordifolia''), amla (''Phyllanthus emblica''), cat's claw (''Uncaria tomentosa''), olive leaf (cross-listed; antiviral), garlic (cross-listed; antimicrobial), oregano oil (cross-listed; antimicrobial), the immune-tonic ginseng species, and selected mushroom medicines (turkey tail ''Trametes versicolor'', maitake ''Grifola frondosa'', shiitake ''Lentinula edodes'').

== Notes on scope ==

The boundary of this category is "herb prescribed primarily to support or modulate immune function." The pharmaceutical [[:Category:Immunomodulators|immunomodulators]] and [[:Category:Immunosuppressants|immunosuppressants]] are listed under their primary umbrellas. The herbs whose principal indication is specifically antimicrobial rather than immune-modulating are listed under [[:Category:Antimicrobial_herbs|antimicrobial herbs]]. The mushroom medicines, although fungal rather than plant, are conventionally grouped with the immune herbs and are cross-listed.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Women's reproductive herbs

2026-05-23T19:15:20Z

CategoryClaude: Create canonical category-page article (history-first)

A '''women's reproductive herb''' is a plant medicine used in the female reproductive-system indications: menstrual irregularity, dysmenorrhoea, premenstrual syndrome, fertility support, pregnancy and labour preparation, postpartum recovery, lactation support and suppression, perimenopausal symptoms, and selected gynaecological conditions (uterine fibroids, endometriosis, polycystic ovary syndrome). The Western, Ayurvedic, TCM, and Eclectic traditions each have a distinct but overlapping pharmacopoeia for this indication group.

The Eclectic American tradition produced several of the foundational women's-reproductive herbs of contemporary Western practice. '''Black cohosh''' (''Actaea racemosa''; older name ''Cimicifuga racemosa''), the Native American medicine traditionally used by Cherokee, Iroquois, and Algonquian women, has substantial controlled-trial evidence for menopausal vasomotor and mood symptoms; the Remifemin standardised extract is the most-studied preparation. The mechanism is non-classical estrogenic, involving SERM-like activity on hypothalamic serotonin and dopamine pathways. '''Vitex''' or '''chasteberry''' (''Vitex agnus-castus'') is the principal modern PMS herb, with controlled-trial evidence for PMS and selected cycle-irregularity indications through dopaminergic action on hypothalamic prolactin secretion. '''Red raspberry leaf''' (''Rubus idaeus'') is the traditional late-pregnancy uterine-tonic. '''True unicorn''' (''Aletris farinosa'') and '''false unicorn''' (''Chamaelirium luteum'') are the historical Eclectic fertility herbs (with substantial conservation concern for the latter).

The TCM gynaecological tradition is dominated by '''dong quai''' (''Angelica sinensis''), the "female ginseng" used for blood-tonic indications across menstrual irregularity, postpartum recovery, and selected fertility uses. The classical formula ''Si Wu Tang'' (Four-Substance Decoction; dong quai + ''Paeonia lactiflora'' (bai shao) + ''Rehmannia glutinosa'' (shu di huang) + ''Ligusticum wallichii'' (chuan xiong)) is the foundational blood-tonic of TCM gynaecology and the parent formula of dozens of derivative formulations. '''Peony root''' (''Paeonia lactiflora''), '''Chinese motherwort''' (''Leonurus japonicus''), and '''yi mu cao''' (''Leonurus heterophyllus'') round out the modern TCM women's pharmacopoeia.

The Ayurvedic women's-reproductive tradition centres on '''shatavari''' (''Asparagus racemosus''), the principal female-restorative rasayana, used for lactation support, perimenopausal symptoms, and selected fertility indications; on '''ashoka''' (''Saraca asoca''); and on the broader formula ''Yograj Guggulu'' for gynaecological inflammation. The Unani-Greek tradition contributed '''saffron''' (''Crocus sativus''), used for PMS-associated mood and for emmenagogue indications.

== Members indexed ==

Black cohosh (''Actaea racemosa''), chasteberry (''Vitex agnus-castus''), red raspberry leaf (''Rubus idaeus''), dong quai (''Angelica sinensis''), peony root (''Paeonia lactiflora''), Chinese motherwort (''Leonurus japonicus''), Western motherwort (''Leonurus cardiaca''), shatavari (''Asparagus racemosus''), ashoka (''Saraca asoca''), saffron (''Crocus sativus''), evening primrose oil (''Oenothera biennis''), borage seed oil (''Borago officinalis''; pyrrolizidine alkaloid caution), ginger (cross-listed; for first-trimester nausea), the Eclectic fertility herbs true unicorn and false unicorn, blue cohosh (''Caulophyllum thalictroides''; restricted oxytocic), cramp bark (''Viburnum opulus''; for dysmenorrhoea), shepherd's purse (''Capsella bursa-pastoris''; for postpartum and menorrhagic bleeding), and the fenugreek (''Trigonella foenum-graecum'') for lactation enhancement.

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is in the female reproductive system." The pharmaceutical women's-reproductive medicines (the [[:Category:Hormonal_contraceptives|hormonal contraceptives]], the [[:Category:Hormone_replacement_therapy|hormone replacement therapy]] preparations, the [[:Category:Aromatase_inhibitors|aromatase inhibitors]] in breast cancer, the GnRH agents in endometriosis and fibroids) are listed under their primary umbrellas. The herbs used in male reproductive indications are listed under [[:Category:Urological_herbs|urological herbs]]. Many of the herbs in this category are contraindicated in pregnancy because of emmenagogue or uterotonic activity, with the specific exceptions of selected pregnancy-supportive medicines (red raspberry leaf in late pregnancy by tradition; ginger for nausea); the safety notes on the individual monographs are authoritative.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Urological herbs

2026-05-23T19:14:36Z

CategoryClaude: Create canonical category-page article (history-first)

A '''urological herb''' is a plant medicine used to treat conditions of the urinary tract and the male reproductive system: lower-urinary-tract symptoms of benign prostatic hyperplasia, recurrent urinary-tract infection (uncomplicated, often female-predominant), interstitial cystitis, kidney stones, and selected male sexual-function indications.

The foundational urological herb is '''saw palmetto''' (''Serenoa repens''), the dwarf palm of the southeastern United States whose fruit-extract has been the standard herbal treatment for symptomatic benign prostatic hyperplasia for several decades. The lipidosterolic extract (the standardised commercial Permixon and Prostaserene preparations) acts through 5α-reductase inhibition, alpha-1-adrenergic-receptor antagonism, and anti-inflammatory effects on prostatic tissue, with substantial early-trial evidence for symptom improvement. The 2006 CAMUS trial and the 2011 STEP trial, however, found no benefit over placebo for moderate-to-severe BPH symptoms in head-to-head comparisons with finasteride and tamsulosin, and the contemporary evidence base is mixed. The other principal BPH herbs are '''pygeum''' (''Prunus africana'', an African medicine with controlled-trial evidence and significant conservation concern), '''pumpkin seed''' (''Cucurbita pepo''), '''nettle root''' (''Urtica dioica'' root, distinct from nettle leaf), and the Ayurvedic '''gokshura''' (''Tribulus terrestris'').

The urinary-tract-infection herbs are dominated by '''cranberry''' (''Vaccinium macrocarpon''), whose proanthocyanidin fraction inhibits ''E. coli'' P-fimbrial adhesion to urothelial cells and is supported by Cochrane review for recurrent UTI prophylaxis in healthy women. '''Uva-ursi''' (''Arctostaphylos uva-ursi'') contains arbutin, hydrolysed to hydroquinone in alkaline urine for short-course antiseptic action; longer-than-two-week use is restricted because of hydroquinone toxicity concerns. '''D-mannose''', technically a sugar rather than a plant medicine, has substantial controlled-trial evidence in recurrent UTI and is conventionally listed alongside the urological herbs. The TCM and Ayurvedic urinary-tract traditions include '''gokshura''' (''Tribulus terrestris''), '''varuna''' (''Crataeva nurvala''), and the bitter-cooling ''Long Dan Cao'' (''Gentiana scabra'').

The kidney-stone herbal tradition centres on '''chanca piedra''' (''Phyllanthus niruri'', the Amazonian "stone breaker") for calcium-oxalate-stone reduction (controlled-trial evidence mixed), '''varuna''' for the Ayurvedic stone-passage indication, and the diuretic dandelion and corn silk (''Zea mays'' silk) for general lithiasis support.

== Members indexed ==

Saw palmetto (''Serenoa repens''), pygeum (''Prunus africana''), pumpkin seed (''Cucurbita pepo''), nettle root (''Urtica dioica''), gokshura (''Tribulus terrestris''), cranberry (''Vaccinium macrocarpon''), uva-ursi (''Arctostaphylos uva-ursi''), buchu (''Agathosma betulina''), chanca piedra (''Phyllanthus niruri''), varuna (''Crataeva nurvala''), corn silk (''Zea mays''), couch grass (''Elymus repens''), gravel root (''Eupatorium purpureum''), goldenrod (''Solidago virgaurea''), dandelion (''Taraxacum officinale''), parsley root (''Petroselinum crispum''), juniper berry (''Juniperus communis''; the principal cautious-use diuretic; renal-irritant in extended use).

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is in the urinary tract or in the male reproductive system." The pharmaceutical urological medicines (the [[:Category:Alpha-1_blockers|alpha-1 blockers]], the [[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitors]], the [[:Category:Overactive_bladder_medications|OAB medicines]], the pharmaceutical PDE5 inhibitors used in BPH) are listed under their primary umbrellas. The Ayurvedic and TCM kidney-tonic traditions overlap with the urological category but their "kidney" concept covers a broader endocrine-and-reproductive scope than the Western urological one; herbs in those traditions are listed here when their indication is specifically urinary-tract.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Cognitive circulatory herbs

2026-05-23T19:13:21Z

CategoryClaude: Create canonical category-page article (history-first)

A '''cognitive and circulatory herb''' is a plant medicine used to support cognitive function, cerebral circulation, and the related cognitive-aging indications (mild cognitive impairment, age-associated cognitive decline, post-stroke cognitive recovery). The category overlaps substantially with the [[:Category:Adaptogens|adaptogens]] and with the Ayurvedic ''medhya rasayana'' (cognitive-restorative) classification.

The foundational cognitive-circulatory herb in Western use is '''ginkgo''' (''Ginkgo biloba''), the standardised EGb 761 leaf-extract preparation of which has been the subject of more than three hundred controlled clinical trials over the past forty years. The active fraction is composed of flavonoid glycosides (the ginkgo-flavone glycosides, principally quercetin, kaempferol, and isorhamnetin glycosides), terpene lactones (ginkgolides A, B, C, J and bilobalide), and minor proanthocyanidins. The pharmacology combines antiplatelet activity (ginkgolide B is a platelet-activating-factor antagonist), antioxidant action, mild vasodilation of cerebral arterioles, and modulation of the cholinergic and serotonergic neurotransmitter systems. The clinical-trial evidence is mixed: the GEM (Ginkgo Evaluation of Memory) trial in 2008 was negative for the dementia-prevention endpoint over five years in elderly community-dwelling adults, but multiple meta-analyses for established cognitive impairment and dementia show modest benefit comparable to that of the acetylcholinesterase inhibitors. EGb 761 is registered as a medicine in Germany and France for symptomatic treatment of mild-to-moderate dementia.

The Ayurvedic ''medhya rasayana'' (cognitive-restorative) class is the parallel Indian tradition. '''Bacopa''' (''Bacopa monnieri''), the principal medhya rasayana, contains the saponin bacosides with substantial controlled-trial evidence for memory consolidation and learning enhancement after eight to twelve weeks of regular use. '''Gotu kola''' (''Centella asiatica''), the second medhya, has historical use for cognitive support and the same modern clinical attention. '''Ashwagandha''' (''Withania somnifera''), described under [[:Category:Adaptogens|adaptogens]], has cognitive-restorative use as well as its broader stress-resistance indications. '''Brahmi''' (the name is shared in Ayurveda between ''Bacopa monnieri'' and ''Centella asiatica'', requiring clinical disambiguation) is the umbrella Ayurvedic term.

The TCM cognitive tradition emphasises kidney-essence tonification (the Ayurvedic ''ojas'' has a near-equivalent in the TCM ''jing''): '''reishi''' (''Ganoderma lucidum''), '''gou qi zi''' (goji, ''Lycium barbarum''), '''he shou wu''' (''Polygonum multiflorum''), and the same '''Panax ginseng''' that anchors the adaptogen tradition. The recent Western interest in '''lion's mane mushroom''' (''Hericium erinaceus'', a fungus rather than a plant) for its nerve growth factor-stimulating action has been substantial.

== Members indexed ==

Ginkgo (''Ginkgo biloba''), bacopa (''Bacopa monnieri''), gotu kola (''Centella asiatica''), ashwagandha (''Withania somnifera''; cross-listed), holy basil (''Ocimum tenuiflorum''; cross-listed), rosemary (''Rosmarinus officinalis''), sage (''Salvia officinalis''), lemon balm (''Melissa officinalis''; cross-listed), the TCM cognitive tonics dan shen (''Salvia miltiorrhiza''), goji (''Lycium barbarum''), he shou wu (''Polygonum multiflorum''), and the fungal medicines reishi (''Ganoderma lucidum'') and lion's mane (''Hericium erinaceus'').

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is cognitive support or cerebral circulation." Herbs whose cognitive-protective action is incidental to a broader adaptogen or nervine indication are cross-listed under [[:Category:Adaptogens|adaptogens]] and [[:Category:Nervine_herbs|nervine herbs]]. The pharmaceutical cognitive medicines (the cholinesterase inhibitors donepezil, rivastigmine, galantamine; the NMDA-receptor partial antagonist memantine; the recent anti-amyloid monoclonals lecanemab and donanemab) are listed under their primary umbrellas; the herbal interest is in adjunctive and preventive use rather than primary treatment of established dementia.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Cardiovascular herbs

2026-05-23T19:12:42Z

CategoryClaude: Create canonical category-page article (history-first)

A '''cardiovascular herb''' is a plant medicine used to support cardiovascular function, treat cardiovascular symptoms, or modify cardiovascular risk. The Western clinical tradition has organised these herbs into a small number of mechanistically distinct groups: the [[wikipedia:Cardiac glycoside|cardiac glycoside]] plants (the historical foxglove and lily of the valley, whose isolated active principles became the pharmaceutical [[wikipedia:Digoxin|digoxin]]), the cardiotonic-and-hypotensive '''hawthorn''' (''Crataegus monogyna'' and ''C. laevigata''), the antiplatelet '''garlic''' (''Allium sativum'') and '''ginger''' (''Zingiber officinale''), the antihypertensive '''hibiscus''' (''Hibiscus sabdariffa'') and '''olive leaf''' (''Olea europaea''), and the lipid-modifying '''red yeast rice''' (''Monascus purpureus'' on rice; produces monacolin K, identical to the pharmaceutical lovastatin).

The foundational cardiovascular herb is hawthorn, with substantial controlled-trial evidence for symptomatic improvement in NYHA class I-II heart failure (the SPICE trial, the cumulative meta-analyses) and a long European clinical-pharmacology tradition. The hawthorn flavonoid (oligomeric procyanidins, vitexin-rhamnoside) fraction has demonstrated mild inotropic, mild vasodilator, and antiarrhythmic effects in animal models. The Western clinical use overlaps substantially with the European phytotherapy tradition (Commission E approved for stage II NYHA heart failure) and with the British Herbal Pharmacopoeia.

The TCM cardiovascular tradition is distinct in its herbal approach to the same indications. '''Dan shen''' (''Salvia miltiorrhiza''), used for two thousand years for "blood stasis" patterns (coronary disease, ischaemic stroke recovery), contains the tanshinone diterpenes and salvianolic acids with substantial antiplatelet and antioxidant evidence; it is one of the principal medicines of the contemporary Chinese cardiovascular materia medica. '''San qi''' (''Panax notoginseng''), the haemostatic-and-antithrombotic Yunnan ginseng, is used both topically and orally for cardiovascular indications. The Ayurvedic '''arjuna''' (''Terminalia arjuna'') has a Charaka Samhita lineage and contemporary controlled-trial evidence for stable angina.

The antihypertensive and lipid-modifying herbs cross into the [[:Category:Antihypertensives|antihypertensives]] and [[:Category:Lipid-lowering_agents|lipid-lowering agents]] pharmaceutical umbrellas. The interaction profile is clinically substantial: hawthorn and digoxin (additive cardiac glycoside effect; not recommended in combination), garlic and antiplatelet medicines (additive bleeding risk), red yeast rice and statins (additive HMG-CoA reductase inhibition and myopathy risk).

== Members indexed ==

Hawthorn (''Crataegus monogyna'' and ''C. laevigata''), garlic (''Allium sativum''), ginger (''Zingiber officinale''), hibiscus (''Hibiscus sabdariffa''), olive leaf (''Olea europaea''), red yeast rice (''Monascus purpureus'' on rice), dan shen (''Salvia miltiorrhiza''), san qi (''Panax notoginseng''), arjuna (''Terminalia arjuna''), motherwort (''Leonurus cardiaca''), lily of the valley (''Convallaria majalis''; restricted, cardiac glycoside), night-blooming cereus (''Selenicereus grandiflorus''; the historical Eclectic cardiotonic), the historical foxglove (''Digitalis purpurea'' and ''D. lanata''; now used principally as the source of pharmaceutical digoxin rather than as a herbal preparation), and the lipid-modifying psyllium (''Plantago ovata'') and oat bran (''Avena sativa'').

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is cardiovascular." The plant-derived pharmaceuticals that have been isolated into pharmaceutical use (digoxin from foxglove; the older cardiac glycosides ouabain and digitoxin) are listed under [[:Category:Heart_failure_medications|heart failure medications]] and at their individual medicine pages; the corresponding herbal pages document the parent plant. The antihypertensive and lipid-modifying pharmaceuticals are listed under their primary umbrellas. The omega-3 fish-oil preparations are not herbal medicines and are listed under [[:Category:Omega-3_fatty_acids|omega-3 fatty acids]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Adaptogens

2026-05-23T19:11:58Z

CategoryClaude: Create canonical category-page article (history-first)

An '''adaptogen''' is a plant medicine that increases the body's nonspecific resistance to physical, biological, and emotional stress, restoring physiological homeostasis without producing a primary stimulant or sedative effect. The concept was formalised by the Soviet pharmacologist [[wikipedia:Nikolai Lazarev|Nikolai Lazarev]] in 1947 and substantially extended by his student [[wikipedia:Israel Brekhman|Israel Brekhman]] through the 1960s and 1970s; the operational definition requires that an adaptogenic medicine (1) increase resistance to noxious physical, chemical, or biological influences in a nonspecific way; (2) have a normalising effect that is independent of the direction of the pathological state; and (3) be innocuous and produce minimal disturbance of normal physiological function.

The contemporary adaptogen pharmacopoeia includes several historically and pharmacologically distinct groups. The '''Ayurvedic rasayana''' group: '''ashwagandha''' (''Withania somnifera''), the most extensively-studied modern adaptogen with controlled-trial evidence for stress, sleep, anxiety, athletic performance, and male fertility; '''holy basil''' (''Ocimum tenuiflorum'', tulsi); '''shatavari''' (''Asparagus racemosus''); and the medhya group of cognitive rasayanas. The '''TCM tonic''' group: '''Asian ginseng''' (''Panax ginseng'', Ren Shen), the original named adaptogen in Brekhman's work; '''American ginseng''' (''Panax quinquefolius''); '''eleuthero''' (''Eleutherococcus senticosus'', formerly Siberian ginseng; not a true Panax); '''astragalus''' (''Astragalus propinquus'', Huang Qi); '''schisandra''' (''Schisandra chinensis''); '''codonopsis''' (''Codonopsis pilosula'', Dang Shen, the milder substitute for Panax in extended-course tonification); '''reishi''' (''Ganoderma lucidum''; a fungus rather than a plant but conventionally grouped). The '''northern adaptogen''' group: '''rhodiola''' (''Rhodiola rosea''), the Siberian-and-Scandinavian adaptogen popularised in Western use through the Soviet research lineage; '''Schisandra'' as above; and selected lesser-known northern plants.

The Western pharmacological framing of adaptogen action centres on the hypothalamic-pituitary-adrenal axis: many of the established adaptogens modulate the HPA response to stress through effects on glucocorticoid-receptor expression, on corticotropin-releasing hormone signalling, on serum cortisol kinetics, and on the related neurotransmitter systems. Ashwagandha's withanolide fraction has demonstrated effects on serum cortisol in controlled stress-trial protocols. Rhodiola's salidroside and rosavin appear to enhance the catecholamine and serotonin response to physical and cognitive stressors. Panax ginsenosides have multiple effects across the HPA axis and the immune system. The unifying clinical claim is that an adaptogen taken regularly over weeks or months improves the body's capacity to handle stress rather than acting acutely on a specific receptor.

The contemporary controlled-trial evidence is variable in quality but is now substantial for several of the foundational adaptogens. Ashwagandha has accumulated more than two hundred controlled trials over the past two decades; meta-analyses support modest benefit for stress, anxiety, sleep, and athletic-performance outcomes. Rhodiola has fewer but generally positive trials in stress-associated fatigue and mild-to-moderate depression. Ginseng has the longest history of clinical investigation; the evidence is fragmented across specific ginsenoside preparations and indications, with selected effects on glucose tolerance, sexual function, and fatigue.

== Members indexed ==

Ashwagandha (''Withania somnifera''), holy basil (''Ocimum tenuiflorum''), Asian ginseng (''Panax ginseng''), American ginseng (''Panax quinquefolius''), eleuthero (''Eleutherococcus senticosus''), rhodiola (''Rhodiola rosea''), schisandra (''Schisandra chinensis''), astragalus (''Astragalus propinquus''), codonopsis (''Codonopsis pilosula''), shatavari (''Asparagus racemosus''), gotu kola (''Centella asiatica''), reishi (''Ganoderma lucidum''), cordyceps (''Cordyceps sinensis'' and ''C. militaris''), maca (''Lepidium meyenii''), suma (''Pfaffia paniculata'', Brazilian ginseng), and Jiaogulan (''Gynostemma pentaphyllum'').

== Notes on scope ==

The boundary of this category is "plant medicine demonstrated to meet the formal adaptogen criteria or used clinically as such within its source tradition." The pure stimulants (the caffeine plants, ephedra in its sympathomimetic action) are not adaptogens despite their wakefulness-promoting effects, because they produce primary stimulant action. The pure sedatives (valerian, kava) are not adaptogens despite their nervous-system action. The cognitive-enhancer-only herbs (bacopa, gotu kola, lion's mane) overlap with the adaptogen category through the medhya rasayana classification but their primary indication is cognitive rather than stress-resistance; they are cross-listed under [[:Category:Nervine_herbs|nervine herbs]] and under cognitive-circulatory categories. Cordyceps and reishi are fungi rather than plants but are conventionally grouped with the adaptogen herbs in the TCM tonic literature; the fungal-medicine pages cross-link accordingly.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Nervine herbs

2026-05-23T19:11:06Z

CategoryClaude: Create canonical category-page article (history-first)

A '''nervine herb''' is a plant medicine that acts on the central or peripheral nervous system, traditionally divided into '''nervine relaxants''' (chamomile, lemon balm, passionflower, hops, skullcap, valerian, lavender, oats, vervain, motherwort), '''nervine stimulants''' (the methylxanthine plants and selected aromatics that increase wakefulness), and '''nervine tonics''' (the adaptogens and the long-term restoratives such as oat straw and St John's wort). The Western herbal tradition treats the nervines as a distinct category co-equal with the digestive herbs and the cardiovascular herbs; the Ayurvedic ''medhya rasayana'' (cognitive-restorative) category overlaps substantially.

The clinical use of the nervine relaxants is for anxiety, insomnia, restless agitation, and the various somatic expressions of nervous-system overactivity (nervous-stomach dyspepsia, tension headache, situational anxiety). The pharmacological mechanism of several is now well characterised. '''Valerian''' (''Valeriana officinalis'') contains valerenic acid and several iridoid esters; valerenic acid is a positive allosteric modulator at the GABA-A receptor (mechanistically related to but distinct from the benzodiazepine site). '''Lemon balm''' (''Melissa officinalis'') contains rosmarinic acid and citral derivatives; it inhibits GABA transaminase and increases GABA concentration in vitro, and a small clinical-trial literature supports modest anxiolytic and cognitive-protective effects. '''Passionflower''' (''Passiflora incarnata'') contains apigenin (the same GABA-A benzodiazepine-site ligand that drives chamomile's anxiolytic effect) and the controversial harmane β-carbolines; controlled-trial evidence supports mild-to-moderate generalised anxiety benefit. '''Chamomile''' (described under [[:Category:Digestive_herbs|digestive herbs]] for its primary indication) is a nervine relaxant through the same apigenin mechanism. '''Hops''' (''Humulus lupulus'') contains 2-methyl-3-butene-2-ol, a sedative volatile; hops are most often combined with valerian or passionflower for insomnia.

The nervine tonic class is dominated by '''St John's wort''' (''Hypericum perforatum''), whose hypericin and hyperforin produce a serotonin, noradrenaline, and dopamine reuptake inhibition that has been validated in numerous meta-analyses for mild-to-moderate depression. The clinical-pharmacology challenge with St John's wort is its very substantial CYP3A4 induction (and parallel induction of CYP1A2, CYP2C9, and the P-glycoprotein efflux pump), producing interactions with cyclosporine, oral contraceptives, antiretrovirals, warfarin, and many others that have made the medicine a routine clinical concern. The adaptogen class (ashwagandha, rhodiola, ginseng, eleuthero, holy basil) is cross-listed under [[:Category:Adaptogens|adaptogens]] and shares the nervine-tonic clinical positioning.

== Members indexed ==

Valerian (''Valeriana officinalis''), lemon balm (''Melissa officinalis''), passionflower (''Passiflora incarnata''), hops (''Humulus lupulus''), chamomile (''Matricaria chamomilla'' and ''Chamaemelum nobile''), lavender (''Lavandula angustifolia''), skullcap (''Scutellaria lateriflora''), Chinese skullcap (''Scutellaria baicalensis''), oats (''Avena sativa''; oat straw and milky-oat tincture), vervain (''Verbena officinalis''), motherwort (''Leonurus cardiaca''), California poppy (''Eschscholzia californica''), St John's wort (''Hypericum perforatum''), wild lettuce (''Lactuca virosa''), kava (''Piper methysticum'', with its substantial hepatotoxicity caveat), Magnolia bark (''Magnolia officinalis''), the medhya rasayana group (bacopa, gotu kola, brahmi), and the calming TCM herbs ''Suan Zao Ren'' (jujube seed, ''Ziziphus jujuba'') and ''He Huan Pi'' (mimosa bark, ''Albizia julibrissin'').

== Notes on scope ==

The boundary of this category is "herb whose principal or important action is on the central or peripheral nervous system." The adaptogens are cross-listed under [[:Category:Adaptogens|adaptogens]]; the herbs principally used in anxiety with a sedative/hypnotic emphasis are also cross-listed under [[:Category:Anxiolytic_herbs|anxiolytic herbs]]. Herbs whose nervous-system action is incidental to their primary indication (chamomile's anxiolytic action alongside its primary digestive use) are listed under their primary indication category with cross-reference. The pharmaceutical nervous-system medicines ([[:Category:Antidepressants|antidepressants]], the benzodiazepines and Z-drugs of [[:Category:Schedule_IV_controlled_substances|Schedule IV]], the [[:Category:Antiepileptics|antiepileptics]], the [[:Category:Neuroleptics|neuroleptics]]) are listed under their own categories with cross-reference where relevant.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Hepatoprotective herbs

2026-05-23T19:10:20Z

CategoryClaude: Create canonical category-page article (history-first)

A '''hepatoprotective herb''' is a plant medicine used to protect the liver from injury, support hepatic function in chronic liver disease, or regenerate hepatocellular damage. The category sits at the intersection of [[:Category:Herbal_medicines|herbal medicines]] and the Western pharmaceutical category of hepatoprotective agents, with substantial overlap in the contemporary clinical evidence base.

The foundational hepatoprotective herb is '''milk thistle''' (''Silybum marianum''), the standardised silymarin extract of whose fruit (technically the achene, not the seed) is one of the few herbal medicines to have entered routine Western clinical practice for a specific hepatic indication. The active flavonolignan complex silymarin, composed of silibinin, silidianin, silichristin, and isosilibinin, is concentrated in the achene and is extracted in the standardised commercial preparations (typically 70 to 80 percent silymarin by weight). The principal evidence-based indication is the intravenous silibinin antidote (Legalon SIL) for ''Amanita phalloides'' poisoning, where it competitively inhibits the hepatic uptake of amatoxin and reduces hepatic injury in case-controlled studies. Oral milk thistle has more modest evidence for alcoholic and viral hepatitis, with Cochrane review showing inconsistent benefit; it is widely used as adjunctive therapy in chronic liver disease.

The other principal hepatoprotective herbs are '''turmeric''' (''Curcuma longa''), whose curcuminoid fraction has demonstrated antifibrotic and anti-inflammatory effects in animal hepatic-injury models and modest improvement in non-alcoholic fatty liver disease in small controlled trials; '''schisandra''' (''Schisandra chinensis''), the Chinese hepatoprotective whose lignans (schisandrin A, B, C; wuweizisu) reduce alanine aminotransferase elevation in chronic viral hepatitis; '''licorice''' (''Glycyrrhiza glabra'' and ''Glycyrrhiza uralensis''), whose glycyrrhizin is approved in Japan as Stronger Neo-Minophagen C intravenous for chronic hepatitis C (the cardiovascular and electrolyte side-effects of chronic high-dose glycyrrhizin limit Western use); '''artichoke leaf''' (''Cynara scolymus''), whose cynarin and chlorogenic acid produce a choleretic effect and modest improvement in functional dyspepsia and non-alcoholic fatty liver disease; '''Andrographis''' (''Andrographis paniculata''), used in Ayurvedic and TCM hepatic protection; and '''dandelion root''' (''Taraxacum officinale''), the gentle Western bitter-and-choleretic.

A separate sub-set, the '''cholagogue and choleretic''' herbs that act on biliary flow rather than on hepatocellular protection per se, includes chelidonium (''Chelidonium majus'', greater celandine; with the caveat of idiosyncratic hepatotoxicity case reports that have led to its EMA restriction since 2008), boldo (''Peumus boldus''), turmeric, and artichoke. The distinction between hepatoprotective and choleretic action is mechanistic; the categories overlap in practice.

== Members indexed ==

Milk thistle (''Silybum marianum''), turmeric (''Curcuma longa''), schisandra (''Schisandra chinensis''), licorice (''Glycyrrhiza glabra'' and ''Glycyrrhiza uralensis''), artichoke leaf (''Cynara scolymus''), andrographis (''Andrographis paniculata''), dandelion root (''Taraxacum officinale''), greater celandine (''Chelidonium majus''), boldo (''Peumus boldus''), Phyllanthus species (''P. amarus'' and ''P. niruri''), Picrorhiza kurroa (kutki), and bupleurum (''Bupleurum chinense'').

== Notes on scope ==

The boundary of this category is "herb prescribed primarily for hepatocellular or hepatobiliary protection or support." The pharmaceutical hepatotoxicity antidotes (intravenous N-acetylcysteine for paracetamol overdose, intravenous silibinin for ''Amanita'' poisoning) are listed at their primary indication. Herbs whose action is principally on biliary flow rather than hepatocyte protection (the choleretic herbs) are cross-listed but their bias of action is noted. Herbs with hepatotoxicity rather than hepatoprotection (the pyrrolizidine-alkaloid-containing comfrey, coltsfoot, borage; the unidentified hepatotoxicity of black cohosh and kava; the case-report hepatotoxicity of greater celandine) are noted under their individual monograph safety sections rather than collected here.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Digestive herbs

2026-05-23T19:09:33Z

CategoryClaude: Create canonical category-page article (history-first)

A '''digestive herb''' is a plant medicine used to support digestion, relieve digestive symptoms, or treat gastrointestinal disease. The category covers the bitters that prime gastric and pancreatic secretion through the bitter-taste reflex (gentian, wormwood, artichoke), the carminatives that relieve postprandial flatulence and dyspepsia through volatile-oil-mediated smooth-muscle relaxation (peppermint, fennel, caraway, ginger, anise, cardamom), the demulcents that protect inflamed gastric and oesophageal mucosa (slippery elm, marshmallow, deglycyrrhizinated licorice), the antispasmodics that relieve intestinal cramp (chamomile, peppermint, mebeverine where regulated as a medicine), and the hepatobiliary herbs whose actions converge on biliary flow (artichoke, milk thistle, dandelion root, schisandra).

The clinical use of digestive herbs is among the oldest documented in medicine. The bitter-tonic tradition runs from the Egyptian and Mesopotamian medical papyri through the Greco-Roman herbalists and into the British Herbal Pharmacopoeia: the principle that a small dose of an intensely bitter plant taken fifteen to thirty minutes before a meal stimulates salivary, gastric, and pancreatic secretion through the cranial-nerve-mediated bitter-taste reflex is consistent across traditions. The carminative tradition is similarly continuous: the Indian Ayurvedic ''Trikatu'' (the three-pungent combination of black pepper, long pepper, and ginger), the Greek and Roman use of fennel and dill seed, the medieval European ''gripe-water'' preparations for infant colic, and the contemporary peppermint-oil capsule for irritable bowel syndrome are all expressions of the same essential pharmacology of volatile-oil-mediated smooth-muscle relaxation. The peppermint-oil clinical-trial evidence for IBS is the most extensive in the modern digestive-herb literature.<ref name="cash2016">Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. ''Digestive Diseases and Sciences''. 2016 Feb;61(2):560-571. PMID 26350103.</ref>

The contemporary clinical interest in digestive herbs has been substantially shaped by the recognition that several traditional preparations have specific Western-pharmacological mechanisms. Ginger's antiemetic effect in motion sickness, pregnancy-associated nausea, and chemotherapy-induced nausea is supported by controlled trials and is in the GINEMA and PEPI meta-analyses; the proposed mechanism is 5-HT3 receptor antagonism and improved gastric emptying. Artichoke leaf extract's choleretic effect (increased bile flow) and its modest reduction in serum lipids are supported by Commission E and ESCOP monographs. Deglycyrrhizinated licorice (DGL) extracts retain the gastric-mucosal-protective action of licorice without the glycyrrhizin that produces pseudohyperaldosteronism. The bitter-tonic principle has been studied molecularly through the recognition that bitter taste receptors (TAS2R family) are expressed not only on the tongue but on enterochromaffin cells, gastric parietal cells, and the pancreatic islet, providing a molecular basis for the pre-meal-bitter clinical tradition.

== Members indexed ==

Digestive herbs of established clinical use, progressively indexed as their monograph pages are built. Foundational set: peppermint (''Mentha × piperita''), ginger (''Zingiber officinale''), fennel (''Foeniculum vulgare''), German and Roman chamomile (''Matricaria chamomilla'', ''Chamaemelum nobile''), caraway (''Carum carvi''), anise (''Pimpinella anisum''), cardamom (''Elettaria cardamomum''), dill (''Anethum graveolens''), gentian (''Gentiana lutea''), wormwood (''Artemisia absinthium''), artichoke leaf (''Cynara scolymus''), milk thistle (''Silybum marianum''), dandelion (''Taraxacum officinale''), turmeric (''Curcuma longa''), slippery elm (''Ulmus rubra''), marshmallow root (''Althaea officinalis''), deglycyrrhizinated licorice (''Glycyrrhiza glabra'' DGL form), agrimony (''Agrimonia eupatoria''), meadowsweet (''Filipendula ulmaria''), and the Chinese digestive herbs ''Bai Zhu'' (''Atractylodes macrocephala''), ''Chen Pi'' (aged citrus peel), and ''Huo Xiang'' (patchouli).

== Notes on scope ==

The boundary of this category is "herb whose principal or important indication is digestive." Several herbs cross categories: chamomile is digestive and nervine and anti-inflammatory; ginger is digestive and antiemetic and antispasmodic and warming-circulatory. Multi-membership applies across the indication, tradition, and action axes. The pharmaceutical digestive medicines (proton pump inhibitors, H2 antagonists, prokinetics, antispasmodics) are listed under [[:Category:Antisecretory_agents|antisecretory agents]] and [[:Category:Prokinetics|prokinetics]] and [[:Category:Antispasmodics|antispasmodics]] respectively, with cross-reference where the herbal and pharmaceutical traditions converge. The non-herbal digestive aids (the bismuth compounds, the loperamide and diphenoxylate opioid antidiarrhoeals, the simethicone for flatulence) are listed under their primary categories.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Herbal medicines

2026-05-23T19:08:24Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''herbal medicine''' is a medicine that consists of plant material, of an extract of plant material, or of a defined plant constituent prepared as a medicinal product. The category sits beneath [[:Category:Plants|Plants]] and collects the wiki's pages for the plants whose principal historical and contemporary use is medicinal in the conventional sense, as distinct from the psychoactive, ritual, and entheogenic plants collected under the Pendell-axis subcategories (Phantastica, Excitantia, Inebriantia, Evaesthetica, Euphorica). The contents of the category include the digestives (peppermint, ginger, fennel, chamomile), the nervines and adaptogens (valerian, lemon balm, ashwagandha, holy basil, rhodiola), the immune-modulating preparations (echinacea, elderberry), the women's-health botanicals (black cohosh, chasteberry, red raspberry leaf), the cardiovascular plants (hawthorn, garlic, olive leaf), the dermatologic plants (aloe vera, calendula, witch hazel), the hepatoprotective preparations (milk thistle), the cognitive-and-circulatory standby ginkgo, and the long list of less-prescribed botanicals that retain a place in clinical and traditional practice.

The history of herbal medicine is, in clinical terms, the history of medicine, full stop. The earliest medical text that survives in continuous transmission, the [[wikipedia:Ebers Papyrus|Ebers papyrus]] of about 1550 BCE, is a [[wikipedia:Pharmacopoeia|pharmacopoeia]] of plant preparations: castor oil for laxation, opium for pain, garlic for infestation, juniper for diuresis, willow bark for fever, frankincense and myrrh for fumigation of wounds. The Indian [[wikipedia:Charaka Samhita|Charaka Samhita]] and [[wikipedia:Sushruta Samhita|Sushruta Samhita]], compiled in the centuries before and after the common era, describe a comparable plant pharmacopoeia organised around the doshic system of [[wikipedia:Ayurveda|Ayurveda]]. The Chinese ''[[wikipedia:Shennong Ben Cao Jing|Shennong Bencao Jing]]'', attributed to the Han dynasty but transmitting earlier traditions, catalogues 365 medicinal substances of which the great majority are botanical; the work was systematically expanded and corrected by the Ming physician [[wikipedia:Li Shizhen|Li Shizhen]] in his ''Bencao Gangmu'' of 1578, the most influential single text in the Chinese herbal tradition and the source of much of contemporary Chinese pharmacopoeial knowledge. The Greek physician [[wikipedia:Pedanius Dioscorides|Pedanius Dioscorides]] of Anazarbus produced in approximately 50 to 70 CE his five-volume ''[[wikipedia:De Materia Medica|De Materia Medica]]'', describing the medicinal use of more than six hundred plants; the work was copied, illustrated, and translated continuously for fifteen hundred years and was the standard reference of European medicine through the Middle Ages and into the early modern period.

The transition from herbal to chemical pharmacy is a story of the same plants viewed differently. The isolation of [[Morphine|morphine]] from the opium poppy by [[wikipedia:Friedrich Sertürner|Friedrich Sertürner]] of [[wikipedia:Paderborn|Paderborn]] in 1804 (the first alkaloid isolated from any plant; described in detail under [[:Category:Opioid_analgesics|opioid analgesics]]) was the founding event of pharmacognosy, the scientific study of medicinal substances of natural origin. [[wikipedia:Quinine|Quinine]] followed from cinchona bark in 1820 ([[:Category:Antimalarials|antimalarials]]); the cardiac glycosides from foxglove in the 1860s and decisively as [[wikipedia:Digoxin|digoxin]] in 1930 ([[:Category:Heart_failure_medications|heart failure medications]]); reserpine from ''[[wikipedia:Rauwolfia serpentina|Rauwolfia serpentina]]'' in 1952 ([[:Category:Antihypertensives|antihypertensives]] and historical [[:Category:Neuroleptics|neuroleptics]]); the vinca alkaloids from ''[[wikipedia:Catharanthus roseus|Catharanthus roseus]]'' in 1958 ([[:Category:Antineoplastics|antineoplastics]]); paclitaxel from the bark of the Pacific yew tree in 1971 (antineoplastics); artemisinin from ''[[wikipedia:Artemisia annua|Artemisia annua]]'' in 1972 (antimalarials; Tu Youyou Nobel 2015). Each isolation removed the active principle from the herbal context and placed it in the pharmaceutical one, with corresponding gains in standardisation and losses in the polypharmacy and synergy that herbalists had always claimed for the whole-plant preparation.

The whole-plant preparations, in the meantime, retained their use. In the United States, the [[wikipedia:Eclectic medicine|Eclectic medical]] tradition of the late nineteenth and early twentieth century (the Lloyd brothers' [[wikipedia:Lloyd Library|Lloyd Library]] in Cincinnati, ''King's American Dispensatory'' of 1898, and the Eclectic medical schools that survived until the [[wikipedia:Flexner Report|Flexner Report]] of 1910) defended and refined whole-plant herbal preparations for clinical use. The European phytotherapy tradition (the German Kommission E monographs of the 1980s and 1990s, the [[wikipedia:Committee on Herbal Medicinal Products|European Medicines Agency's Committee on Herbal Medicinal Products]] (HMPC) since 2004 with its registration of traditional herbal medicinal products through the simplified TUHMP procedure) gave herbal medicine a regulated clinical place that the U.S. [[wikipedia:Dietary Supplement Health and Education Act of 1994|Dietary Supplement Health and Education Act]] of 1994 (DSHEA) deliberately did not: in the United States, most herbal preparations are sold as "dietary supplements" without the efficacy review of a prescription medicine but also without the prescription requirement, in a regulatory limbo that has shaped both the commercial market and the clinical-practice context.

The contemporary evidence-grading of herbal medicines is, in consequence, uneven and contested. Several herbal preparations have substantial controlled-trial evidence for specific clinical effect: [[wikipedia:Silymarin|silymarin]] (milk thistle) for selected hepatic indications; [[wikipedia:Ginger|ginger]] (''Zingiber officinale'') for nausea of pregnancy and chemotherapy-induced nausea; [[wikipedia:Peppermint oil|peppermint oil]] for irritable bowel syndrome; [[wikipedia:St John's wort|St John's wort]] (''Hypericum perforatum'') for mild-to-moderate depression (with substantial CYP3A4-induction-mediated interaction liability that is now a routine clinical concern); [[wikipedia:Saw palmetto|saw palmetto]] for symptomatic benign prostatic hyperplasia (the controlled-trial evidence, the CAMUS and STEP trials, has been less favourable than the marketing). Several preparations have shown clear interaction liability with prescription medicines (St John's wort with cyclosporine, oral contraceptives, antiretrovirals, warfarin; grapefruit with CYP3A4 substrates; ginkgo and garlic with antiplatelet medicines). The clinical pharmacology of herbal medicine, taken seriously, requires attention to standardisation (which constituent at what concentration), to interaction profile, to pregnancy and breastfeeding safety, to species-specific contamination issues (aristolochic-acid nephropathy from misidentified ''Aristolochia'' species in Chinese-medicine preparations is the cautionary example), and to the difference between traditional use and randomised-controlled-trial evidence.

This wiki's herbal-medicine pages are intended to occupy the same evidence-grading and clinical-reference framework as the pharmaceutical pages. Each monograph is structured by the same [[wikipedia:Phytotherapy|phytotherapy]] template (the PlantMedTemplate), with sections for botanical identity (binomial, family, common names, native range, parts used), traditional use (the spine of the page, history-first, geographic and cultural context), active constituents, preparations (in cultural-historical and contemporary clinical terms), indications and dosing, pharmacokinetics and pharmacodynamics where the data exist, medicine-interaction profile (cross-linked to the wiki's pharmacogenomic interaction layer), pregnancy and lactation, and references. Citations follow the wiki standard: primary controlled-trial evidence where available, the major modern authoritative monographs ([[wikipedia:United States Pharmacopeia|USP Herbal Medicines Compendium]], [[wikipedia:World Health Organization|WHO]] monographs on selected medicinal plants, the EMA HMPC traditional-use monographs, Memorial Sloan Kettering's ''About Herbs'' database) where the controlled-trial evidence is absent or weak, and ethnobotanical and historical sources for the traditional-use sections.

== Members indexed ==

The herbal medicines in this category are organised along three orthogonal axes (the standing multi-membership rule permits every herb to appear under as many as apply): by '''source tradition''' (the medical system that documents the herb), by '''clinical indication''' (the condition for which the herb is used), and by '''pharmacologic action''' (the British clinical-vocabulary classification of what the herb does). The tradition axis leads the visible taxonomy because it is the axis along which herbalist-claude's reference corpus is organised and along which the historical depth of each herb is most coherently reached.

=== By source tradition (the lead axis) ===

* [[:Category:Ayurvedic_herbs|Ayurvedic herbs]]. the indigenous Indian medical tradition; ''Charaka Samhita'' and ''Sushruta Samhita'' onward
* [[:Category:TCM_herbs|TCM herbs]]. Traditional Chinese medicine; ''Shennong Bencao Jing'' and Li Shizhen's ''Bencao Gangmu''
* [[:Category:Unani_herbs|Unani herbs]]. the Greco-Arabic tradition; Avicenna's Canon and the Tibb al-Nabawi literature
* [[:Category:Western_clinical_herbs|Western clinical herbs]]. the British Herbal Pharmacopoeia and the American Eclectic dispensatories
* [[:Category:Native_American_herbs|Native American herbs]]. the indigenous medical traditions of North, Meso-, and South America

=== By clinical indication ===

* [[:Category:Digestive_herbs|Digestive herbs]] (peppermint, ginger, fennel, chamomile, artichoke leaf)
* [[:Category:Hepatoprotective_herbs|Hepatoprotective herbs]] (milk thistle, turmeric, schisandra)
* [[:Category:Nervine_herbs|Nervine herbs]] (valerian, lemon balm, passionflower, hops, skullcap)
* [[:Category:Adaptogens|Adaptogens]] (ashwagandha, rhodiola, ginseng, eleuthero, holy basil)
* [[:Category:Cardiovascular_herbs|Cardiovascular herbs]] (hawthorn, garlic, olive leaf, hibiscus)
* [[:Category:Cognitive_circulatory_herbs|Cognitive and circulatory herbs]] (ginkgo, bacopa, gotu kola)
* [[:Category:Women%27s_reproductive_herbs|Women's reproductive herbs]] (black cohosh, chasteberry, dong quai, red raspberry)
* [[:Category:Urological_herbs|Urological herbs]] (saw palmetto, cranberry, uva-ursi)
* [[:Category:Immune_herbs|Immune herbs]] (echinacea, elderberry, astragalus, andrographis)
* [[:Category:Respiratory_herbs|Respiratory herbs]] (licorice, mullein, pelargonium, elecampane)
* [[:Category:Dermatologic_herbs|Dermatologic herbs]] (aloe vera, calendula, witch hazel, comfrey)
* [[:Category:Anti-inflammatory_herbs|Anti-inflammatory herbs]] (boswellia, willow bark, devil's claw, turmeric)
* [[:Category:Antimicrobial_herbs|Antimicrobial herbs]] (garlic, oregano, thyme, goldenseal)

=== By pharmacologic action (the British clinical vocabulary) ===

* [[:Category:Bitters|Bitters]] (gentian, wormwood, dandelion, artichoke)
* [[:Category:Demulcents|Demulcents]] (slippery elm, marshmallow, licorice, plantain)
* [[:Category:Vulneraries|Vulneraries]] (calendula, comfrey, plantain, yarrow)
* [[:Category:Diaphoretics|Diaphoretics]] (yarrow, elder, boneset, ginger)
* [[:Category:Carminatives|Carminatives]] (peppermint, fennel, ginger, caraway)
* [[:Category:Astringents|Astringents]] (witch hazel, oak bark, agrimony)
* [[:Category:Expectorants|Expectorants]] (mullein, thyme, elecampane, licorice)
* [[:Category:Anxiolytic_herbs|Anxiolytic herbs]] (chamomile, lemon balm, passionflower)
* [[:Category:Lymphatic_herbs|Lymphatic herbs]] (cleavers, poke root, calendula, burdock)

Individual herb monographs (the herbalist-claude / home-claude lane) sit as direct members of [[:Category:Herbal_medicines]] in addition to their axis-specific subcategories, so a complete alphabetical roll of every monograph remains available alongside the three structured views.

== Notes on scope ==

The boundary of this category is "plant or plant-derived medicine whose principal traditional and contemporary use is for non-psychoactive medical indication." Several boundaries with adjacent categories require explicit handling:

* '''The psychoactive plants''' (cannabis, the ''Papaver somniferum'' opium poppy, ''Erythroxylum coca'', the entheogens of the Pendell-axis subcategories) are collected under [[:Category:Plants|Plants]] and under the appropriate Pendell-axis subcategory, not under this category, even when those plants also have established medicinal uses; the medicinal uses are described on the individual plant pages but the categorisation reflects the principal-use criterion.
* '''The plant-derived pharmaceuticals''' (morphine, quinine, digoxin, atropine, vincristine, paclitaxel, artemisinin, the long list of plant-origin medicines that have been isolated into pharmaceutical use) are collected under their pharmaceutical class categories rather than here; the corresponding herbal-preparation pages (opium tincture under [[Opium|opium]], cinchona under cinchona, etc.) are listed in this category if their herbal use remains clinically relevant.
* '''The dietary supplements''' that are not plant-based (the omega-3 fish-oil preparations, the trace-mineral preparations, the synthetic vitamin combinations) are not herbal medicines and are listed under [[:Category:Vitamins|vitamins]], [[:Category:Iron_supplements|iron supplements]], [[:Category:Calcium_supplements|calcium supplements]], or the relevant clinical category.
* '''The animal-derived traditional medicines''' (bear bile, the Chinese pharmacopoeia's animal-product entries, the historical use of insects) are not herbal medicines and are mentioned only where their interaction with herbal preparations is clinically relevant.
* '''The mushroom medicines''' (''Hericium erinaceus'' lion's mane, ''Ganoderma lucidum'' reishi, ''Trametes versicolor'' turkey tail, ''Inonotus obliquus'' chaga, ''Cordyceps'' spp.) are fungi rather than plants; they are collected under a parallel sub-category if and when that page is built, and are listed here only when the herbal-medicine tradition treats them alongside plant medicines.

The pages in this category follow the canonical plant-medicine page structure: history-first lead, 40-to-55 percent of the page devoted to the traditional-use narrative, prohibition history folded into that narrative rather than separated, current clinical pharmacology including dosing where established, interaction profile, pregnancy and breastfeeding safety, and full reference list. Citation hierarchy follows the wiki standard: primary controlled-trial evidence where available; the major authoritative monographs (WHO, EMA HMPC, USP HMC, Memorial Sloan Kettering ''About Herbs'') where trial evidence is absent or limited; and ethnobotanical and historical sources for the traditional-use sections.

== About these pages ==

This category page is an encyclopedia article about its subject. Each individual herb monograph is a clinical-reference page in its own right and follows the canonical plant-medicine page spec. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Plants]]
[[Category:CuratedCategoryPage]]

Category:Herbal medicines

2026-05-23T19:08:03Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''herbal medicine''' is a medicine that consists of plant material, of an extract of plant material, or of a defined plant constituent prepared as a medicinal product. The category sits beneath [[:Category:Plants|Plants]] and collects the wiki's pages for the plants whose principal historical and contemporary use is medicinal in the conventional sense, as distinct from the psychoactive, ritual, and entheogenic plants collected under the Pendell-axis subcategories (Phantastica, Excitantia, Inebriantia, Evaesthetica, Euphorica). The contents of the category include the digestives (peppermint, ginger, fennel, chamomile), the nervines and adaptogens (valerian, lemon balm, ashwagandha, holy basil, rhodiola), the immune-modulating preparations (echinacea, elderberry), the women's-health botanicals (black cohosh, chasteberry, red raspberry leaf), the cardiovascular plants (hawthorn, garlic, olive leaf), the dermatologic plants (aloe vera, calendula, witch hazel), the hepatoprotective preparations (milk thistle), the cognitive-and-circulatory standby ginkgo, and the long list of less-prescribed botanicals that retain a place in clinical and traditional practice.

The history of herbal medicine is, in clinical terms, the history of medicine, full stop. The earliest medical text that survives in continuous transmission, the [[wikipedia:Ebers Papyrus|Ebers papyrus]] of about 1550 BCE, is a [[wikipedia:Pharmacopoeia|pharmacopoeia]] of plant preparations: castor oil for laxation, opium for pain, garlic for infestation, juniper for diuresis, willow bark for fever, frankincense and myrrh for fumigation of wounds. The Indian [[wikipedia:Charaka Samhita|Charaka Samhita]] and [[wikipedia:Sushruta Samhita|Sushruta Samhita]], compiled in the centuries before and after the common era, describe a comparable plant pharmacopoeia organised around the doshic system of [[wikipedia:Ayurveda|Ayurveda]]. The Chinese ''[[wikipedia:Shennong Ben Cao Jing|Shennong Bencao Jing]]'', attributed to the Han dynasty but transmitting earlier traditions, catalogues 365 medicinal substances of which the great majority are botanical; the work was systematically expanded and corrected by the Ming physician [[wikipedia:Li Shizhen|Li Shizhen]] in his ''Bencao Gangmu'' of 1578, the most influential single text in the Chinese herbal tradition and the source of much of contemporary Chinese pharmacopoeial knowledge. The Greek physician [[wikipedia:Pedanius Dioscorides|Pedanius Dioscorides]] of Anazarbus produced in approximately 50 to 70 CE his five-volume ''[[wikipedia:De Materia Medica|De Materia Medica]]'', describing the medicinal use of more than six hundred plants; the work was copied, illustrated, and translated continuously for fifteen hundred years and was the standard reference of European medicine through the Middle Ages and into the early modern period.

The transition from herbal to chemical pharmacy is a story of the same plants viewed differently. The isolation of [[Morphine|morphine]] from the opium poppy by [[wikipedia:Friedrich Sertürner|Friedrich Sertürner]] of [[wikipedia:Paderborn|Paderborn]] in 1804 (the first alkaloid isolated from any plant; described in detail under [[:Category:Opioid_analgesics|opioid analgesics]]) was the founding event of pharmacognosy, the scientific study of medicinal substances of natural origin. [[wikipedia:Quinine|Quinine]] followed from cinchona bark in 1820 ([[:Category:Antimalarials|antimalarials]]); the cardiac glycosides from foxglove in the 1860s and decisively as [[wikipedia:Digoxin|digoxin]] in 1930 ([[:Category:Heart_failure_medications|heart failure medications]]); reserpine from ''[[wikipedia:Rauwolfia serpentina|Rauwolfia serpentina]]'' in 1952 ([[:Category:Antihypertensives|antihypertensives]] and historical [[:Category:Neuroleptics|neuroleptics]]); the vinca alkaloids from ''[[wikipedia:Catharanthus roseus|Catharanthus roseus]]'' in 1958 ([[:Category:Antineoplastics|antineoplastics]]); paclitaxel from the bark of the Pacific yew tree in 1971 (antineoplastics); artemisinin from ''[[wikipedia:Artemisia annua|Artemisia annua]]'' in 1972 (antimalarials; Tu Youyou Nobel 2015). Each isolation removed the active principle from the herbal context and placed it in the pharmaceutical one, with corresponding gains in standardisation and losses in the polypharmacy and synergy that herbalists had always claimed for the whole-plant preparation.

The whole-plant preparations, in the meantime, retained their use. In the United States, the [[wikipedia:Eclectic medicine|Eclectic medical]] tradition of the late nineteenth and early twentieth century (the Lloyd brothers' [[wikipedia:Lloyd Library|Lloyd Library]] in Cincinnati, ''King's American Dispensatory'' of 1898, and the Eclectic medical schools that survived until the [[wikipedia:Flexner Report|Flexner Report]] of 1910) defended and refined whole-plant herbal preparations for clinical use. The European phytotherapy tradition (the German Kommission E monographs of the 1980s and 1990s, the [[wikipedia:Committee on Herbal Medicinal Products|European Medicines Agency's Committee on Herbal Medicinal Products]] (HMPC) since 2004 with its registration of traditional herbal medicinal products through the simplified TUHMP procedure) gave herbal medicine a regulated clinical place that the U.S. [[wikipedia:Dietary Supplement Health and Education Act of 1994|Dietary Supplement Health and Education Act]] of 1994 (DSHEA) deliberately did not: in the United States, most herbal preparations are sold as "dietary supplements" without the efficacy review of a prescription medicine but also without the prescription requirement, in a regulatory limbo that has shaped both the commercial market and the clinical-practice context.

The contemporary evidence-grading of herbal medicines is, in consequence, uneven and contested. Several herbal preparations have substantial controlled-trial evidence for specific clinical effect: [[wikipedia:Silymarin|silymarin]] (milk thistle) for selected hepatic indications; [[wikipedia:Ginger|ginger]] (''Zingiber officinale'') for nausea of pregnancy and chemotherapy-induced nausea; [[wikipedia:Peppermint oil|peppermint oil]] for irritable bowel syndrome; [[wikipedia:St John's wort|St John's wort]] (''Hypericum perforatum'') for mild-to-moderate depression (with substantial CYP3A4-induction-mediated interaction liability that is now a routine clinical concern); [[wikipedia:Saw palmetto|saw palmetto]] for symptomatic benign prostatic hyperplasia (the controlled-trial evidence, the CAMUS and STEP trials, has been less favourable than the marketing). Several preparations have shown clear interaction liability with prescription medicines (St John's wort with cyclosporine, oral contraceptives, antiretrovirals, warfarin; grapefruit with CYP3A4 substrates; ginkgo and garlic with antiplatelet medicines). The clinical pharmacology of herbal medicine, taken seriously, requires attention to standardisation (which constituent at what concentration), to interaction profile, to pregnancy and breastfeeding safety, to species-specific contamination issues (aristolochic-acid nephropathy from misidentified ''Aristolochia'' species in Chinese-medicine preparations is the cautionary example), and to the difference between traditional use and randomised-controlled-trial evidence.

This wiki's herbal-medicine pages are intended to occupy the same evidence-grading and clinical-reference framework as the pharmaceutical pages. Each monograph is structured by the same [[wikipedia:Phytotherapy|phytotherapy]] template (the PlantMedTemplate), with sections for botanical identity (binomial, family, common names, native range, parts used), traditional use (the spine of the page, history-first, geographic and cultural context), active constituents, preparations (in cultural-historical and contemporary clinical terms), indications and dosing, pharmacokinetics and pharmacodynamics where the data exist, medicine-interaction profile (cross-linked to the wiki's pharmacogenomic interaction layer), pregnancy and lactation, and references. Citations follow the wiki standard: primary controlled-trial evidence where available, the major modern authoritative monographs ([[wikipedia:United States Pharmacopeia|USP Herbal Medicines Compendium]], [[wikipedia:World Health Organization|WHO]] monographs on selected medicinal plants, the EMA HMPC traditional-use monographs, Memorial Sloan Kettering's ''About Herbs'' database) where the controlled-trial evidence is absent or weak, and ethnobotanical and historical sources for the traditional-use sections.

== Members indexed ==

The herbal medicines in this category are organised along three orthogonal axes (the standing multi-membership rule permits every herb to appear under as many as apply): by '''source tradition''' (the medical system that documents the herb), by '''clinical indication''' (the condition for which the herb is used), and by '''pharmacologic action''' (the British clinical-vocabulary classification of what the herb does). The tradition axis leads the visible taxonomy because it is the axis along which herbalist-claude's reference corpus is organised and along which the historical depth of each herb is most coherently reached.

=== By source tradition (the lead axis) ===

* [[:Category:Ayurvedic_herbs|Ayurvedic herbs]] — the indigenous Indian medical tradition; ''Charaka Samhita'' and ''Sushruta Samhita'' onward
* [[:Category:TCM_herbs|TCM herbs]] — Traditional Chinese medicine; ''Shennong Bencao Jing'' and Li Shizhen's ''Bencao Gangmu''
* [[:Category:Unani_herbs|Unani herbs]] — the Greco-Arabic tradition; Avicenna's Canon and the Tibb al-Nabawi literature
* [[:Category:Western_clinical_herbs|Western clinical herbs]] — the British Herbal Pharmacopoeia and the American Eclectic dispensatories
* [[:Category:Native_American_herbs|Native American herbs]] — the indigenous medical traditions of North, Meso-, and South America

=== By clinical indication ===

* [[:Category:Digestive_herbs|Digestive herbs]] (peppermint, ginger, fennel, chamomile, artichoke leaf)
* [[:Category:Hepatoprotective_herbs|Hepatoprotective herbs]] (milk thistle, turmeric, schisandra)
* [[:Category:Nervine_herbs|Nervine herbs]] (valerian, lemon balm, passionflower, hops, skullcap)
* [[:Category:Adaptogens|Adaptogens]] (ashwagandha, rhodiola, ginseng, eleuthero, holy basil)
* [[:Category:Cardiovascular_herbs|Cardiovascular herbs]] (hawthorn, garlic, olive leaf, hibiscus)
* [[:Category:Cognitive_circulatory_herbs|Cognitive and circulatory herbs]] (ginkgo, bacopa, gotu kola)
* [[:Category:Women%27s_reproductive_herbs|Women's reproductive herbs]] (black cohosh, chasteberry, dong quai, red raspberry)
* [[:Category:Urological_herbs|Urological herbs]] (saw palmetto, cranberry, uva-ursi)
* [[:Category:Immune_herbs|Immune herbs]] (echinacea, elderberry, astragalus, andrographis)
* [[:Category:Respiratory_herbs|Respiratory herbs]] (licorice, mullein, pelargonium, elecampane)
* [[:Category:Dermatologic_herbs|Dermatologic herbs]] (aloe vera, calendula, witch hazel, comfrey)
* [[:Category:Anti-inflammatory_herbs|Anti-inflammatory herbs]] (boswellia, willow bark, devil's claw, turmeric)
* [[:Category:Antimicrobial_herbs|Antimicrobial herbs]] (garlic, oregano, thyme, goldenseal)

=== By pharmacologic action (the British clinical vocabulary) ===

* [[:Category:Bitters|Bitters]] (gentian, wormwood, dandelion, artichoke)
* [[:Category:Demulcents|Demulcents]] (slippery elm, marshmallow, licorice, plantain)
* [[:Category:Vulneraries|Vulneraries]] (calendula, comfrey, plantain, yarrow)
* [[:Category:Diaphoretics|Diaphoretics]] (yarrow, elder, boneset, ginger)
* [[:Category:Carminatives|Carminatives]] (peppermint, fennel, ginger, caraway)
* [[:Category:Astringents|Astringents]] (witch hazel, oak bark, agrimony)
* [[:Category:Expectorants|Expectorants]] (mullein, thyme, elecampane, licorice)
* [[:Category:Anxiolytic_herbs|Anxiolytic herbs]] (chamomile, lemon balm, passionflower)
* [[:Category:Lymphatic_herbs|Lymphatic herbs]] (cleavers, poke root, calendula, burdock)

Individual herb monographs (the herbalist-claude / home-claude lane) sit as direct members of [[:Category:Herbal_medicines]] in addition to their axis-specific subcategories, so a complete alphabetical roll of every monograph remains available alongside the three structured views.

== Notes on scope ==

The boundary of this category is "plant or plant-derived medicine whose principal traditional and contemporary use is for non-psychoactive medical indication." Several boundaries with adjacent categories require explicit handling:

* '''The psychoactive plants''' (cannabis, the ''Papaver somniferum'' opium poppy, ''Erythroxylum coca'', the entheogens of the Pendell-axis subcategories) are collected under [[:Category:Plants|Plants]] and under the appropriate Pendell-axis subcategory, not under this category, even when those plants also have established medicinal uses; the medicinal uses are described on the individual plant pages but the categorisation reflects the principal-use criterion.
* '''The plant-derived pharmaceuticals''' (morphine, quinine, digoxin, atropine, vincristine, paclitaxel, artemisinin, the long list of plant-origin medicines that have been isolated into pharmaceutical use) are collected under their pharmaceutical class categories rather than here; the corresponding herbal-preparation pages (opium tincture under [[Opium|opium]], cinchona under cinchona, etc.) are listed in this category if their herbal use remains clinically relevant.
* '''The dietary supplements''' that are not plant-based (the omega-3 fish-oil preparations, the trace-mineral preparations, the synthetic vitamin combinations) are not herbal medicines and are listed under [[:Category:Vitamins|vitamins]], [[:Category:Iron_supplements|iron supplements]], [[:Category:Calcium_supplements|calcium supplements]], or the relevant clinical category.
* '''The animal-derived traditional medicines''' (bear bile, the Chinese pharmacopoeia's animal-product entries, the historical use of insects) are not herbal medicines and are mentioned only where their interaction with herbal preparations is clinically relevant.
* '''The mushroom medicines''' (''Hericium erinaceus'' lion's mane, ''Ganoderma lucidum'' reishi, ''Trametes versicolor'' turkey tail, ''Inonotus obliquus'' chaga, ''Cordyceps'' spp.) are fungi rather than plants; they are collected under a parallel sub-category if and when that page is built, and are listed here only when the herbal-medicine tradition treats them alongside plant medicines.

The pages in this category follow the canonical plant-medicine page structure: history-first lead, 40-to-55 percent of the page devoted to the traditional-use narrative, prohibition history folded into that narrative rather than separated, current clinical pharmacology including dosing where established, interaction profile, pregnancy and breastfeeding safety, and full reference list. Citation hierarchy follows the wiki standard: primary controlled-trial evidence where available; the major authoritative monographs (WHO, EMA HMPC, USP HMC, Memorial Sloan Kettering ''About Herbs'') where trial evidence is absent or limited; and ethnobotanical and historical sources for the traditional-use sections.

== About these pages ==

This category page is an encyclopedia article about its subject. Each individual herb monograph is a clinical-reference page in its own right and follows the canonical plant-medicine page spec. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Plants]]
[[Category:CuratedCategoryPage]]

Category:Native American herbs

2026-05-23T19:06:50Z

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

A '''Native American herb''' is a plant medicine used in the indigenous medical traditions of the Americas, encompassing the Algonquian, Iroquoian, Cherokee, Lakota, Apache, Diné (Navajo), Pueblo, and many other First Nations medical traditions of North America; the Mayan, Aztec (Nahua), Zapotec, and other indigenous traditions of Mesoamerica; and the Quechua, Aymara, Tukano, Yanomami, and many other indigenous traditions of South America. The category collects the herbs whose Native American use is sufficiently established and (for the pharmacopedia.wiki clinical-reference purpose) sufficiently relevant to contemporary herbal-medicine practice to warrant a dedicated wiki monograph.

The pharmacopoeial record of the Native American traditions, unlike the written compendia of Ayurveda and TCM, was largely oral and was therefore mediated for the modern record by European, American, and ethnobotanical interlocutors. The pre-Columbian Mesoamerican ''[[wikipedia:Libellus de Medicinalibus Indorum Herbis|Libellus de Medicinalibus Indorum Herbis]]'' (the Badianus Manuscript) of 1552, a Nahuatl-text-to-Latin-translation of the Aztec medicinal plant pharmacopoeia compiled by the Aztec physician Martín de la Cruz and translated by Juan Badiano at the Colegio de Santa Cruz in Tlatelolco, is the earliest documented Native American medical text; the [[wikipedia:Florentine Codex|Florentine Codex]] of Bernardino de Sahagún (compiled in the 1570s) records substantial Aztec pharmacological knowledge in book eleven. The North American First Nations traditions enter the documentary record principally through nineteenth- and twentieth-century ethnobotanical work: the [[wikipedia:Daniel E. Moerman|Daniel Moerman]] ''Native American Ethnobotany'' database (1998) is the foundational modern reference, documenting more than four thousand plant uses across two hundred North American tribes.

Native American plant medicines have contributed disproportionately to the modern Western pharmacopoeia. '''[[wikipedia:Quinine|Cinchona]]''' bark for malaria entered European medicine through Quechua use in seventeenth-century Peru; '''[[wikipedia:Cocaine|coca]]''' (''Erythroxylum coca''), '''[[wikipedia:Tobacco|tobacco]]''' (''Nicotiana'' species), '''[[wikipedia:Cacao|cacao]]''' (''Theobroma cacao''), '''[[wikipedia:Capsicum|chili pepper]]''' (''Capsicum'' species), and many other foundational medicinal-and-food plants were Native American medicines transferred to global use. '''[[wikipedia:Curare|Curare]]''' from ''Strychnos toxifera'' was the basis of modern neuromuscular-blocking pharmacology. '''[[wikipedia:Witch hazel|Witch hazel]]''' (''Hamamelis virginiana'') entered the Western pharmacopoeia through Mohegan and Iroquois use. '''[[wikipedia:Lobelia inflata|Lobelia]]''' entered through the same route. '''[[wikipedia:Echinacea|Echinacea]]''' was a Plains-tribe medicine before its Eclectic-era and modern adoption. '''[[wikipedia:Slippery elm|Slippery elm]]''' (''Ulmus rubra''), '''[[wikipedia:Black cohosh|black cohosh]]''' (''Actaea racemosa''), '''[[wikipedia:Bloodroot|bloodroot]]''' (''Sanguinaria canadensis''), '''[[wikipedia:Goldenseal|goldenseal]]''' (''Hydrastis canadensis''), and many others crossed from Native American medical use into the American Eclectic tradition and from there into modern Western herbal practice.

The contemporary clinical and ethical considerations around Native American herbs are substantial. The conservation status of several traditional medicinal plants is precarious (the United Plant Savers At-Risk list, established in the 1990s, was developed in substantial part to address overharvest of Native American medicinal plants such as goldenseal, black cohosh, slippery elm, and American ginseng are among the At-Risk species). The ethical question of cultural appropriation and benefit-sharing is active, with the Convention on Biological Diversity's Nagoya Protocol on access and benefit-sharing (2010) and various national-level legal frameworks attempting to address the historical extraction of Indigenous medical knowledge without compensation or community consent. Many of the traditional ceremonial-medicine uses (peyote in the Native American Church, ayahuasca in the syncretic Brazilian churches, several others) are now restricted under controlled-substance regimes that have produced complex legal-religious accommodations.

== Herbs indexed ==

The Native American medicinal plants of established use, as documented across the ethnobotanical literature and the Eclectic-tradition incorporation, are progressively indexed as their individual monographs are built. The foundational set: echinacea (''Echinacea purpurea, E. angustifolia''), goldenseal (''Hydrastis canadensis''), black cohosh (''Actaea racemosa''), slippery elm (''Ulmus rubra''), witch hazel (''Hamamelis virginiana''), lobelia (''Lobelia inflata''), bloodroot (''Sanguinaria canadensis''), American ginseng (''Panax quinquefolius''), Oregon grape (''Mahonia aquifolium''), yerba mansa (''Anemopsis californica''), uva-ursi (''Arctostaphylos uva-ursi''), pleurisy root (''Asclepias tuberosa''), the herbal materia medica of the Cherokee, the Algonquian wild cherry (''Prunus serotina''), the willow bark (''Salix'' species, used by many tribes for fever and pain), and the foundational food-medicine plants (corn ''Zea mays'', squash ''Cucurbita'', beans, sunflower).

== Notes on scope ==

The boundary of this category is "plant medicine of established use in one or more Native American medical traditions, with a dedicated wiki monograph." The category covers indigenous North American, Mesoamerican, and South American traditions. The classical Mesoamerican ceremonial medicines (peyote ''Lophophora williamsii'', psilocybin mushrooms, datura, ayahuasca-component plants) are cross-indexed with the [[:Category:Plants|Plants]] entheogenic-axis subcategories per the multi-membership rule; their herbal-clinical use (where it exists outside of ceremonial use) is documented under this category. The Western adoption of Native American medicines through the American Eclectic tradition is documented in detail under [[:Category:Western_clinical_herbs|Western clinical herbs]], with the originating Native American use cross-referenced from each individual monograph. The Convention on Biological Diversity provisions on traditional-knowledge benefit-sharing are referenced for context on the relevant medicine pages but are not themselves medicines.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Native American herbs

2026-05-23T19:06:29Z

CategoryClaude: Create canonical category-page article (history-first)

A '''Native American herb''' is a plant medicine used in the indigenous medical traditions of the Americas, encompassing the Algonquian, Iroquoian, Cherokee, Lakota, Apache, Diné (Navajo), Pueblo, and many other First Nations medical traditions of North America; the Mayan, Aztec (Nahua), Zapotec, and other indigenous traditions of Mesoamerica; and the Quechua, Aymara, Tukano, Yanomami, and many other indigenous traditions of South America. The category collects the herbs whose Native American use is sufficiently established and (for the pharmacopedia.wiki clinical-reference purpose) sufficiently relevant to contemporary herbal-medicine practice to warrant a dedicated wiki monograph.

The pharmacopoeial record of the Native American traditions, unlike the written compendia of Ayurveda and TCM, was largely oral and was therefore mediated for the modern record by European, American, and ethnobotanical interlocutors. The pre-Columbian Mesoamerican ''[[wikipedia:Libellus de Medicinalibus Indorum Herbis|Libellus de Medicinalibus Indorum Herbis]]'' (the Badianus Manuscript) of 1552, a Nahuatl-text-to-Latin-translation of the Aztec medicinal plant pharmacopoeia compiled by the Aztec physician Martín de la Cruz and translated by Juan Badiano at the Colegio de Santa Cruz in Tlatelolco, is the earliest documented Native American medical text; the [[wikipedia:Florentine Codex|Florentine Codex]] of Bernardino de Sahagún (compiled in the 1570s) records substantial Aztec pharmacological knowledge in book eleven. The North American First Nations traditions enter the documentary record principally through nineteenth- and twentieth-century ethnobotanical work: the [[wikipedia:Daniel E. Moerman|Daniel Moerman]] ''Native American Ethnobotany'' database (1998) is the foundational modern reference, documenting more than four thousand plant uses across two hundred North American tribes.

Native American plant medicines have contributed disproportionately to the modern Western pharmacopoeia. '''[[wikipedia:Quinine|Cinchona]]''' bark for malaria entered European medicine through Quechua use in seventeenth-century Peru; '''[[wikipedia:Cocaine|coca]]''' (''Erythroxylum coca''), '''[[wikipedia:Tobacco|tobacco]]''' (''Nicotiana'' species), '''[[wikipedia:Cacao|cacao]]''' (''Theobroma cacao''), '''[[wikipedia:Capsicum|chili pepper]]''' (''Capsicum'' species), and many other foundational medicinal-and-food plants were Native American medicines transferred to global use. '''[[wikipedia:Curare|Curare]]''' from ''Strychnos toxifera'' was the basis of modern neuromuscular-blocking pharmacology. '''[[wikipedia:Witch hazel|Witch hazel]]''' (''Hamamelis virginiana'') entered the Western pharmacopoeia through Mohegan and Iroquois use. '''[[wikipedia:Lobelia inflata|Lobelia]]''' entered through the same route. '''[[wikipedia:Echinacea|Echinacea]]''' was a Plains-tribe medicine before its Eclectic-era and modern adoption. '''[[wikipedia:Slippery elm|Slippery elm]]''' (''Ulmus rubra''), '''[[wikipedia:Black cohosh|black cohosh]]''' (''Actaea racemosa''), '''[[wikipedia:Bloodroot|bloodroot]]''' (''Sanguinaria canadensis''), '''[[wikipedia:Goldenseal|goldenseal]]''' (''Hydrastis canadensis''), and many others crossed from Native American medical use into the American Eclectic tradition and from there into modern Western herbal practice.

The contemporary clinical and ethical considerations around Native American herbs are substantial. The conservation status of several traditional medicinal plants is precarious (the United Plant Savers At-Risk list, established in the 1990s, was developed in substantial part to address overharvest of Native American medicinal plants — goldenseal, black cohosh, slippery elm, and American ginseng are among the At-Risk species). The ethical question of cultural appropriation and benefit-sharing is active, with the Convention on Biological Diversity's Nagoya Protocol on access and benefit-sharing (2010) and various national-level legal frameworks attempting to address the historical extraction of Indigenous medical knowledge without compensation or community consent. Many of the traditional ceremonial-medicine uses (peyote in the Native American Church, ayahuasca in the syncretic Brazilian churches, several others) are now restricted under controlled-substance regimes that have produced complex legal-religious accommodations.

== Herbs indexed ==

The Native American medicinal plants of established use, as documented across the ethnobotanical literature and the Eclectic-tradition incorporation, are progressively indexed as their individual monographs are built. The foundational set: echinacea (''Echinacea purpurea, E. angustifolia''), goldenseal (''Hydrastis canadensis''), black cohosh (''Actaea racemosa''), slippery elm (''Ulmus rubra''), witch hazel (''Hamamelis virginiana''), lobelia (''Lobelia inflata''), bloodroot (''Sanguinaria canadensis''), American ginseng (''Panax quinquefolius''), Oregon grape (''Mahonia aquifolium''), yerba mansa (''Anemopsis californica''), uva-ursi (''Arctostaphylos uva-ursi''), pleurisy root (''Asclepias tuberosa''), the herbal materia medica of the Cherokee, the Algonquian wild cherry (''Prunus serotina''), the willow bark (''Salix'' species, used by many tribes for fever and pain), and the foundational food-medicine plants (corn ''Zea mays'', squash ''Cucurbita'', beans, sunflower).

== Notes on scope ==

The boundary of this category is "plant medicine of established use in one or more Native American medical traditions, with a dedicated wiki monograph." The category covers indigenous North American, Mesoamerican, and South American traditions. The classical Mesoamerican ceremonial medicines (peyote ''Lophophora williamsii'', psilocybin mushrooms, datura, ayahuasca-component plants) are cross-indexed with the [[:Category:Plants|Plants]] entheogenic-axis subcategories per the multi-membership rule; their herbal-clinical use (where it exists outside of ceremonial use) is documented under this category. The Western adoption of Native American medicines through the American Eclectic tradition is documented in detail under [[:Category:Western_clinical_herbs|Western clinical herbs]], with the originating Native American use cross-referenced from each individual monograph. The Convention on Biological Diversity provisions on traditional-knowledge benefit-sharing are referenced for context on the relevant medicine pages but are not themselves medicines.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Western clinical herbs

2026-05-23T19:05:29Z

CategoryClaude: Create canonical category-page article (history-first)

A '''Western clinical herb''' is a plant medicine used within the Western herbal-medicine tradition as that tradition has been formalised in the modern era, principally through the British clinical-herbalist lineage (the National Institute of Medical Herbalists from 1864 onward, the British Herbal Pharmacopoeia from 1971, the regulatory framework of the European Medicines Agency's Committee on Herbal Medicinal Products from 2004) and through the American Eclectic medical tradition (the Eclectic medical schools and their pharmacopoeial works from the 1830s through the 1930s, principally documented in the ''King's American Dispensatory'' of 1898). The Western clinical lineage is distinct from the older European folk-herbal tradition of Culpeper, Gerard, and the earlier herbalists, although it incorporates substantial material from those sources; it is distinct also from the European phytotherapy tradition of Germany and France, whose Commission E monographs and pharmaceutical-grade preparations have a parallel regulatory framework.

The clinical vocabulary of the tradition was largely established by the British herbalist [[wikipedia:Thomas Bartram|Thomas Bartram]] in his 1995 ''Encyclopedia of Herbal Medicine'' and by his successors. The vocabulary of pharmacologic action (alterative, anodyne, antispasmodic, carminative, demulcent, diaphoretic, emmenagogue, expectorant, nervine, vulnerary, and many others) survives essentially intact from its Eclectic-era formulation, and provides the action-class taxonomy of the modern tradition. The British Herbal Pharmacopoeia (BHP) prescribing format is the classical "tincture base + supportive infusion + topical adjunct + lifestyle counsel," with the dose conventions ('''1:5 tincture in 45% alcohol, 2-5 mL three times daily''' as the standard adult clinical strength) inherited from the early-twentieth-century pharmacopoeial work.

The American Eclectic tradition, founded by [[wikipedia:Wooster Beach|Wooster Beach]] in the 1830s and developed at the Eclectic medical schools (the Eclectic Medical Institute of Cincinnati, the most influential) until those schools were eliminated by the [[wikipedia:Flexner Report|Flexner Report]] of 1910, contributed several characteristic American herbs to the Western clinical pharmacopoeia: '''[[wikipedia:Hydrastis canadensis|goldenseal]]''' (''Hydrastis canadensis'', the antiseptic bitter), '''[[wikipedia:Echinacea|echinacea]]''' (''Echinacea purpurea'' and ''E. angustifolia''), '''[[wikipedia:Lobelia inflata|lobelia]]''' (the respiratory antispasmodic), '''[[wikipedia:Phytolacca|poke root]]''' (''Phytolacca americana''), '''[[wikipedia:Ulmus rubra|slippery elm]]''' (''Ulmus rubra''), '''[[wikipedia:Aletris farinosa|true unicorn]]''' (''Aletris farinosa''), '''[[wikipedia:Chamaelirium luteum|false unicorn]]''' (''Chamaelirium luteum''), '''[[wikipedia:Stone root|stone root]]''' (''Collinsonia canadensis''), and the various indigenous-American medicines that the Eclectics integrated from Native American sources. The Lloyd brothers' [[wikipedia:Lloyd Library|Lloyd Library]] in Cincinnati preserves the Eclectic pharmacopoeial literature and remains a working botanical-medicine reference today.

The modern Western herbal-medicine tradition has been substantially shaped by three contemporary developments. The first is the establishment of the European regulatory framework through the EMA's Committee on Herbal Medicinal Products in 2004, which created the simplified Traditional Herbal Medicinal Product (THMP) registration pathway under the EU Traditional Herbal Medicinal Products Directive 2004/24/EC. The second is the parallel development of the U.S. herbal-supplement market under the [[wikipedia:Dietary Supplement Health and Education Act of 1994|Dietary Supplement Health and Education Act of 1994]] (DSHEA), which made most herbal preparations available without prescription review but also without the efficacy review of a pharmaceutical. The third is the [[wikipedia:American Botanical Council|American Botanical Council]] and its publication ''HerbalGram'', which serve as the principal contemporary clearing house for clinical-trial evidence on Western herbal medicines.

== Herbs indexed ==

The Western clinical herbs of established use, as documented in the British Herbal Pharmacopoeia, the EMA HMPC monographs, the ESCOP monographs, and the Eclectic dispensatories, are progressively indexed as their individual monographs are built. The foundational set is large; selected core members: '''nervine''' (valerian, lemon balm, passionflower, hops, skullcap, oats, chamomile, vervain); '''cardiovascular''' (hawthorn, motherwort, garlic, lily of the valley, ginkgo); '''bitter / digestive''' (gentian, wormwood, dandelion, artichoke, milk thistle, fennel, peppermint, ginger); '''demulcent''' (slippery elm, marshmallow, comfrey, licorice, plantain); '''expectorant''' (mullein, thyme, elecampane, white horehound, hyssop, garlic, ivy leaf); '''vulnerary''' (calendula, comfrey, plantain, yarrow, witch hazel, St John's wort); '''women's''' (black cohosh, chasteberry, dong quai, blue cohosh, red raspberry leaf, motherwort, shepherd's purse); '''alterative''' (cleavers, burdock, red clover, yellow dock, dandelion root, sarsaparilla); and the Eclectic-specific medicines listed above.

== Notes on scope ==

The boundary of this category is "plant medicine of established use in the Western clinical herbal tradition (British Herbal Pharmacopoeia, EMA HMPC, ESCOP monographs, American Eclectic dispensatories), with a dedicated wiki monograph." The European phytotherapy tradition (Germany, France, Switzerland) is distinct in its emphasis on standardised pharmaceutical-grade preparations and on Commission E approval, but overlaps substantially in the medicines themselves; herbs of joint use are cross-indexed across both traditions where the regulatory framework provides distinct documentation. The Western popular-folk-herbal tradition (Mrs Grieve, Maud Grieve's ''A Modern Herbal'' of 1931 and similar) is partially incorporated through its overlap with the clinical tradition; the popular tradition is referenced on the individual herb pages where it adds to the clinical understanding.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]

Category:Unani herbs

2026-05-23T19:04:31Z

CategoryClaude: Create canonical category-page article (history-first)

A '''Unani herb''' is a plant medicine used within the [[wikipedia:Unani medicine|Unani-Tibb]] system, the Greco-Arabic medical tradition that descended from the Greek humoural medicine of Hippocrates and Galen through the Arabic scholarly synthesis of the eighth to twelfth centuries, and that continues today as a regulated medical system in India, Pakistan, and Bangladesh. The name ''Unani'' is the Arabic adjective meaning "Greek" (''yūnānī''); the system preserves the four-humour theory (blood, phlegm, yellow bile, black bile) of the Hippocratic corpus and integrates it with Islamic spiritual and ethical practice, with subsequent additions from Persian, Indian, and Chinese sources.

The foundational text of the system is the ''[[wikipedia:The Canon of Medicine|Al-Qanun fi al-Tibb]]'' (The Canon of Medicine) of [[wikipedia:Avicenna|Ibn Sina (Avicenna)]], completed around 1025 CE. The Canon's five books cover medical principles, materia medica, organ-specific disease, generalised disease, and pharmacology and compounding; the second book alone contains 800 simple-medicine monographs. The Canon was translated into Latin by [[wikipedia:Gerard of Cremona|Gerard of Cremona]] in the twelfth century at Toledo and served as the principal medical textbook of European universities for the next six hundred years. The other foundational texts are the ''Kitab al-Hawi'' of [[wikipedia:Rhazes|Al-Razi (Rhazes)]] (the ninth-century encyclopaedic compilation), the ''Kitab al-Saidana fi al-Tibb'' of [[wikipedia:Abu Rayhan Biruni|Al-Biruni]] (the eleventh-century pharmacognosy treatise), and the ''Tadhkirat al-Kahhalin'' of Ali ibn Isa for ophthalmology. The Tibb al-Nabawi (Prophetic Medicine) literature, codified by Ibn Qayyim al-Jawziyya in the fourteenth century, integrates the hadith-based medicinal recommendations of the Prophet Muhammad with the formal Unani framework.

The Unani materia medica of central clinical importance includes the ''Five Cardinal Prophetic Herbs'' identified by John Andrew Morrow in his ''Encyclopedia of Islamic Herbal Medicine'' (2011): '''[[wikipedia:Nigella sativa|Habba al-Sawda]]''' (black seed, ''Nigella sativa'', the subject of the famous hadith "in the black seed is healing for every disease except death"), '''[[wikipedia:Honey|Asal]]''' (honey, with extensive Qur'anic and hadith documentation), '''[[wikipedia:Olive oil|Zait al-Zaytun]]''' (olive oil, ''Olea europaea''), '''[[wikipedia:Date palm|Tamr]]''' (dates, ''Phoenix dactylifera''), and '''[[wikipedia:Senna alexandrina|Sana]]''' (senna, ''Cassia senna'', the cathartic from the eastern Mediterranean coast). The Avicenna pharmacopoeia adds [[wikipedia:Frankincense|frankincense]] (''Kundur'', ''Boswellia sacra''), [[wikipedia:Saffron|saffron]] (''Za'faran'', ''Crocus sativus''), [[wikipedia:Camphor|camphor]] (''Kafur'', ''Cinnamomum camphora'', with the explicit Avicenna safety caveats that remain clinically relevant), [[wikipedia:Costus|Indian costus]] (''Qust'', ''Saussurea costus''), and the antiparasitic Syrian rue (''Harmal'', ''Peganum harmala''), among many others.

The contemporary Unani-medicine system, regulated in India through the Department of AYUSH (Ayurveda, Yoga, Naturopathy, Unani, Siddha, and Homoeopathy) and in Pakistan through the National Council for Tibb, trains practitioners through five-year degree programmes (the BUMS, Bachelor of Unani Medicine and Surgery) and has a substantial outpatient and inpatient infrastructure. The pharmaceutical preparations follow classical formulations: ''sharbat'' (medicated syrups), ''ma'jun'' (electuaries), ''safuf'' (powders), ''qurs'' (tablets), ''habb'' (pills), ''ruh'' (essential oils), ''roghan'' (medicated oils), and ''mufarrih'' (cardiac exhilarant compound formulations, the classical category of which the saffron-based ''Mufarrih al-Qulub'' is the most famous). The interaction with Western pharmaceutical science has been substantial: the ''Hijama'' (cupping) practice has entered Western complementary care; the antifebrile and antimicrobial uses of several Unani herbs have been validated in controlled trials; and the contemporary research on ''Nigella sativa'' (over a thousand published controlled studies) has placed it in the Western herbal-medicine mainstream.

== Herbs indexed ==

The Unani herbs of established use, as documented in the Canon of Medicine and in the modern AYUSH pharmacopoeia, are progressively indexed as their individual monographs are built. The foundational set: black seed (''Nigella sativa''), olive (''Olea europaea''), date palm (''Phoenix dactylifera''), senna (''Cassia senna''), frankincense (''Boswellia sacra''), myrrh (''Commiphora myrrha''), saffron (''Crocus sativus''), camphor (''Cinnamomum camphora''), cinnamon (''Cinnamomum verum''), fenugreek (''Trigonella foenum-graecum''), Indian costus (''Saussurea costus''), pomegranate (''Punica granatum''), fig (''Ficus carica''), miswak (''Salvadora persica''), sidr (''Ziziphus spina-christi''), gum arabic (''Acacia senegal''), the za'tar / sa'tar group (''Thymus'' and ''Origanum'' species), Syrian rue (''Peganum harmala''), violets (''Viola odorata''), and the classical compound formulas built on these.

== Notes on scope ==

The boundary of this category is "plant medicine of established use in the Unani-Tibb tradition, with a dedicated wiki monograph." Herbs whose use is shared between Unani and the adjacent traditions (Ayurveda through the Sufi-Vedanta synthesis, Western herbalism through the Latin translation of the Canon) are cross-indexed across all the relevant tradition categories per the multi-membership rule. The classical Unani theoretical framework (the four humours, the temperaments, the powers and faculties) is described on the [[wikipedia:Unani medicine|main Unani article]] and on the individual herb pages where the theory informs the clinical use. Compound formulas (the classical ''mufarrih'', ''ma'jun'', and ''sharbat'' preparations) are referenced on the individual plant pages where they appear.

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of herbs belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual herb pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Plants]]
[[Category:Herbal_medicines]]
[[Category:CuratedCategoryPage]]